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Summary
Studies were performed on a human cyclic AMP specific 
phosphodiesterase (PDE) o f the PDE4A fam ily. The cDNA for this isoform had 
been isolated from a human T-lymphocyte cDNA library and engineered for 
expression in  Saccharomyces cerivisiae (D r M .Sullivan, Sandoz). 
Characterisation of the PDE activity o f h6.1 demonstrated that both pellet and 
soluble forms were kinetically identical, hydrolysing cyclic AMP specifically. 
Substrate hydrolysis was unaffected by low concentrations {2piM) o f cyclic 
GMP or calcium / calmodulin but was selectively inhibited by the PDE4 class 
selective inhibitors rolipram and RO-20-1724. The PDE3 class inh ib itor 
cilostimide and the non-selective inhibitor IBM X served as weak inhibitors. 
Both rolipram and IB M X  were shown to inh ib it pellet and soluble h6 ,l 
activities in a simple competitive manner. EDTA-treated h6.1 could be dose- 
dependently activated by the divalent cations Mg^+ and Mn^+. This suggested 
that there was a site specific interaction between the divalent cations and h6.1.
Pelleted h6.1 was not affected by NaCl or detergent treatment. 
Thus PDE activity was neither peripherally bound or an integral membrane 
protein. Indeed, the only difference found between pellet and soluble h6.1 was 
that the pellet activity was more thermostable. In each case, activity decayed as a 
single exponential, which suggested that only a single population o f enzyme 
was expressed in each compartment
The function o f the distinct N and C terminal domains o f h6.1 
were investigated. The N-terminal region o f h6.1 was shown to be important in 
such functions as substrate hydrolysis, inhibitor interaction and thermostability. 
This analysis of a human PDE4A isoform (lOAORF) which differed from h6.1 
in having a larger N-terminal domain, showed that it  exhibited a significantly 
low er Km fo r cyc lic  AM P (1.9±0.2//M , p=0,025) compared to h6.1 
(4.1+1.7/^M). In  addition, lOAORF exhibited an IC50 (0.19±0.02/fM , 
p=0.004) fo r rolipram  which was considerably low er than that fo r
XV
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h6.1(0.5±0.15/fM). Importantly, it has been suggested that a conformational 
change, induced by the larger N-terminal region of lOAORF occured, which 
resulted in  a change in the way in which rolipram inhibited enzyme activity. 
W hilst rolipram was a simple competitive inhibitor of h6.1, partial competitive 
inh ib ition  was seen w ith  lOAORF. The enzyme lOAORF also showed 
increased thermostability with ato.s (>30 mins) significantly greater than that of 
h6.1 at 45°C (lOmins). The role o f the N-terminal region in modulating PDE 
properties was emphasised further upon the analysis of H Y B l. The chimeric 
PDE, H YB1 was a construct formed by the substituition o f the N-terminus of 
h6.1 w ith that o f the inactive splice variant 2EL. W hilst this had no significant 
effect on the AMP  ^ it  significantly increased the IC 50 fo r rolipram
(1.93+0.23//M) and reduced the thermostability of H Y B l (3 mins), compared 
to h6.1. Thus, the distinct N-terminal domain o f lOAORF contributed to 
changing the potency o f rolipram action, the Km for cyclic AMP hydrolysis and 
thermostability. The C-terminal domain was shown to be involved in the 
interaction w ith rolipram also, since the truncation o f this region (YMS 12) 
resulted in a significantly greater IC50 (1.7±0.14jmM, p-0.0001) fo r rolipram 
inhibition compared to h6.1.
The cellular expression o f an analogous PDE4A rat isoform, 
R D I, was investigated in rat brain. The in vivo expression o f the rat PDE4A 
splice variant, RDI was studied in rat cerebellum synaptosomal fractions. Sub- 
fractionation o f those synaptosomal fractions which contained the greatest 
amount of R D I immunoreactivity, determined that R DI was enriched in the 
plasma membrane fraction. The location of R D I was identified w ith the plasma 
membrane markers 5'-nucleotidase and adenylyl cyclase. This has been 
previously shown in COS-1 cells transfected w ith R D I cDNA (Shakur et al 
1993). Location at the plasma membrane, along with adenylyl cyclcase, places 
R D I at a site alongside other components o f the cyclic AMP signalling
XVI
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pathway, and provides a route fo r the termination o f the signal generated by 
cyclic AMP.
XVll
Chapter ■ 1
Introduction
 : ______
■ • I f f
1. Intrg.d.u.gii9.a
1.1 Cyclic adenosine 3*. 5'- monophosphate as a Second Messenger
Signal transduction can be defined as the mechanism by which a
primary messenger, such as a hormone, binds to a specific receptor on the cells 
surface coupled to an effector system and generates an intracellular signal 
resulting in the biochemical response. The intracellular signal triggers a cascade 
o f molecular reactions the result o f which culmanates in the biochemical 
response. One such intracellular signal, or second messenger, is cyclic 
adenosine 3', 5 - monophosphate (cyclic AMP). Since the discovery o f cyclic :: 
nucleotides their synthesis, modulation by hormones, neurotransmitters and ( 
pharmacological agents are mechanisms which are now among the most well 
established in cellular signalling.
1.2 Cyclic AMP Dependent Protein Kinase
The biochemical response to cyclic AMP is initiated by the 
binding o f the second inessenger to its intracellular 'receptor', cyclic AMP 
dependent protein kinase (PKA). PKA is the only known receptor protein for 7
cyclic AMP in eukaryotic cells (Krebs 1985) and exists as 2 holoenzyme forms 
types I and II. The inactive holoenzyme form  o f PKA is a cytoplasmic, 
tetrameric complex o f both regulatory (R) and catalytic (C) subunits. High 
a ffin ity binding o f 4 molecules o f cyclic AMP to the R subunit, activates the 
complex by dissociation o f the two catalytic subunits from the R subunit dimer 
(Beebe and Corbin 1986), therefore, liberating the catalytic subunits to 
phosphorylate substrate proteins or to migrate to the nucleus (Nigg 1990). This 
can be summerised in the reaction scheme:
R2C2 + 4 cyclic AMP R2 • (cyclic AMP)4 + 2C 
Studies have shown that the R II subunit has an additional function, namely the 
localisation o f PKA (Scott 1991).
Specificity o f PKA for a particular substrate protein, may be 
explained by the hypothesis that individual pools o f PKA are compartmentalised
C
  _
to a subcellular location in close proxim ity to that particular substrate protein 
(Scott and Carr 1992). Therefore, activation o f a particular PKA pool can only 
arise when elevation o f cyclic AMP occurs in response to an appropriate 
hormone. Activation o f a particular PKA isoform is dependent on the hormone 
and tissue involved (table 1). Each subtype exists as an alpha and beta isoform, 
the alpha isoform is expressed in most cell types but the beta isoform is 
expressed preferentially in brain tissue (Scott and Carr 1992). In general, type I 
isoforms are prim arily cytoplasmic whereas most (-75% ) type I I  activity is 
found associated with the particulate fraction.
1.3 Biological Effects Mediated bv Cvclic AMP
Cellular activity, and its control, is dependent upon a variety o f 
neurotransmitters, growth factors and hormones which transduce their effects 
through the extracellular binding to specific plasma membrane spanning 
receptors. The mechanism by which receptor occupation, by such ligands, leads 
to an intracellular response has been the subject o f much investigation. Work by 
Sutherland and Rail in  the 1950's demonstrated that, in  the presence o f 
glucagon or adrenaline, then phosphorylase present in the supernatant fraction 
o f liver homogenates was activated by a heat stable factor. For this activation to 
occur it was noted that the plasma membrane fraction was required (Rail et al 
1957). Later work identified this heat stable factor as cyclic AMP. The 
observation that glucagon and adrenaline could not activate phosphorylase 
directly, suggested that the point o f hormonal regulation was at adenylyl 
cyclase, the enzyme which catalyses the formation o f cyclic AMP from ATP, 
(R ail et al 1957). This work was the basis o f the "second messenger 
hypothesis", namely, a secondary messenger e.g. cyclic AMP is formed in 
response to a ligand binding to its specific receptor and, once formed, this 
intracellular messenger can then alter cell function.
(i)Cvclic AMP as a Hormonal Second Messenger
---------------------------------------------------1
Since its discovery, the second messenger cyclic AMP has 
shown to be central in the functioning o f a diverse range o f biological systems. 
O f great importance is the role o f cyclic AMP in the hormonal control o f blood 
glucose and fatty acid levels. Cyclic AMP has a dual effect in the hormonal 
control o f lipolysis in adipocytes. On the one hand, cyclic AMP mediates the 
lip o ly tic  action o f hormones such as catecholamines, corticotrophin and 
glucagon (Steinberg et al 1975). The second messenger promotes lipolysis 
through the activation o f cyclic AMP-dependent protein kinase, which 
phosphorylate s and activates hormone sensitive lipase resulting in hydrolysis o f 
stored triglyceride to glycerol and free fatty acids (Strâfors et al 1984). 
Conversely, the degradation o f cyclic AMP and the subsequent reduction in 
cyclic AMP-dependent protein kinase has been shown to be o f functional 
importance in the antilipolytic action o f insulin (Smith and Manganiello 1988, 
Vasta et al 1992 and Anderson et al 1989).
Homeostatic control o f blood glucose levels has been shown to 
be a cyclic AMP mediated event. Glucagon, the hormone produced by the alpha 
cells o f the pancreas is involved in the promotion o f glycogenolysis, 
gluconeogenesis and the release o f free fatty acids. The receptor for glucagon is 
coupled to the cyclic AMP synthesising enzyme adenylyl cyclase through the 
stimulatory G-protein Gg. In the liver, elevation o f the intracellular levels o f 
cyclic AMP, via activation o f the glucagon receptor, triggers an enzymatic 
cascade initiated by PKA mediated phosphorylation (Cohen 1985). Primarily 
this is the phosphorylation o f glycogen phosphorylase, leading to the 
breakdown o f glycogen and glucose release, and o f glycogen synthase which 
results in the inactivation o f the enzyme. This cyclic AMP signal in response to 
glucagon in hepatocytes has been shown to be transient (Heyworth et al 1983). 
Following the in itia l increase in cyclic AMP, rapid desensitisation o f adenylyl 
/ cyclase occurs (Heyworth and Houslay 1983), in which the glucagon receptor 
uncouples from Gg. Several lines o f evidence have shown that the uncoupling
'_____ :_______________________ :_________________   I
is due to a protein kinase C mediated phosphorylation o f the receptor (Murphy 
et al 1987, Murphy &  Houslay 1988),
(ii^Cvclic AMP in the Central Nervous System 
A role for cyclic AMP in the central nervous system (CNS), 
associated w ith the processes o f learning, memory, neurotransmission and 
mood regulation has been highlighted. In particular numerous genetic mutations 
in genes associated w ith learning in Pros op hi la melanogaster have been 
isolated. These genetic mutations have been associated w ith alterations o f the 
cyclic AMP signalling pathway including dune , which encodes a cyclic AMP 
specific phosphodiesterase, and rut which encodes a calcium-calmodulin 
stimulated adenylyl cyclase (Dudai 1988, Levin et al 1992,Qiu et al 1991), 
These studies have shown alterations in olfactory learning (Byres et al 1981) 
associated with mutations o f the dune gene, resulting from altered cyclic AMP 
metabolism (Nighom et al, 1991). In the mammalian CNS the role o f cyclic 
AMP is less w ell characterised, however it  has been associated w ith the 
processes o f neurotransmission by virtue o f its synaptic localisation (Therien 
and Mushynski 1979) and in mood regulation (Schneider et al 1986).
(iiilC vclic AMP in the Immune Svstem
In the mammalian immune system, cyclic AMP is known to be 
an important regulator o f such functions as attenuation o f lymphocyte 
blastogenesis (Epstein et al 1984), lymphocyte proliferation and differentiation 
(Coffey et al 1978, Hadden 1988), inh ib ition o f release o f inflammatory 
mediators histamine and leukotriene C4 from basophils (Peachell et al, 1992) 
and the blockade o f the cytokine pathway due to the suppression o f tumour 
necrosis factor alpha production from human mononuclear cells (Semraler et al 
1993).
(iv)Cvclic AMP in the Cardiovascular Svstem
 ■
Cyclic AMP has been shown to be crucial in the control o f 
cardiac contraction (Trautwein &  Heschler 1990) and diastolic relaxation 
(Morgan 1991b).
The force o f cardiac contraction is related to the cross-linking o f 
the actin and myosin filaments o f the myocardium which, in turn, shortens the 
contractile apparatus (Robertson et al 1982) and results in the actual contraction. 
Cross-linking o f actin and myosin is itse lf dependent upon the availabilty o f 
intracellular calcium to bind to the regulatory protein troponin C (Fabiato &  
Fabiato 1979). Cyclic AMP mediates the contraction through the elevation o f 
intracellular calcium via the PKA mediated phosphorylation o f voltage 
dependent calcium channels o f the sarcolemma. This in turn causes the release 
o f more calcium from the sarcoplasmic reticulum (Morgan et al 1991a). Indeed 
it has been shown that agents which elevate intracellular levels o f cyclic AMP 
are therapeutically useful as positive inotropic agents (Brunkhorst 1989).
Z' Relaxation o f cardiac muscle is initiated by the phosphorylation ~ ’
o f troponin C by PKA, causing a decrease in the affin ity o f the calcium binding 
I site, and o f the sarcoplasmic calcium pump. Therefore there is reduced * 
availability o f calcium for the contractile proteins (Morgan et al 1991b).
Contractile agonists such as PAF (platelet activation factor), 
induce the contraction o f airway smooth muscle via phospholipase C catalysed 
hydrolysis o f phosphatidylinositol (4,5) biphosphate into inositol (1,4,5) 
triphosphate and sn - 1,2-diacylglycerol (Rodger &  Pyne 1992). Vascular 
smooth muscle relaxation (Chasin 1972) and airway smooth muscle relaxation 
(Toiphy 1988) are both under the influence o f cyclic AMP, in that, this 
nucleotide inhibits contraction by causing a net efflux o f calcium firom the cell, 
which is necessary for contraction (Kukovetz et al 1981).
Stimulation response o f platelets involves the adhesion to sub- 
endothelial tissues, secretion o f secretory granule components, the formation o f 
platelet aggregates, increased glycogenolysis and the rapid synthesis o f
___________________________
oxidative metabolites o f arachodonic acid, a ll o f which are dependent in one 
way or another on intra/extra cellular calcium. Cyclic AMP itself, and agents 
which elevate cyclic AMP, inh ib it these responses by regulation o f the free 
calcium level in the platelet, or by the control o f calcium-dependent reactions 
which are essential fo r these responses. Cyclic AMP is therefore central to the 
control o f platelet activation (Feinstein et al 1981).
The above summary o f the processes involving cyclic AMP is 
by no means expansive, however it  highlights the complex systems w ithin 
which cyclic AMP is a major component.
1.4 Adenvlvl Cvclase
(i'jSvnthesis o f Cvclic AMP
Synthesis o f cyclic AMP from  ATP is dependent upon the 
regulation o f the enzyme adenylyl cyclase [B.C. 4.6.1.1; ATP pyrophosphate - 
lyase (cyclysing)]. The reaction catalysed by this enzyme can be represented by
Mg2+ATP 3’5’ cyclic A M P + 2Pi (fig  1.4.1)
(ii)Adenvlvl Cvclase Structure
The adenylyl cyclases comprise a diverse fam ily o f enzymes 
with variations both w ithin and between species. W ith regard to cellular location 
adenylyl cyclase is exclusively plasma membrane associated with exception o f 
certain bacterial forms which are cytosolic.
Three general classes o f adenylyl cyclase exist which are distinct 
w ith respect to the way in which they are associated w ith the membrane and 
include the periphally membrane bound form o f Saccharomvces cerivisiae and 
Escherichia co li. the form o f the enzyme from Dictyostelium which has a single 
transmembrane spanning region and the integral membrane enzyme found in 
eukaryotic cells. (Tang and Gilman 1992). Eight isoforms (types I  - Vni) o f the 
eukaryotic integral membrane adenylyl cyclase are known (Krupinski et al 
1992) and have been shown to be the products o f distinct genes. An overall,
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w ell conserved structure for this enzyme can be seen throughout the eight 
isoforms, comprising a short amino-terminal region (N) and two 40kDa 
cytoplasmic domains, C i and C2, between which lies two alternating extremely 
hydrophobic stretches, M l and M%, each o f which are predicted to contain six 
transmembrane helices (Ishikawa et al 1992).
Among the eight adenylyl cyclases considerable sequence 
homology exists between the C l a and C2a regions (fig  1.4.2). These regions 
are reputed to be the catalytic sites due to the sim ilarity (-35% identity) to what 
is known to be the catalytic domain o f guanylyl cyclases (Chinkers and Garbers
1991). Presumably the hydrophobic domain is involved in the anchorage o f the 
enzyme to the membrane for accessability to the membrane receptors.
CiiilAdenvlvl Cvclase regulation bv G-Proteins
The signal between receptor and effector (adenylyl cyclase) is 
transduced by the heterotrimeric guanine nucleotide-binding proteins or G- 
proteins (Gilman 1987). Adenylyl cyclase activity is modulated by receptors 
interacting w ith either Gg (stimulatory) or G j (inhibitory) which are bound to 
the inner surface o f the plasma membrane. Heterotrimeric G-proteins consist o f 
three subunits, alpha which is the largest and which confers G-protein 
specificity, together with beta and gamma.
In the resting state the alpha, beta and gamma subunits are 
complexed together w ith GDP (guanosine diphosphate) bound to the alpha 
subunit. Receptor occupancy results in the activation o f the G-protein complex 
and release o f the GDP from the alpha subunit, which is in turn replaced by 
GTP (guanosine triphosphate). The alpha-GTP subunit dissociates from the 
beta-gamma and diffuses along the inner plasma membrane surface and couples 
w ith the effector. A fter a few seconds the signal is 'switched o ff by the 
intrinsic GTPase activity o f the alpha subunit which hydrolyses the bound GTP 
to GDP, hence rendering the alpha subunit inactive. Once inactivated the alpha 
subunit reassociates with the beta-gamma and the complex returns to its resting
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State (fig 1.4.3). There is evidence o f cross-talk between the phospholipase C 
signalling system where it has been shown that activators o f PKC, phorbol 
esters, increase basal adenylyl cyclase activity (Pyne et al 1993). Phorbol esters 
have also been shown to enhance the ADP-ribosylation o f the Gg-alpha sub-unit 
by cholera toxin (Pyne et al 1993). Indeed, PKC itse lf has been shown to 
phosphorylate alpha Gg m vitro , in which it was shown that the substrate o f the 
reaction was the guanine nucleotide free form o f the alpha sub-unit (Pyne et al 
1992).
Regulation o f adenylyl cyclase is not an exclusive role for the 
alpha subunit, for, adenylyl cyclase activity can be modulated by beta-gamma 
subunits but in a type-specific fashion. Whereas beta-gamma inhibits type-I 
adenylyl cyclase when stimulated by either Gg-alpha or calcium-calmodulin, 
beta-gamma greatly potentiates the stimulatory effect of Gg-alpha on either type- 
I I  or type-IV adenylyl cyclase (Tang and Gilman 1991). These interactions are 
dependent on the prénylation o f the G-protein gamma subunit (Iniguez-Lluhi et 
al 1992). Recent evidence also suggests a role for the beta-gamma subunits in 
the activation o f mitogen-activated protein kinases (M APK), or extracellular 
signal-regulated kinases (ERKS), in COS-7 cells transfected with muscarinic 
receptor (Crespo et al 1994) and the alpha2A adrenoceptor (Van Blesen et al 
1995).
Inhibition o f the adenylyl cyclases is mediated by the Gi fam ily 
o f G-proteins. These include G n , G i2, Gi3 and Gq (M illigan  1988). 
Considerable evidence suggests that the major trigger fo r the inhibition o f 
adenylyl cyclase is Gi-alpha 2, which has been implicated in a variety o f 
receptor systems including the thrombin receptor in P9 cells (Watkins et al
1992), leukotriene B4 receptors in H l-60 cells (Goetzel et al 1994), 5 -H T lA  
receptors in  C H Q -K l cells (Raymond et al 1993) and w ith  the glucagon 
receptor in hepatocytes (Bushfield et al 1990 and 1991). As with the Gg family, 
the beta-gamma complex o f G i proteins plays an important role in adenylyl
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/  cyclase regulation. In platelet and the S49 cell line, exogenously added beta- 
gamma complex o f G i proteins was able to inh ib it adenylyl cyclase by a 
Z mechanism involving the deactivation o f Gg-alpha (Katada et al 1984).
1.5 Inactivation o f the Cvclic AMP Signal 
In this introduction the mechanisms by which cyclic AMP
synthesis is regulated, the range o f biological effects the second messenger is 
involved and the funcions o f PKA have been discussed. Another vita l 
component o f the cyclic AMP signalling pathway is its degradation. The only 
way in which the cells o f eukaryotic organisms can terminate the cyclic AMP 
signal is through its hydrolysis catalysed by a heterologous fam ily o f enzymes 
known as the cyclic nucleotide phosphodiesterases (PDEs) (EC 3.1.4.17). 
Certainly some organisms such as Dictyostelium (Pitt et al 1992) can extrude 
cyclic AMP from the cell, however, the most important method o f control o f 
intracellular concentration o f cyclic AMP are the PDEs.
1.6 Cvclic Nucleotide Phosphodiesterases 
General Introduction
Following the first experiments by Butcher and Sutherland in the 
early 1960's demonstrating enzymatic degradation o f cyclic nucleotides, it  was 
soon apparent, based on the studies by Appleman and co-workers, that multiple 
froms o f PDE could catalyse the same reaction (Butcher and Sutherland 1962, 
Thompson and Appleman 1971, Appleman and Terasaki 1975). We now know 
that at least seven different isoenzyme families o f PDEs exist which d iffe r in 
respect o f substrate specificity, regulation, kinetics and inhibitor profile.
Originally PDEs were classified simply on the basis o f substrate 
hydrolysing ability into cyclic GMP and cyclic AMP PDEs. However, with the 
realisation that multiple forms o f each class existed it was necessary to develope 
a more sophisticated system. The classification system used in this thesis is as 
described by Beavo et al (1994). Most o f the individual types o f PDE have 
closely related subfamilies, that is, are products o f d istinct but highly
______
homologous genes, which give rise to alternatively spliced mRNAs. Indeed, 
members o f one fam ily generally share -20-25% sequence sim ilarity with 
members o f another fam ily, which occurs in the region thought to be involved 
in catalysis (Chen et al 1986, Charbonneau et al 1986). Therefore, PDEs are 
classified into species (capital letter), gene family (PDE + Arabic numeral), gene 
(capital letter) and splice variant, for example HSPDE4A1.
The functional relevance fo r the existance o f so many 
isoenzymes o f PDEs can be explained by the differential expression in selected 
cell types, and the regulation o f the different isoenzyme forms by a variety o f 
intracellular components, which allow the manipulation o f specific isoforms in 
an individual cell type. Also the opportunity is there fo r the development o f 
specific pharmacological tools which could be used to target an isoenzyme 
form, and therefore be potentially useful from a therapeutic perspective.
1.7 Cvclic GMP Metabolising Phosphodiesterases
rilPD E l - Calmodulin Stimulated PDE
The fam ily o f calmodulin (CaM) stimulated PDEs (PDEl) is one 
o f the best characterised. Discovered in the 1960s from experiments on bovine 
brain (Cheung 1967), it was one o f the firs t cyclic nucleotide PDEs to be 
purified to homogeneity and characterised in terms o f molecular properties. 
Although detected in various tissues the enzyme is predominantly found in 
mammailian brain (Sharma et al 1980) and heart (La Porte 1979). 
aiCellular Distribuition
Although CaM stimulated PDE is generally considered to be 
cytosolic, as shown in neuronal cytoplasmic preparations (Kincaid et al 1987), 
the precise cellular location varies w ith tissue type. For example PDEl activity 
has been localised to the synaptic density membrane fraction o f rat brain (Grab 
1981) and to particulate fractions o f heart and kidney (Kakiuchi et al 1978). The 
differences noted in  cellular distribution occur because o f tissue specific 
differential isoenzyme expression.
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blStructure
Structural characterisation studies have shown the CaM 
stimulated PDE to be a dimer composed o f identical subunits which vary in 
molecular weight between 58 to 63kDa w ith each individual isoenzyme. Each 
subunit can bind 2 molecules o f CaM in the presence o f Ca^+, w ith CaM and 
Ca^+ synergistically interacting to activate the PDE. Therefore, an elevation o f 
the intracellular concentration o f Ca "^*" results in the increased affin ity o f the 
enzyme for CaM (Richman and Klee 1978).
ciSubstrate Specificitv and Regulation
Basal PDEl activity can be increased up to 20 fo ld  in the 
presence o f Ca^+ and CaM w ith both the basal and stimulated activities 
showing Mg2+ dependency (Wang et al 1990). K inetic analysis on purified 
preparations have shown that although PDEl can utilise both cyclic AMP and 
cyclic GMP as substrate the predominant isoenzyme species show a higher 
affin ity for cyclic GMP in vitro (Kakurchi et al 1973), hence these enzymes are 
classified as cyclic GMP PDEs.
Hormonal regulation o f PDEl has been reported in studies in
which agonists which increase intracellular Ca^+, cause a decrease in
intracellular cyclic nucleotide (Sumners and Myers 1991). This was shown to
be independent o f adenylyl or guanylyl cyclase inh ib ition, therefore the
regulation o f PDEl is an essential component o f the Ca^+ signal transduction
/ pathway. The PDEl isoenzyme is selectively inhibited by vinpocetine with \  
/  . .  . : L inhibition resulting in  effects on the central nervous system (de Noble et al /
y  ^^  1986) and vasculature (Hidaka and Endo 1984).
Recent evidence (Spence et al 1995) has identified a novel link  
between the lip id  and cyclic AMP signalling systems involving PD El. Spence 
et al (1995) has shown that upon selective overexpression o f PKC isoforms in 
Chinese hamster ovary cells, an induction o f PDEl activity occured. It has been
1 1
suggested that this PKC mediated induction, was via regulation o f PDEl gene 
expression by the AP-1 (fosfjun ) complex.
fiilPDES Cvclic GMP Specific Phosphodiesterase
Originally the PDE5 fam ily encompased subgroups including the 
retinal cyclic GMP PDE rod outer segment PDE (ROS) (Yamazaki et al 1980), 
cone PDE (Gillespie and Beavo 1988) and the cyclic GMP specific PDE from 
lung (Francis et al 1980). However on the basis o f distinct sequence differences 
between the retinal and lung PDEs these were categorised as PDE6 and PDE5 
respectively.
The cyclic GMP-binding-cyclic GMP-specific PDE (cGBPDE) 
or PDE5 was firs t recognised in  the supernatant fractions from  lung 
preparations by Lincoln et al (Î976). This PDE isoenzyme fam ily is 
characterised by the hydrolytic activity being highly specific fo r hydrolysis o f 
cyclic GMP w ith the inability to hydrolyse cyclic AMP. PDE5 is present in 
tissues including rat (Thomas et al 1990a) and bovine lung (Francis and Corbin
1988), human platelets (Hamet and Coquil 1978), rat spleen (Coquil 1983), 
guinea-pig lung (Bums et al 1992) and vascular smooth muscle (Hamet et al 
1984).
(a'iCharacteristics
The native molecular weight o f PDE5 from rat and bovine lung 
has been delineated to be -177 kDa (Frances et al 1980) and from guinea-pig 
^ lung ~90kDa (Bums &  Pyne 1992). PDE5 has been partially purified from 4 
guinea-pig lung (Bums et al 1992), and has been characterised by its specificity 
fo r cyclic GMP w ith a Km o f -2 .2pM  and Vmax o f 1.2nM /  min /  mg. 
Purification o f the enzyme from guinea-pig lung has shown it  to be kinetically 
sim ilar to, and with an inhibitor profile resembling, that isolated from bovine 
(Francis &  Corbin 1988) and rat lung (Thomas et al 1990a,b).
PDE5 has in addition to the catalytic site a non-catalytic binding 
site, to which, a function has not yet been clearly attributed. Thomas et al
12
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( 1990a,b) suggest that the function o f the non-catalytic site may be to stimulate 
the hydrolytic activity o f the PDE. The non-specific PDE inhib itor IB M X, 
which potently and competitively inhibits PDE5, binds to the catalytic site o f 
PDE5 and is known to increase the binding o f cyclic GMP to the non-catalytic
Protein Kinase G 
Partially purified PDE5 from guinea-pig lung (Bums et al 1992) 
has been shown to be phosphorylated in vitrn  by both protein kinase A and 
protein kinase G (Burns et al 1992, Bums &  Pyne 1992, Thomas et al 
1990a,b). PKA mediated increase in PDE activity was sensitive, in a dose 
dependant manner, to alkaline phosphatase treatment (Bums &  Pyne 1992). 
Bums and Pyne (1992) suggest that it  is not necessary for cyclic GMP to bind 
to the enzyme prior to the activation by PKA. This is in contrast to the study by
site (Frances and Corbin 1988). It is thought that this situation can work in 
reverse, in that, binding o f compounds to the non-catalytic site can increase the 
binding and hydrolysis o f cyclic GMP at the catalytic site (Thomas et al 
1990a,b).
(blPhosphorvlation bv Protein Kinase A and
I
1
Thomas et al (1990b), in which it was shown that cyclic GMP binding was a 
pre-requisit to activation by PKA. Bums and Pyne (1992) propose that either
the differences are due to different PDE5 isoforms, or that a regulatory protein 
.which binds to the non-catalytic site, is present in the purified preparations
■which enables the phosphorylation to occur.
Phosphorylation by PKA increases the Vmax o f the reaction o f #1cyclic GMP hydrolysis and also decreases the sensitivity o f PDE5 to inhibition 
by zaprinast (Bums et al 1992). The loss o f sensitivity to zaprinast is shown
' ■through the loss o f non-competitive inhibition when phosphorylated by PKA.
. a
Thus, PDE activation via PKA, may involve a mechanism where the non-
catalytic sites to which zaprinast binds are perturbed (Bums &  Pyne 1992). -Si
■■ •J
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The phys io log ica l conseqences o f PKA  mediated 
phosphorylation are unknown. There is evidence however, o f cross-talk 
between the cyclic AMP and cyclic GMP signalling systems. Agonists which 
induce contraction o f smooth muscle are known to accumulate cyclic GMP 
(Nakatuso &  Diamond 1989). Thus, an increase in cyclic AMP, for example via 
beta-adrenoceptor agonists in  smooth muscle, would decrease the inhibitory 
cyclic GMP pool by activating PDE5 in a PKA dependent manner (Bums et al 
1992).
fcllsolation o f Murine cDNAs Representing PDE5 
A  fu ll length cDNA clone has been isolated from a bovine lung 
cDNA library, which upon expression in COS-7 cells was shown to encode a 
protein kinetically similar to that isolated and purified from bovine lung (Bums 
et al 1995). Partial clones form  a murine lung cDNA library have been 
subsequently isolated using the bovine cDNA 32p-iabelled clone as a probe. 
Two partial clones isolated were o f interest and were shown to encode the PDE 
catalytic domain found throughout the PDE fam ily, and a region which is 
proposed to contain the cyclic GMP binding site. These mouse clones are the 
subject o f present study and are being used to isolate the fu ll length mouse 
clone, to identify the localisation o f the mouse PDE5 in tissues and the identity 
o f any spliced variants which may exist (Bums et al 1995).
Corbin and coworkers have cloned and expressed bovine PDE5 
and have shown that the enzyme is phosphorylated in the whole cell. 
Mutagenesis studies by this group have also shown that at least two different 
types o f cyclic GMP binding sites are present. This group have also noted a 
conserved m otif in  all PDEs, Hx3Hx-20E, which is thought to function as a 
zinc binding site (Francis et al 1994). O f interest, Pyne and coworkers have 
shown that the inhibitory effect o f zaprinast on PDE5 could be due to its ability 
to chelate zinc (Beavo et al 1994).
(iülPDEô Retinal Rod and Cone Phosphodiesterses
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The mammailian visual pathway is modulated by cyclic GMP 
specific PDE6 isoenzyme fam ily, which hydrolyses cyclic GMP in response to 
light in both rod and cone photoreceptors.
(aWisual Pathwav
In rod photoreceptors the visual pathway is triggered when the 
protein rhodopsin absorbs a photon o f ligh t (Wald 1968). This converts the 
rhodopsin into its activated form which in turn activates transducin. Transducin 
is a heterotrimeric guanine-nucleotide-binding protein o f three subunits Taipha 
which has GDP bound in its inactive state , Tbeta and Tgamma- Activation o f 
transducin by rhodopsin involves the exchange o f GDP bound to the Taipha 
subunit w ith GTP. Once GTP is bound the Taipha subunit dissociates from the 
Tbeta-Tgamma complex to activate the PDE through the removal o f its 
inhibitory subunit and leaves the PDE free to hydrolyse cyclic GMP (Fung et al 
1981). A  cation channel in the plasma membrane o f rod photoreceptors, which 
prim arily transports Na+, is gated and activated by cyclic GMP, therefore 
lowering the cyclic GMP concentration by PDE decreases the Na"*’ in flux by 
closing the channel (Yau and Nakatani 1985, Matthews 1987). This membrane 
hyperpolerisation generates the neuronal signal and constant Na+ flow  
maintains depolarisation o f the membrane in the dark. A  Ca^+ sensitive 
guanylate cyclase is stimulated by low levels o f Ca^+, which results from the 
action o f a Na+/Ca^+ exchanger, and restores cyclic GMP levels after 
illumination (Zuckermann 1973).
L ittle  is known about the role o f the cone PDEs in 
photoperception. Obvious physiological differences occur between rods and 
cones which come into play in  low  and high luminesence situations 
respectively. Despite this, cone specific PDE isoenzymes exist and it  is expected 
that cone visual transduction processes are similar to that o f rods.
(b)Rod Cvclic GMP Phosphodiesterases
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The bovine rod cyclic GMP PDEs are composed o f three types 
o f subunit, the 88kDa alpha subunit, the 84kDa beta subunit and two inhibitory 
13kDa gamma subunits which keep the PDE in an inactive state during resting 
(Baehr et al 1979, Deterre et al 1988), Evidence suggests that all three types o f 
subunit undergoe significant post translational modification. Relevance o f these 
post translational modifications are unclear however, the C-terminal cysteine 
modification presumably orientate the PDE correctly in the membrane and are 
neccessary for the normal function o f the PDE, Both the alpha and beta subunits 
are methylesterified at a C-terminal cysteine and are differentially prenylated by 
famesylation and geranylgeranylation respectively. In addition, PDE alpha and 
gamma can be phosphorylated by a protein kinase C (PKC) isoenzyme but no 
change in activity was noted (Udovichenko 1993, Anant et al 1992).
1.8 Cvclic AMP Phosphodiesterases
filPDE2 - Cvclic GMP Stimulated Phosphodiesterase 
A fter in itia l identification o f a cyclic GMP stimulated PDE 
(cGsPDE) or PDE2 activity in soluble fraction o f a rat liver preparation (Beavo 
et al 1970), several other tissues were sim ilarily studied for evidence o f this 
PDE. cGsPDE was found in rat brain (Beavo et al 1971), adipose tissue (Klotz 
and Stock 1972) and human platelets (Hidaka and Asano 1976).
The PDE2 fam ily is characterised by the allosteric regulation o f 
cyclic AMP and cyclic GMP hydrolysis w ith positive co-operative kinetics. 
Two distinct subfamilies o f this enzyme e x is t, PDE2A1 the heart /  adrenal 
isoenzyme (Martins et al 1982), PDE2A2 the membrane bound form  
(Yamamoto et al 1983) and the PDE2B1 liver form (Pyne et al 1986) which 
may be a proteolytic product o f PDE2A due to its smaller molecular size. 
However, both membrane and soluble phosphorylated proteins are found, 
which might imply the existence o f two distinct splice variants,
(alKinetics
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Studies on the purified enzyme have shown that the PDE is 
dimeric and hydrolyses both cyclic GMP and cyclic AMP. Cyclic GMP 
however, is both the prefered substrate and activator o f cyclic AMP hydrolysis. 
Allosteric regulation o f the enzyme is considered to occur distal to the catalytic 
site (Moss et al 1977). Reports on the bovine adrenal isoenzyme have shown 
that stimulation o f cyclic AMP hydrolysis correlates w ith the binding o f En­
cyclic GMP at a distinct site (M iot et al 1985). It is as yet unclear as to whether 
cyclic AMP and cyclic GMP are hydrolysed at the same or different sites.
blPhvsiological Role
One important aspect o f this enzyme fam ily is the ability to 
hydrolyse both cyclic AMP and cyclic GMP. In situations where both cyclic 
nucleotide concentrations are elevated, then the hydrolysis o f one cyclic 
nucleotide can be stimulated by the other. Studies have shown that cyclic GMP 
is a more potent activator o f cyclic AMP hydrolysis (Moss et al 1977) than vice 
versa. This unique situation has been shown to be o f key physiological 
significance in the adrenal gland, particularily associated w ith aldosterone 
production. Stimulation o f the atrial natriuretic factor receptor, coupled to the 
guanylate cyclase effector system in the adrenal gland results in an elevated 
cyclic GMP concentration w ith a concominant decrease in  cyclic AMP, 
ultimately effecting cyclic AMP mediated responses (MacFarland et al 1987). 
The search for an isoenzyme selective inhibitor o f this PDE has been relatively 
unsuccessful, except fo r the compound EHNA (erythro-9-(2-hydroxyl-3- 
nonyl)-adenine) which is commonly used as an adenosine deaminase inhibitor 
(Méry &  Fischmeister 1994). EHNA was reported to be the same compound as 
previously described (MEP-1) by Podzuweit (1995). The IC 50  fo r PDE 
inhibition (-Ip M ) is significantly less than the concentration o f EHNA used to 
inh ib it adenosine deaminase. EHNA was shown to antagonise cyclic GMP 
effects, mainly inhibition o f L-type Ca2+ current, in isolated frog ventricular
17
myocytes (Méry et al 1995). It would therefore seem that this compound w ill be 
invaluable in determining other functions o f cGsPDE.
In addition cGsPDE functions as an important transducer o f 
cyclic GMP as a second messenger in the brain. Evidence to support this comes 
from the abundance o f the enzyme responsible fo r cyclic GMP formation, 
guanylate cyclase (Nakane et al 1983) in various neuronal cell types. 
Expression o f the molecular target fo r cyclic GMP the cyclic GMP dependent 
protein kinase (Lohmann et al 1981) and a more widespread expression o f 
cGsPDE (Repaske et al 1993, Sonnenberg et al 1991) has also been 
demonstrated in mammilian brain.
(ii^PDE3 - Cvclic GMP Inhibited Phosphodiesterase 
The PDE3 cyclic GMP inhibited enzymes (cGIPDE) form an 
isoenzyme class o f cyc lic  AM P hydrolysing enzymes which are 
characteristically inhibited by micromolar concentrations o f cyclic GMP. This 
isoenzyme form has been identified in and purified from tissues such as adipose 
(Degerman et al 1987, Saltiel and Steigerwalt 1986), bovine cardiac ventricle 
(Harrison et al 1986) and rat liver (Pyne et al 1987).
(alStructure and Kinetics
From tissues which have been studied so far, w ith the exception 
o f the 'dense-vesicle' PDE, the PDE3 fam ily appear to be peptides o f native 
molecular size 105 - 135 kDa. However, these PDEs are particularily sensitive 
to endogenous proteolysis producing fragments of around 30 - 80 kDa in size.
'Dense-vesicle' PDE has been purified to apparent homogeneity 
from rat liver (Pyne et al 1987), and is activated in hepatocytes by glucagon in a 
cyclic AMP dependent manner (Heyworth et al 1983) and also by insulin 
through an unknown mechanism (Loten et al 1978, Loten et al 1983, Hey worth 
et al 1983, Houslay et al 1983). The rat live r hormonally activated 'dense- 
vesicle' PDE was shown to be an integral membrane protein anchored to the 
membrane bilayer via a 5 kDa peptide (Pyne et al 1987). Native 'dense-vesicle'
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enzyme has a molecular mass o f approximately 62 kDa. However, during 
purification this 5 kDa membrane anchor becomes cleaved yielding a 57 kDa 
clipped species (Pyne et al 1987). Evidence also suggests that the PDE may 
exist as a 1 lOkDa dimer in situ (Pyne et al 1987).
Sim ilar Km values have been reported fo r the hydrolysis of 
cyclic AMP and cyclic GMP by the PDE3 PDEs isolated, with concentrations 
ranging from 0,1 - 0.8pM fo r both substrates and Vmax values greater for 
cyclic AMP than cyclic GMP. These enzymes also exhibited linear Michaelis- 
Menten kinetics fo r substrate hydrolysis (Degerman et al 1986, Degerman et al 
1988 and Harrison et al 1986). On analysis o f the 'dense-vesicle' PDE it  was 
shown to be unusual in its class by virtue o f it being a high-affinity cyclic AMP 
PDE which has low Km and Vmax values for cyclic GMP, suggesting a high 
affin ity for cyclic GMP (Pyne and Anderson 1987, Marchmont et al 1981 and 
Pyne et al 1986).
The hallmark o f the PDE3 class, including the 'dense-vesicle' 
PDE, is the potent competitive inhibition by cyclic GMP w ith an IC50 value in 
the range o f < IpM . S im ilarily the compound cilostim ide is selective for the 
inhibition o f PDE3 w ith reported IC 50 values o f < 0,1 (xM fo r PDE3 from 
human and bovine platelets (MacPhee et al 1986, Grant and Colman 1984). 
Functional effects o f pharmacological inhibition o f PDE3 include inhibition o f 
platelet aggregation (Simpson 1988) and stimulation o f lipolysis (Elks and 
Manganiello 1984).
(b)Regulation o f Cyclic GMP Inhibited Phosphodiesterase
Hormonal regulation o f PDE3 has been investigated and well 
characterised in rat adipocytes (Anderson et al 1989), in 3T3-L1 adipocyte cell 
line (Vasta et al 1992) and in hepatocytes (Heyworth et al 1983). In  adipocytes, 
lipolysis is promoted by hormones such as adrenaline via beta adrenoceptor 
stimulation (Anderson et al 1989) which results in  the elevation o f the 
intracellular cyclic AMP concentration. Conversely stimulation o f these cells by
...iôS
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insulin causes an antilipolytic effect by reduction o f cyclic AMP within the cell. 
Thus, in adipocytes there is a fine balance between cyclic AMP production by 
adenylyl cyclase and cyclic AMP degradation via PDEs. Reduction in cyclic 
AMP levels in adipocytes has been shown to be centrally controlled by a PDE3 
which is found exclusively associated w ith the endoplasmic reticulum  
subfraction and is stimulated by both insulin and isoproterenol, a beta 
adrenoceptor agonist (Anderson et al 1989).
The activation o f PDE3 in adipocytes is the result o f 
phosphorylation o f specific serine residues (Smith et al 1991). The kinase 
involved in the activation o f the PDE via beta adrenoceptor occupancy is 
thought to be PKA (see chapter section 1.2) (Vasta et al 1992), however the 
identity o f the kinase involved in vivo mediating the action o f insulin is more 
1 intrigu ing. In  vitro  experiments w ith 3T3-L1 cells have shown PDE3 
phosphorylation and activation through PKA. However, it  is unlikely that 
) insulin promotes PDE3 phosphorylation via PKA in vivo since the challenge of 
adipocytes with insulin inhibits lipolysis through cyclic AMP reduction.
An analogous PDE3 to the hepatocyte 'dense-vesicle' form 
(Heyworth et al 1983) is present in adipocytes (Anderson et al 1989). Both 
adipocyte and hepatocyte cGIPDE are phosphorylated by PKA in vitro and are 
sim ilarily activated by insulin and isoproteronol.
Inhibition o f PDE3 is thought to be the underlying mechanism of 
action o f PDE3 inhibitors such as milrinone (Brechler et al 1992). In  light o f 
this a human PDE3 has been cloned from myocardial tissues (Meacci et al
1992). Subcellular fractionation studies on mammalian myocardium by other 
investigators has shown a PDE3 activity associated with the sarcoplasm (Smith 
et al 1993), which presumably has functional relevance in  controlling 
intracellular Ca^+ leading to a positive inotropic response. This has been shown 
to be the case for the positive inotropy produced by glucagon, which activates a
2 0
specific Ca^+ channel type in myocytes, mediated by the inhibition o f PDE3 
(Méiy et al 1990) in a pertussis toxin sensitve manner (Brechler et al 1992).
1.9 PDE4 Cvclic AMP Specific PDEs
The PDE4 cyclic AMP specific enzymes are, like the other PDE 
classes, a diverse isoenzyme fam ily which are characterised by a high 
specificity and affin ity for cyclic AMP. In view o f their complexity the PDE4 
fam ily have been known by a variety o f names, namely peak I I I  PDEs due to 
their elution profile from DEAE - cellulose (Weishaar et al 1985), cyclic AMP 
PDEs and high-affinity or low Km PDEs (Weishaar et al 1985, Thompson et al 
1984), type IV  PDEs (Strada and Thompson 1985, Beavo 1990) and PDE4 
(Beavo et al 1994). Their substrate specificity aside, cyclic AMP specific PDEs 
are also distinguishable by their inhibition by a selective group o f compounds 
including the antidepressant drug rolipram  and Ro-20-1724 and their 
insensitivity to inhibition by cyclic G M P.
fiilsolation and Purification o f PDE4
Most cells possess cyclic AMP PDEs which hydrolyse substrate 
w ith both 'high* and low ' a ffin ity  (Emeaux et al 1980). A t cyclic AMP 
concentrations in the lower range o f 0.1 - lOpM the 'high' a ffin ity  PDEs 
rapidly reach Vmax, whereas the 'low' affin ity PDEs operate in the range o f 10 
- 50|xM. Therefore, it seems like ly that the 'high' a ffin ity cyclic AMP PDEs 
play a key role in the signal transduction initiated by hormones which produce 
only a minor change in the cyclic AMP intracellular concentration. However, it 
should be noted that the labelling o f cyclic AMP PDEs as either low affin ity' or 
'high a ffin ity ' is indeed a sim plification , where it  is possible that even one
enzyme can possess both properties giving rise to anomolous kinetics
«(Marchmont et al 1981) or, that the cyclic AMP hydrolysing activity in a given 
cell type could be made up o f PDE4 isoforms hydrolysing substrate at different 
rates. It is therefore neccesary to isolate the PDE to characterise its activity, 
which is possible by physical separation such as DEAE-cellulose (Weishaar et
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al 1985, Lavan et al 1990), by analysis w ith a specific inh ib itor or by the 
cloning the PDE activity using sequence specific probes.
Prior to molecular cloning technology the isolation o f PDE4 
isoforms proved to be d ifficu lt because o f various factors including the PDE4 
isoforms being present only in trace amounts, they can be compartmentalised 
within the cell, and like other PDEs are unstable and easily proteolysed. Despite 
this, PDE4 isoforms have been isolated from a variety o f tissues and species 
including human heart (Reeves et al 1987) and rat live r and hepatocytes 
(Marchmont et al 1981, Lavan et al 1990). One o f the firs t characterised and 
purified to apparent homogeneity was the peripheral plasma membrane (PPM) 
PDE from rat liver (Marchmont et al 1981, Houslay &  Marchmont 1981, Pyne 
et al 1987, Pyne et al 1989).
riilPeripheral Plasma Membrane PDE
The PPM PDE has been purified to apparent homogeneity from 
rat live r and is hormonally activated by insulin (Marchmont et al 1981). 
Marchmont et al (1981) have shown this PDE to be a 52 kDa monomer which is 
associated w ith the cytosolic surface o f the plasma membrane through ionic 
interactions, and is localised via an integral membrane protein (Houslay &  
Marchmont 1981). PPM PDE is also found, and expressed in sim ilar levels, in 
rat kidney, heart and white adipose tissue (Pyne et al 1987). This PDE was 
shown to be distinct from  the 'dense vesicle' live r PDE by virtue o f their 
different subcellular locations (Heyworth et al 1983) and that the PPM PDE is 
activated by insulin via tyrosyl phosphorylation (Pyne et al 1989). Most 
important was the observation that the PPM PDE was insensitive to inhibition 
by cyclic GMP (Marchmont et al 1981) or IC Il 18233 (Pyne et al 1987) which 
are known to inhibit the 'dense vesicle' PDE but it was sensitive to inhibition by 
the type IV  PDE inhibitor Ro 20-1724.
1.10 PDE Activities isolated from Drosophila meîano^aster.
2 2
One o f the early approaches into studying PDE4 isoforms was 
concerned w ith the cyclic AMP specific PDE from Drosophila melanogaster. 
Early observations by Davis and Kiger in 1978, demonstrated that cyclic AMP 
levels could be genetically manipulated in Drosophila adults. It was shown that 
the levels o f cAMP in these flies were dependent on the presence o f the region 
3D3-3D4 o f the X-chromosome, and that by varying the number o f doses o f 
chromomere 3D3-3D4, the activity o f the cyclic AMP PDE could be controlled 
in a dose dependent manner. Flies completely deficient in chromomere region 
3D3-3D4, had elevated levels o f cyclic AMP compared to those flies with 1,2 
or 3 doses o f this chromomere region. However, cyclic GMP levels were not 
altered by the absence o f chromomere region 3D3-3D4. These observations 
demonstrated that the cyclic AMP levels in these flies were genetically 
determined, and suggested that this particular chromomere region contained a 
structural or regulatory gene necessary for cyclic AMP PDE activity.
Subsequent studies (Kiger and Golanty 1979, Davis and Kiger 
1980, Davis and Kiger 1981) supported the idea that chromomere region 3D3- 
3D4 did contain the gene or genes which conferred PDE activity. It was shown 
that two distinct forms o f PDE activity. Forms I  and II, could be isolated from 
normal adult Drosophila. Form I  was characterised as a heat stable enzyme, 
which hydrolyses both cyclic AMP and cyclic GMP with equal affin ity, and is 
activated by calcium. PDE Form I I  was also a heat labile enzyme with a lower 
molecular weight than Form I  but was specific fo r hydrolysis o f cyclic AMP 
only. The activity o f the Form I I  enzyme was dependent on high magnesium 
concentrations but unlike Form I  was insensitive to calcium activation. Form I I  
was shown to be absent in  flies deficient in  chromomere region 3D3-3D4. 
Therefore, genetic dosage o f chromomere region 3D3-3D4 affects the activity o f 
Form II, in  a manner which suggests this region may include the structural 
gene. However, the calcium /  calmodulin dependent enzyme. Form I, was not 
affected. Using present day isoenzyme nomenclature. Form I  could be
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characterised as a member o f PDEl (see section 1.7.(i), and Form n , the PDE 
deficient in flies with a genetic deletion o f chromomere region 3D3-3D4, a 
PDE4 isoenzyme.
(riMutants o f Drosophila melanomster.
Mutant flies carrying a genetic deletion at the chromomere region 
3D3-3D4 are termed dunce mutants. This arose from the observations that 
deletions o f this region o f the X-chromosome results in a particular phenotypic 
learning defect. Dunce mutants fa il to learn in olfaction tests associated with 
electric shock (Byres et al 1981) Other physiological characteristics o f dunce 
mutants are known and include, female (Mohler 1973 and 1977) and male 
(Kiger 1977) in fe rtility  . The absense o f imaginai disc derivatives such as legs, 
halteres, hemitergites and genitilia (K iger 1977) has been shown to be a 
maternal defect in the dunce mutants. The connection between each o f the 
aforementioned phenotypic characteristics is a genetic mutation o f the dunce 
gene which results in an aberration o f cyclic AMP metabolism.
riiïïdentification o f the dune Gene Product 
Previous reports have implied that cyclic AMP metabolism is 
closely involved in reproduction and learning/memory in Drosophila. However 
some ambiguity existed as to the identity o f the dunce gene product. Originally 
it was suggested that either the gene encoded a cyclic AMP PDE (Davis and 
Kiger 1981), or that the dunce gene encodes a protein which has an effect post- 
translationally to interact and activate the PDE catalytic activity. The later was a 
possibility considered by Chen et al (1986) who conducted experiments 
screening drosophila adult, pupal and embryonic cDNA libraries using unique 
genomic restriction fragments o f dnc^ as probes. The dnc^ gene was isolated 
by the chromosome walking technique (Davis and Davidson 1984) which 
generated six RNAs subsequently reported as dnc^ gene products (Davis and 
Davidson 1986).
(iiilM olecular Analvsis o f the dune Gene
2 4
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Molecular analysis o f cDNAs isolated by Chen et al (1986) 
revealed that the open reading frame o f dnc'^ showed sim ilarity to other protein 
encoding genes which suggests that dnc^ does indeed encode protein in vivo. 
Comparison o f the protein sequence o f Drosophila dunce gene (Chen et al 
1986) w ith the protein sequences from  other PDEs such as the calcium /  
calmodulin stimulated PDE from bovine brain, the cyclic GMP stimulated PDE 
from bovine heart and the yeast PDE2 gene (Sass et al 1986), revealed a 200- 
270 residue segment in each that is homologous to the others and which appears 
to be constrained to the carboxyl segment o f this protein (Charbonneau et al 
1986) ( fig  1.10.4). The homologous segment is proposed to comprise the 
catalytic domains in the set o f enzymes analysed. Bacterial expression systems 
used to express truncated cDNA clones lacking this -270 amino acid sequence 
are devoid o f PDE activity (Swinnen et al 1989). W ithin the -270 amino acid 
sequence several residues are conserved, in particular histidine which could 
determine protein folding or substrate interaction. However, outside this region 
o f homology which is proposed to contain the catalytic region, there are no 
common sequences found throughout the PDE superfamily, however sequence 
sim ilarities are known to exist w ithin an isoform fam ily. The dunce gene 
product was found to share a seven amino acid sequence w ith the R II sub-unit 
o f the cyclic AMP-dependent protein kinase that is predicted to be part o f the 
cyclic AMP binding site. Thus, considering the region o f sequence homology 
w ith other PDEs and w ith the cyclic AMP dependent protein kinase, this 
evidence strongly suggested that the dunce encoded protein is a functional PDE 
(Chabonneau et al 1986, Chen et al 1986).
1.11 Rat Homologues o f the DrosophiWwMC Gene
Further evidence in support o f the Drosophila dunce gene 
encoding a functional PDE, came from studies which involved the molecular 
cloning o f rat homologues o f the Drosophila gene (Swinnen et al 1989, 
Swinnen and Joseph et al 1989, Swinnen et al 1991). The approach used to
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isolate mammalian dunce gene counterparts involved the screening o f a rat 
cDNA library o f rat testis origin, w ith a 32p- labelled Drosophila dune cDNA 
clone (Swinnen et al 1989). Four cDNA clones (ratPDE 1 - 4 )  were 
subsequently isolated and demonstrated that not only were the four clones 
homologous to each other, they also contained w ithin the sequences the 270 
amino acid region discussed in section (iv) (fig  1.10.4). D ifferentia l tissue 
expression o f the PDE clones, and the existence o f little  homology outwith the 
270 amino acid region suggested that the cDNAs originated from genes which 
were distinct and related, as opposed to products o f alternative splicing o f the 
one gene. The existence o f distinct PDE genes provides some basis, at least 
from a molecular point o f veiw, fo r the heterogeneity observed throughout the 
PDE superfamily. These studies resulted in the isolation o f four groups o f 
cDNA clones o f rat testis origin with considerable homology to the Drosophila 
dunce gene. Three o f these cDNA clones were used fo r transformation o f 
bacteria (Swinnen and Joseph 1989). These transformations increased PDE 
activity in  the bacterial extracts suggesting that the cDNA clones were derived 
from transcripts encoding functional enzymes. This can also be said o f the 
Drosophila dune gene product due to the significant sequence homology with 
the cDNA clones. The sequence analysis o f dune cDNA clones (Chen et al 
1986) therefore confirms the in itia l biochemical studies which suggested the 
gene encoded a PDE ((Davis and Kiger 1978, Kiger and Golanty 1979, Davis 
and Kiger 1980).
The significance o f the isolation o f these homologous cDNA 
clones o f the Drosophila dune gene is in the origin o f the cDNA library - a rat 
testis cDNA lib rary. This suggested a role fo r cyclic AM P PDEs in 
gametogenesis in a mammalian species. It is therefore interesting to note that 
deficiency o f the dune gene in Drosophila has an effect on both male and 
female fe rtility  (Mohler 1973 and 1977, Kiger 1977)
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Certain ambiguity arose from the in itia l biochemical analysis o f these 
enzymes which highlighted specific problems in the isolation o f these isoforms, 
such as inconsistent reports o f molecular size due to sensitivity o f PDEs to 
proteolysis, which resulted in the purification o f catalytically active fragments, 
and the isolation o f a m ixture o f PDEs as opposed to one isoform. The 
instability o f the PDE4 fam ily is one o f the many problems encountered when 
analysing these proteins. However, studies using Drosophila melanogaster 
and Saccharomyces cerivisiae have had a particular important role to play in the 
study o f PDE4 from a molecular genetic perspective. Two independent groups 
using different strategies have isolated two cDNA clones R D I (rat dunc-l) 
(Davis et al 1989, Davis and Henkle-Tigges 1989) and DPD {dune - like 
phosphodiesterase) (Colicelli 1989) from a rat brain cDNA library.
(insolation o f R D I (PDE4A11 bv Cross-Hvbridisation with
dune Gene Probe
Given that cyclic AMP PDEs play such a central role in  the 
neuronal processes o f learning and memory in Drosophila, and their involvment 
in  the control o f reproduction o f these flies, the investigation for mammilian 
homologues was considered critical. The strategy undertaken by Davis et al 
(1989) involved screening genomic libraries from different species. In itia lly , a 
cDNA probe was constructed which corresponded to a section o f the 
Drosophila dune gene, and was used to screen a variety o f genomic cDNA 
libraries including rat. Subsequently the rat dune -1 gene was isolated. A 
fragment o f the rat dune -1 genomic clone, which had a high degree o f 
homology to the Drosophila dune gene, was used to probe a rat brain cDNA 
library and resulted in the isolation o f the clone R D I. The homology o f the 
predicted product o f R D I with other PDEs was compared (Davis et al 1989). 
Sequence comparison o f cDNA clones R D I and DPD have shown a high 
degree o f homology in the conserved 270 amino acid region. However w ithin 
this homologous region, approximately ha lf o f the identical residues use
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alternative codons, and outwith the regjon little  sequence sim ilarity is seen either 
upstream or downstream suggesting they are products o f distinct genes (Davis 
et al 1989, Colicelli et al 1989).
(ii) Isolation o f DPD (PDE4B1) bv Suppression o f the ras 2va ll9
Mutation o f Saccharomyces cerivisiae
In the study which reported the isolation o f DPD (Colicelli et al
1989) a different strategy to that used in the isolation o f R D I was employed. 
The second strategy involved searching for cDNA clones whose expression 
would suppress the phenotype associated w ith the ras 2^^119 mutation in
Sa.ç£haromyçes çmyisia? ■
Saccharomyces cerivisiae encodes two genes 1 and 2 
homologous to the mammalian RAS oncogene fam ily, RAS genes represent the 
transforming genes found in many human tumours, and encode for 21kDa GTP 
binding proteins (p21) which are associated with the plasma membrane (Gibbs 
et al 1984 and 1985). In Saccharomyces cerivisiae disruptions o f both genes 
results in growth failure, however, normal growth patterns are restored i f  
double mutants are transformed to express either human (Kataoka et al 1985) or 
viral (DeFeo-Jones et al 1985) RAS,
RAS functions to modulate adenylyl cyclase activity in 
Saccharomyces cerivisiae as removal o f the influence of RAS has been shown 
to result in deficient adenylyl cyclase activity (Toda et al 1985). Purified yeast 
RAS 1 or 2, or the human counterparts have been shown to activate yeast 
adenylyl cyclase in reconstituition experiments (Broek et al 1985), where the 
RAS protein is replaced in mutant cells by RAS from either mammalian or 
yeast origin.
Regulation o f adenylyl cyclase by /?A5 in  yeast can be 
attributed to the sim ilarities between G-proteins and RAS> that is, concerning 
their membrane association, ability to bind guanine nucleotides (Shih et al 1980) 
and have intrinsic GTPase activity (McGrath et al 1984). Gilman (1984) has
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suggested that on the basis o f this and o f sequence homology between RAS and 
the alpha subunit o f G-proteins that both proteins do share a sim ilar function. 
Guanine nucleotide binding is associated w ith the activation o f yeast cyclase 
(Casperson 1983) and w ith the cloned yeast RAS~ 2 product (Tamanoi et al 
1984) which is a protein o f similar size to the alpha subunit o f G-proteins.
An analogous situation to the loss o f G-protein alpha subunit, 
that is the loss o f cyclase activation, is reported when the RAS' 2 gene is 
disrupted (Toda et al 1985). This supports the notion that the RAS' 2 gene 
encodes a protein sim ilar to the G-protein alpha subunit. Indeed, in 
Saccharomvces cerivisiae ras 2vall9  mutants which encodes valine at the 
nineteenth codon instead o f glycine, cyclase is constitutively activated (Toda et 
al 1985) presumably due to the loss o f GTPase activity, therefore the activation 
o f cyclase is not terminated by the return to the resting GDP bound RAS . 
Sim ilar levels o f adenylyl cyclase activation to the result o f the ras 2^^119 
mutation are seen with the non-hydrolysable GTP analogue guanosine 5’ -(beta- 
gamma-imido)triphosphate (Gpp(NH)p) (Broek et al 1985).
The ras 2^a ll9  missense mutants are typified by a particular 
phenotype which is manifested as an abnormal response to nutrient stress 
summarised by Toda et al 1985. When the ras 2'vall9 mutants are nutritionally 
deprived o f nitrogen and sulphur they lose viability and terminally arrest at all 
growth phases whereas the wild-type arrest in the unbudded state. Correlation 
exists between the ras 2^^119 mutation and the inability to accumulate glycogen 
and trehalose when entering the stationary phase o f growth. Adenylyl cyclase 
activity in ras 2^^119 mutants is increased ~4 fo ld which would correspond to 
the increase in cyclic AMP levels and the increased PKA dependent control o f 
metabolism, that is glycogen levels. The ras 2^^119 mutation renders yeast 
unable to respond to changes in the nutritional environment and intolerant to 
heat shock (Toda et al 1985, Sass et al 1986). Therefore the overexpression o f 
any o f the contributory elements o f the cyclic AMP signalling pathway in yeast.
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fo r example, high level expression o f adenylyl cyclase (Kataoka et al 1985), 
overexpression o f PKA (Sass et al 1986) or the deletion o f the regulatory 
subunit o f PKA (Matsumoto et al 1982) produce the same phenotype as that 
seen w ith the ras 2^a ll9  mutation. In  order to overcome these nutritional 
restrictions the yeast has to reduce the level o f intracellular cyclic AMP, and the 
only mechanism by which the cell can do this is by a cyclic AMP PDE. As in 
the study by C ollice lll et al (1989) cDNA clones which encode a PDE can be 
isolated in this system, hence the isolation o f DPD and the yeast PDE2 gene 
(Sass et al 1986).
.The mammalian DPD cDNA was shown to encode a protein 
w ith a high degree o f amino acid sequence identity (-80% ) w ith the cognate 
Drosophila dunce species w ithin the conserved region. Protein sequence 
analysis o f the gene products o f R D I and DPD showed little  sequence 
conservation w ith other known PDEs (Charbonneau 1986). However the 
amino acid sequences o f R D I and DPD have approximately 90% homology 
w ithin the conserved domain, and 67% in  the upstream region, but regions o f 
identical residues are separated by intermittent amino acid sequences. Up to
50% o f identical amino acid residues w ithin the conserved domain utilise 
alternative codons, which suggest that the two cDNA clones are encoded by 
distinct but related genes (Swinnen et al 1989).
OiilBiochemical Analvsis o f DPD (PDE4BD and RDI 
(PDB4A1) 1
The homology o f R D I and DPD to the Drosophila dune gene 
product predicted similar properties for the rat homologues to the Drosophila 
cAMP PDE. R D I and DPD were both shown to encode high a ffin ity  cyclic 
AMP PDEs sim ilar to the Drosophila dune PDE upon expression in a yeast 
system (Davis and Henkle-Tigges 1989). K inetic analysis o f the Drosophila i
dune PDE and the cognate mammalian species R D I and DPD characterised 
these proteins as having a high a ffin ity  fo r cyclic AMP (Henkel-Tigges and i
3 0 t
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Davis 1989, Shakur et al 1993). This study confirmed early reports that the 
Drosophila cyclic AMP PDE did not hydrolyse cyclic GMP, even at substrate 
concentrations o f up to Im M  (Kiger and Golanty 1979, Davis and Kiger 1980, 
Chen et al 1986).
A summary o f the properties o f R D I and DPD as compared to 
the Drosophila counterpart is shown in (fig  1.11.6) The most striking 
observation was that the mammalian homologues were potently inhibited by 
rolipram and RO 20-1724 whereas the dunce PDE was insensitive. Hence, the 
sequence divergence between the Drosophila and mammalian proteins allow one 
to speculate the existence o f a binding site fo r pharmacologically important 
compounds (Henkel-Tigges and Davis 1989).
(ivlUnique N-Terminal Region of RDI
The idea that the amino terminal region o f R D I encoded a
" 7
^  membrane association m otif has been the subject o f much investigation (Shakur 
et al 1993, and 1995). Expression o f the R DI cDNA in COS-1 cells resulted in 
an increased cyclic AMP specific PDE activity which was selectively inhibited 
by the PDE4 inh ib itors ro lipram  and RO-20-1724 and was located 
predominantly (-85% ) to the plasma membrane (Shakur et al 1993). An N- 
term inally truncated R D I species which lacked the firs t 25 amino acids (the 
met^^RDl), was shown to be characteristically similar to the fu ll length R DI in 
that they shared inhibitor and substrate specificity however, the met^^RDl was 
found exclusively in the cytosolic fraction. These 25 N-terminal amino acids 
conferred membrane integration which allowed the solubilisation o f RDI with 
the non-ionic detergent TX-lOO, but not by either washing the membrane with 
high concentrations o f NaCl or rehomogenisation (Shakur et al 1993). 
Additionally, the N-terminal 25 amino acids o f R D I have been shown to be 
regulatory in the catalytic function o f the enzyme in parallel w ith membrane 
anchorage (Shakur et al 1995). The engineered deletion o f the firs t 25 amino 
acids o f R DI were previously shown not to alter either the Km for cyclic AMP
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or the selectivity for, or sensitivity to, inhibitors o f PDE activity (Shakur et al
1993). Using C-terminal specific antisera to R D I, Shakur et al (1995) have 
been able to determine the relative amounts o f both R D I and the N-terminal 
truncated enzyme the met^ôRDl expressed in transfected COS-1 cells. The 
unique N-terminal region o f R D I was shown to be inhibitory on catalytic 
function, where deletion o f this domain resulted in a -2  fo ld increase in the 
Vmax value. In addition, Shakur et al (1993) have shown that in thermostability 
experiments, membrane associated R D I was more resistant to dénaturation 
either detergent solubilised R D I or the met^^RDl. It is believed therefore, that 
association o f RDI with the plasma membrane through this N-terminal region 
regulates both the structure and activity o f the enzyme.
fvlFunctional Role for PDE4 Snecies in the CNS 
Rolipram and RO20-1724 are both compounds w ith anti­
depressant properties. Indeed Rolipram has been evaluated in clinical trials as an 
effective drug for the treatment o f depression. The most surprising observation 
was that many o f the patients tested in the tria l did not previously respond to 
other anti-depressant therapy (Watchel 1983), It is intriguing that dune mutants 
lacking the gene encoding a PDE exhibit a learning and memory (Dudai 1983) 
defect, whereas in humans the anti-depressant drug Rolipram elevates mood, |
possibly by the inhibition o f PDEs. I f  the anti-depressant action o f Rolipram is 
indeed via PDE inhibition as has been suggested (Watchel 1983), then a role for 
the Drosophila cyclic AMP PDE and its mammalian homologues in the complex 
processes underlying the neurobiochemical events o f mood regulation in 
mammals, and learning /  memory in insects has been recognised. Further 
evidence to support this suggestion comes from a study by Nighom et al 
(1991), in which it was found that the dune PDE was markedly concentrated in 
the neurophil associated w ith mushroom body cells. These areas have been 
previously implicated in the processes o f learning and memory. A  parallel
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study in rat brain has shown in vivo expression o f DPD and R D I (Lobban et al 
1994, Shakur et al 1995) in particular brain areas.
1.12 Molecular Analvsis of Rat PDE4
Four distinct PDE4 genes representing the four isoform  
subfamilies found in rat have been isolated (Swinnen et al 1990) {fig  1.10.4). 
The fu ll length cDNAs o f RDI (PDE4A1) (Davis et al 1989), DPD (PDE4B1) 
(C ollice lli et al 1989) and ratPDE4 (PDE4B2) (Lobban et al 1994) have been 
isolated and studied. Functional and tissue specific expression o f PDE4B
/  isoforms have been demonstrated in the rat brain (Lobban et al 1994). DPD was
Vy  found to be exclusively cytosolic and was selectively expressed in hippocampal,
I cortex, hypothalamus and striatum regions. ratPDE4 on the other hand wasI located at the membrane o f all brain regions with the exception o f the midbrain
/&  (Lobban et al 1994).
Analysis o f the PDE4B gene (Monaco et al 1994) has shown 
that DPD and ratPDE4 are splice variants o f the same gene, where upon the 
comparison o f the protein sequences it  can be seen that ratPDE4 has an 
extended N-terminus o f 48 amino acids. Products larger than DPD can be 
transcribed according to which methionine in itia tion  codon is utilised. 
Furthermore, Lobban et al (1994) have shown that DPD and ratPDE4 are likely 
to be the only products in vivo o f the PDE4B gene given that only one 
immunoreactive species is detected with the antisera specific fo r ratPDE4 and 
one which recognised ratPDE4 /  DPD.
The R DI clone isolated by Davis et al (1989) was cloned along 
with two partial clones (RD2 and RD3) which suggested that splice variants o f 
the R DI gene existed (Davis 1990, Pyne et al 1986). However, upon analysis 
o f rat brain w ith R D I specific antisera only one immunoreactive band was 
detected in rat brain (Shakur et al 1995) with a molecular mass o f ~68kDa. This 
is in agreement with that calculated from the predicted sequence o f the cDNA. 
From this it seems likely that RDI represents the fu ll length version o f the PDE.
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The complexity o f function o f the cyclic AMP specific PDEs 
encoded by the dunce gene o f Drosophila and its mammalian counterparts RDI 
and DPD has been highlighted. I t  is suffice to say that although these PDEs 
exhibit a certain sequence homology w ithin a central portion o f the protein, the 
flanking sequences o f this conserved region display considerable divergence. 
However, the amino termini o f proteins o f each class often contain sequence 
motifs particular to its own class, fo r example PDE2 enzymes have a cyclic 
GMP regulatory domain located at the amino terminal. These sequences 
surrounding the conserved portion are considered to contain regions which for 
example interact with other proteins, such as membrane association as seen with 
R DI (see section (v ii b) above). Bolger et al (1994) have identified two regions 
present in the amino terminus o f the protein translated from the dnc and human 
cDNA homologues isolated in this study. These two regions, which the authors 
describe as UCR 1 and UCR2 (upstream conserved regions), from both human 
clones and Drosouhila melanogaster share significant homology, although 
UCR 1 and UCR 2 show little  homology with each other. The function o f these 
sequences is as yet unknown, however it  is thought that the UCR 1 site is likely 
to undergoe alternative splicing. Future work may identify common PDE4 
specific motifs, however it  is expected that the flanking sequences o f the 
catalytic domain offer unique identifiers eg UCR 1 and UCR2.
1.13 Human Multigene Familv Encoding Cvclic AMP Specific
Phosphodiesterases
Four human genes have been isolated corresponding to the 
isozyme subtypes o f PDE4A to D (fig  1.13.5). W ithin each o f these PDE4 
subtypes there exists further subdivision which has arisen as the result o f splice 
variantion o f a single gene (Bolger et al 1993). These four human genes have 
been shown to correspond to the four rat genes representing the PDE4 
subclasses isolated by Swinnen et al 1989 {fig  1.10.4, table Ic).
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Bolger et al (1993) have shown that 3 o f the 4 genes encoded 
cyclic AMP specific enzymes which were selectively inhibited by rolipram in 
the pM  range o f drug concentration. The PDE4 enzymes were also shown to be 
selectively expressed in particular cell types in a distinctive pattern fo r each 
gene. Suprisingly, in contrast to the results obtained from the rat Swinnen et al 
(1989) have shown that PDE4 activity was was not detected in human testes 
tissue which suggests that the pattern o f selective expression is also species 
specific.
Engels et al (1994) undertook the investigation o f the cellular 
expression o f PDE4 isoform subtypes in various human tissues and cell lines, 
by the isolation o f mRNA and reverse transcribing it into cDNA. Using isoform 
subtype specific primers, tissue expression patterns o f the four known human 
PDE4 genes was determined using PCR in various tissues and in several 
defined cell lines. A  summary o f the results o f this study is shown in table la. 
In parrallel to this study in humans, a comparitive study was conducted in the 
rat where brain, live r, lung, kidney, heart and blood were tested fo r the 
expression o f each rat isoform subtype. The data clearly demonstrated species 
specific tissue expression o f the various isoform subtypes in rat. In particular 
PDE4A was expressed in a ll tissues w ith the exception o f blood, which is in 
contrast to human PDE4A which was the only isoform found in T cell Jurkat 
cell line. The conclusions o f the study suggest a particular role for PDE4A in T 
cell functioning in humans. Baeker et al (1994) have isolated a human PDE4D 
cDNA clone whose mRNA transcript is predominantly found in skeletal 
muscle.
It is evident that PDE4C is unlikely to be important in controlling 
the cyclic AMP levels in blood since this isoform subtype was undetectable in 
the blood from both human and rat species. Cells o f the human immune system 
display a greater selectivity o f isoform subtype expression. T-cells selectively 
express PDE4A, B -cells express only PDE4A and B, neutrophils
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predominantly express PDE4B and PDE4C is absent from all o f the cells o f the 
immune system. Souness et al (1995) have also shown that it is predominantly 
PDE4D which is responsible for cyclic AMP hydrolysis in eosinophils. This 
suggests that specific isoform subtypes are recruited in the particular cell types 
to control distinct cyclic AMP pools. The reasons as to why cells selectively 
express one isoform  subtype over another can only be understood by 
determining subcellular localisation and characteristics o f these isoform 
subtypes.
1.14 Cellular Regulation o f PDE4
It has been well established that cyclic AMP is at the centre o f 
the control o f many cellular functions, therefore enzymes involved in the 
metabolism o f cyclic AMP such as the PDE4 fam ily are poised to play a crucial 
role in these functions. Evidence suggests that compounds selective for 
inhibition o f PDE4 activity w ill be particularily important in the treatment o f 
inflammatory disorders (Engels et al 1994). PDE4 activity has been shown to 
be crucial in the regulation o f human monocyte activation (Molnar-Kimber et al 
1992) and is elevated in patients w ith inflammatory disorders (Grewe et al 
1982, Chan et al 1993).
Elevation o f cyclic AMP PDE activity can be achieved in various 
cell types by agonists which stimulate adenylyl cyclase and is a homeostatic 
response by which many cells can regulate responses to hormones and drugs. 
This PDE activity has been identified as PDE4 (Conti et al 1991). Up regulation 
o f PDE4 activity has been identified in different mammalian cell types. In 
FRTL-5 cells PDE4 activity is elevated in response to thyroid stimulating 
hormone, which is known to elevate intracellular cyclic AMP (Sette et al 1994). 
This hormone dependent cyclic AMP regulation in FRTL-5 cells involves an 
in itia l rise in cyclic AMP which is returned to basal level within minutes, despite 
the constant presence o f hormone. This is a feature o f many hormone regulated 
systems where the cell is protected form over stimulation by desensitisation o f
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the cell, or by an alteration o f the sensitivity o f the cell to circulating hormone 
by cell adaptation, such as activation o f a protein to remove the stimulus. In 
FRTL-5 cells the intracellular elevation o f cyclic AMP results in an activation o f 
PKA and subsequent phosphorylation and activation o f PDE4, which in turn 
lowers the cyclic AMP level and switches o ff the hormone signal. Previous 
reports (Swinnen et al 1989, 1991) had shown that pituitary hormone, in rat 
sertoli and in FRTL-5 cells, increased the level o f mRNA o f PDE4, however, 
thyroid stimulating hormone in FRTL-5 cells appears to cause simply an 
activation o f PDE via phosphorylation.
Isoform  subtype induction by cyclic AMP has also been 
investigated in Jurkats (T-cell like cell line), U937 cells and neuronal cell lines 
(Engels et al 1994). In U937 cells which express subtypes PDE4A, B and D, 
only PDE4A and B were up regulated in response to elevated cyclic AMP 
(Engels et al 1994). In Jurkats which only express subtype 4A a sim ilar up 
regulatory response was noted. This was shown to be in  contrast to the 
neuronal cell lines tested which express all o f the four isoform subtypes and did 
not show an increase in the levels o f either isoform  subtype. I t  is o f 
considerable importance that the induction o f PDE4 isoform subtypes can occur 
in one cell type, and suggests differential control o f up regulation dependent on 
the cell type.
There is also evidence for activation o f PDE4 via interaction with 
the phospholipid signalling system. Increased PDE4 activity was noted in rat 
thymic lymphocytes (Marcoz et al 1993) in response to mitogenic stimulation, 
and o f PDE4 isolated from  U937 cells (DiSanto &  Heaslip 1995). In rat 
thymocytes (Marcoz et al 1993), arachadonic acid and diacylglycerol, 
phospholipid metabolites formed follow ing mitogenic stimulation, were found 
to be ineffective. In contrast, the phospholipid metabolite phosphatidic acid was 
shown to increase the activity o f a PDE4. In T cell activation cyclic AMP is
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inhibitory, thus lowering the level o f the second messenger through activation 
o f PDE allows T cell activation to proceed in response to a mitogenic stimulus.
1.15 Pharmacological Effects o f PDE4 Inhibition
(iValPDE4 Inhibition in the Treatment o f Asthma 
Asthma is a chronic inflammatory condition characterised by 
inflammation o f the airway submucosa as a result o f the in flux o f infammatory 
cells in response to an allergen. In the progressive state o f the disease the 
airways become irreversibly obstructed (Giembycz 1992). Current drug therapy 
uses mainly bronchodilatiory agents which are useful in the treatment o f the 
symptoms, but have little  effect on the underlying cause o f the condition, that is 
the inflammation. Cyclic AMP elevation produces an anti-inflammatory effect 
(Bourne et al 1978) by inhibiting the release o f inflammatory mediators from 
cells involved in the immune response (Peachell et al 1992), and acheives 
bronchdilation through the relaxation o f airway smooth muscle (Torphy 1988). 
An important role fo r PDE4 activity in  regulating the function o f mast cells 
(Torphy et al 1992), neutrophils (Nielson et al 1990), eosinophils (Dent et al 
1991) and basophils (Peachell et al 1992) has also been reported. In patients 
w ith inflammatory disorders, up regulation o f PDE4 is reported to occur in 
monocytes (Grewe et al 1982, Chan et al 1993). It would therefore be possible 
to restore cyclic AMP effects through the selective inh ib ition o f PDE4, 
providing the inhibitor was specific enough fo r a particular PDE4 subtype in a 
specific cell type.
tblPDE4 in Monocvtes
The prévalant role o f PDE4 in cells involved in the inflammatory 
response is an observation which has been credited w ith much attention. In 
particular, PDE4 has been shown to be central in  the regulation o f human 
monocyte activation (Molnar-Kimber et al 1992). A mediator which has a 
pivotal role in the inflammatory response is tumour necrosis factor-alpha (TNF- 
alpha). TNF-alpha along w ith interleukin-1 (II-1) recruit polymorphonuclear
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leukocytes to the tissues during the inflammatory response (Goto et al 1984). 
Elevation o f cyclic AMP via rolipram has been shown to inh ib it TNF-alpha 
release from monocytes while other cytokines such as II-1 remain unchanged 
(B ailly et al 1990, Semmler et al 1993, Prabhakar et al 1994, Klemm et al 
1995). The PDE4 subtypes present in monocytes has been studied using the 
Mono-mac 6 cell line as a model (Verghese et al 1995), in which is was found 
that mRNA transcripts were present fo r PDE4A, B and D. On analysis o f the 
protein expression it was noted that PDE4B peaked after 24 hours exposure to 
dibutyryl cyclic AMP, where PDE4A maintained a high protein level 24 hours 
after treatment. This data suggests that different PDE4 isotypes are recruited at 
different time points in the cell cycle and that PDE4A may have a greater role to 
play in the reduction o f cyclic AMP levels.
PDE4 activity in the U937 cell line, which is commited to the 
human monocyte-macrophage pathway, has been investigated (DiSanto &  
Heaslip 1993). Two peaks o f PDE4 activity were resolved, one o f which, 
Peak2 became activated after 24 hour storage at 4"C in buffer containing a high 
concentration o f sodium acetateand protease inhibitors. The Vmax o f Peak2 
PDE4 doubled after the 24 hour storage, and was associated w ith a shift in the 
molecular weight. P rior to storage, the molecular weight o f Peak2 was 
determined to be 210 - 250 kDa, whereas after storage there was a larger peak 
o f PDE4 activity corresponding to 45kDa. This could suggest that in U937 cells 
PDE4 is expressed as a high molecular weight species, which is subsequently 
cleaved to produce the 45kDa species. Alternatively, the 45kDa species may 
simply represent a sub-unit o f a larger protein.
(clPDE4 in Eosinophils and T-lvmphocvtes 
O f primary importance in the development o f the inflammatory 
response are eosiniphils and T-lymphocytes. The level o f blood and lung 
eosiniphils in  asthmatics is elevated. Once activated, eosiniphils cause cell 
damage through the release o f reactive oxygen species, cationic proteins.
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products o f the lipooxygenase and cyclooxygenase pathways, cytokines, PAF 
and eosiniphil derived neurotoxin. This release o f a bairage o f inflammatory 
mediators not only destroys airway neurones and epithelia, but increases the 
reactiveness o f the airways so that the individual is more sensitive to the 
allergen (Souness et al 1995, Giembycz 1992). PDE4 inhibitors Rolipram and 
RP734 01 suppressed the production o f oxygen radicals from eosiniphils and 
PAF induced airway hyperresponsiveness (Souness et al 1995, Raeburn et al
1994). Analysis o f the expression o f PDE4 subtypes in eosiniphils showed 
that only the PDE4D isoform was present and that it was most like ly to be 
membrane bound in vivo (Souness et al 1995).
Evidence suggests that the role o f the T-lymphocyte is as an aid 
in the infiltration o f eosiniphils and release o f cytokines (Giembycz 1992), 
and that the PDE4 inhibitor RO-20-1724 decreases the cytotoxic effect o f 
these cells (Robicsek et al 1991), Previous analysis o f the isoforms o f PDE 
which were present in these cells suggested that there was a cytosolic PDB4 
and a membrane bound PDE3 (Robicsek et al 1991). More recently Engels et 
al (1994) have looked at the PDE4 isoforms expressed and have shown that it 
is only the PDE4A subtype which is present.
fiilPD E4intheC N S 
The PDE4 isoform has been shown to be the predominant PDE type 
expressed in the CNS and human myeloid and lymphoid lineages (Beavo and 
Reifschneider 1990, McLaughlin et al 1993). Indeed rolipram has been 
clin ically tried as an effective antidepressant (Fleischhacker et al 1992). 
M ultiple sclerosis, the demyelinating disorder, is beleived to be a T-cell 
mediated autoimmune disease (Martin et al 1992), and that TNF-alpha and 
lymphotoxin-alpha are involved in the demyelination identified in multiple 
sclerosis lesions (Selmaj 1991). Rolipram was found to inhibit the production 
o f TNF-alpha by autoreactive human and rat T-lymphocytes in vitro, and
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prevented the clin ica l signs o f encephalomyelitus which is used as an 
experimental model for multiple sclerosis in vivo (Sommer et al 1995).
(iiilPDE4 in Smooth Muscle
The level o f PDE4 has been found to increase in the pregnant 
human uterus, and is thought to be involved in the preparation o f the 
myometrium for contraction at the time o f parturition through lowering the level 
o f cyclic AMP (Leroy et al 1994).
Rolipram and RP73401 have both been found to be effective in 
the relaxation o f smooth muscle in vitro (Souness et al 1995). Rolipram has 
also been shown to inh ib it non - cholinergic excitatory neurotransmission in 
guinea pig bronchi (Qian et al 1994). These results suggest that PDE4 inhibitors 
may have a dual effect in the treatment o f asthma as an anti - inflammatory and a 
bronchodilator, therefore tackling both problems o f providing symptomatic 
re lie f and treatment o f the underlying causes o f the condition.
Isolation, purification and characterisation o f PDE4 would 
therefore provide some o f the information needed to improve upon current drug 
therapy, by aiding the development o f specific cellular and tissue selective 
inhibitors. Along w ith this, molecular biology would aid identification o f 
further subtypes o f the PDE4 fam ily and improve and build on our knowledge 
o f the distribuition o f PDE4 subtypes.
1.16 Isolation o f a Human Monocvte Cvclic AMP Specific
Phosphodiesterase - hPDE4Ay iv j
In addition to the isolation o f rat homologues to the Drosophila 
cyclic AMP PDEs, a cDNA clone representing a high a ffin ity , rolipram 
sensitive cyclic AMP PDE (hPDE4ALivi> Gene Bank descriptor HPDE4A1 A) 
has been isolated from a human monocyte cDNA library using the conserved 
region o f R DI as a probe (L iv i et al 1990, McHale et al 1991). The human 
cDNA clone hPDE4ALivi» contains significant homology w ith other cloned 
PDEs namely R D I, DPD and Drosophila dunce PDE. These PDEs have
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homologous sequences in two domains, a forty amino acid region located 
amino terminally and a larger 270 amino acid region in the central portion o f the 
sequence. This larger region is conserved throughout a range o f PDEs from 
other species (Charbonneau 1986) and is proposed to contain the catalytic 
domain o f these PDEs. Amino acid sequence divergence exists at both the NH2 
terminal and at the COOH-terminal o f the hPDE4ALivi, sites which most likely 
serve a regulatory function or define subcellular location.
The recombinant protein hPDE4ALivi has been expressed in 
both COS-1 cells (Livi et al 1990) md Saccharomyces cerivisiae (McHale et al 
1991, Torphy et al 1992). A  molecular weight of 77kDa was determined for 
hPDE4ALivi from the predicted amino acid sequence. In COS-1 cells the cDNA 
was shown to encode a high affinity, cyclic AMP specific PDE which was 
selectively inhibited by rolipram (Livi et al 1990). Bolger et al (1993) have since 
isolated the cDNA clone representing the entire sequence of hPDE4ALivi and 
have shown this PDE to be truncated at the amino terminus. Despite this 
hPDE4ALivi is a catalytically active enzyme.
Upon the stable transfection o f hPDE4ALivi into Saccharomyces 
cerivisiae which lacked endogenous PDE activity, the molecular weight was 
determined to be 88kDa (Torphy et al 1992). The molecular weight determined 
from  the predicted amino acid sequence was 77kDa (L iv i et al 1990). 
Presumably the disciepency reflects post translational modification particular to 
Saccharomyces cerivisiae . Yeast expressed hPDE4ALivi displayed sim ilar 
kinetic characteristics to that o f the COS-1 cell expressed enzyme with respect to 
cyclic AMP hydrolysis and that it was selectively inhibited by PDE4 specific 
compounds (Torphy et al 1992).
1.17 Isolation o f a PDE4 PDE From Human Brain
Since the discovery and isolation of rat homologues of the 
drosophila dunce gene (see section 1.9 iv) attention has focused on the human 
counterparts, for example hPDE4ALivi described in section 1.12. McLaughlin
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et al (1992) have since reported the isolation o f another human PDE4 isoform, 
hPDE4B (Gene Bank descriptor HSPDE4B2A), isolated from a human frontal 
cortex cDNA library which was cloned by virtue o f its homology to the 
conserved region o f hPDE4ALivi* The hPDE4B enzyme was found to be 
restrictively expressed in human brain, heart, lung and skeletal muscle. In 
contrast to the study by Engels (1994), McLaughlin et al (1992) were unable to 
detect PDE4B in placenta, live r or kidney. On the basis o f their data 
McLaughlin et al (1992) stated that since PDE4B activity was undetectable in 
blood enriched tissue such as placenta then PDE4B does not have a function in 
monocytes. This must be viewed questionably given the results o f the study by 
Engels 1994, which showed that the PDE4B isoform is present in most 
circulating blood cells except T-cells, although the differences could be due to 
the different techniques employed.
McLaughlin et al (1992) classified the PDE4B gene as such due 
to the observation that it  encoded a low Km, cyclic AMP specific PDE with a 
predicted molecular weight o f 64.2 kDa and was selectively inhibited by 
rolipram and RO20-1724.
1.18 Isolation of a Human PDE4D
The cDNA for a human PDE4D isoform has been isolated from 
a human heart cDNA library using a sequence found in the rat PDE4D as a 
probe (Baecker et al 1994). The cDNA was shown to encode an enzyme which 
was 604 amino acids long w ith predicted molecular weight o f 68.5kDa, and 
was found to be 91.4% homologous w ith the rat PDE4D. The enzyme was 
engineered for expression in a bacterial system and was shown to be sensitive 
to rolipram w ith an IC 50 o f 2 .2|iM . Northern blot analysis found the PDE4D 
transcript to be most abundant in skeletal muscle but was absent from liver and 
pancreas.
1.19 Kinetics o f Cvclic AMP Hvdrolvsis and Inhibition bv Rolipram
o fPDE4
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(ilKinetics o f Cvclic AMP Hvdrolvsis
Cyclic AMP hydrolysis via the human PDE4 isoforms which 
have been reported to date, consistently appear to be o f simple, saturation 
Michaelis-Menten kinetics yeilding Km values which are in the micromolar 
range characteristic o f the PDE4 class. This has shown to be the case for the 
recombinant monocyte isoform hPDE4A_Livi expressed in  COS-1 cells (Km 
2.3pM, L iv i et al 1990) and yeast (Km 3.1}iM, Torphy et al 1992), hPDE4B 
isoform cloned from brain and expressed in yeast (Km 4.3|iM , McLaughlin et 
al 1992) and PDE4 activity isolated and purified from monocytes (Km 1.6p,M,
Torphy et al 1992).
('iiïïnhibition bv Rolipram
The mechanism by which rolipram exerts its inhibitory effect on 
PDE4 has been less well characterised than that o f substrate hydrolysis. Indeed, 
evidence to date has suggested that the mechanism o f inhibition by rolipram 
may be anomolous based on the observation that log dose response curves 
showed a shallow profile (Toiphy et al 1992, Bolger et al 1993, McLaughlin et 
al 1993), that is they ranged over several orders o f magnitude. Additionally, 
double-reciprocal plot data o f kinetic studies on the hPDE4ALivi enzyme (L iv i 
et al 1990, Torphy et al 1992) and the hPDE4B enzyme (McLaughlin et al 
1993) does not f it  to simple competitive kinetics. In ligh t o f this it has been I
suggested that PDE4 PDEs may possess a distinct binding site fo r rolipram i
(L iv i et al 1990, Torphy et al 1992) which could be distinct from  the site o f
catalysis.
(iiilH igh  A ffin itv Rolipram Binding Site Detected in Rat Brain i
High affin ity rolipram binding was firs t reported by Schneider et 
al (1986) where it was shown that ^H-roIipram bound to sites in rat brain with i
high affin ity (Kd ~2nM) in a saturable, reversible and stereoselective manner.
The authors assumed that the rolipram binding site was that o f PDE4, either its 
catalytic site or a distinct allosteric site. Evidence for a distinct rolipram binding
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site in rat brain came from studies in which it was shown that there was a 
difference (-500 fold) in the concentration o f rolipram  needed to achieve 
inhibition o f catalysis o f rat brain PDE4 (ki - Ip M  Némoz et al 1989), and the 
Kd (-2nM  Némoz et al 1989, Schneider et al 1986) o f rolipram binding to its 
high affin ity site. This suggested that the high a ffin ity  rolipram binding site 
observed by Schneider et al (1986) in rat brain was one distinct from the 
catalytic site.
Attempts to prove that the high affinity rolipram binding site was 
associated with PDE4 have been d ifficu lt. Schneider et al (1986) have shown 
that ^H-rolipram binding is mainly restricted to the brain in the rat, and has 
failed to show high affin ity rolipram binding in tissues outwith the CNS, even 
although they are known to contain PDE4 activity. Regardless, the nature o f the 
high a ffin ity  binding detected by Schneider et al (1986) was shown to be 
associated w ith both the soluble and membrane fractions o f rat brain 
homogenates, w ith  Kd values o f 2.4nM and 1.2nM respectively. The 
corresponding H ill coefficients o f rolipram binding were near unity, which 
suggests that rolipram is binding to one site only. Interestingly, rolipram was 
shown to bind stereospecifically w ith the (R )-rolipram conformation being 
more potent at displacing ^H-rolipram, and that binding was dependant upon 
the presence o f divalent cations, particularily magnesium.
The function o f the high affin ity rolipram binding site in brain is 
unknown, although it is thought that the site is preferentially associated with 
neuronal cells as opposed to g lia l cells (Tohda et al 1994). In addition, ^H- 
rolipram binding along w ith ^H-cyclic AMP binding has been located to post- 
synaptic pyramidal cell bodies (Kato et al 1993) in the gerbil brain. In the gerbil 
hippocampus there is a decrease in the binding o f ^ H-cyclic AMP, presumably 
to PKA, and ^H-rolipram  which preceeds the death o f pyramidal cells after 
CNS ischaemia (Kato et al 1993, Murase et al 1993). This suggests that the
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cyclic AMP second messenger system has a role to play in post ischaemic 
neuronal cell death.
(MThe Rolipram Binding Site o f Human PDE4
Analysis o f the mechanism by which PDE4 inhibitors effect 
substrate hydrolysis catalysed by the cloned human PDE4 isoforms has proved 
to be controversial. Although comparable Km values for cyclic AMP hydrolysis 
have been calculated for the monocytic PDE4 activity isolated from purified 
human monocytes to that o f the cloned monocyte PDE hPDE4ALivi (Torphy et 
al 1992), the kinetics o f rolipram inhibition were unclear. Rolipram was shown 
to be a competitive inhibitor o f the PDE4 activity isolated from monocytes but 
not o f the cloned hPD E4ALivi which was also shown to be inhibited 
stereoselectively by (R )-roUpram. W ith the isolation o f human PDE4 it has 
been questioned that these isoforms may posses such a high affin ity binding site 
fo r rolipram, as discussed fo r rat brain, considering the anomolous kinetics 
observed (Torphy et al 1992, L iv i et al 1990, McLaughlin et al 1993).
High a ffin ity  rolipram  binding was observed in the soluble 
fraction o f yeast expressing hPDE4ALivi w ith a Kd o f InM  and H ill coefficient
1.01 (Torphy et al 1992) demonstrating that, akin to rat brain, probably only 
one binding site for rolipram is present on hPDE4ALivi- The two stereoisomers 
o f rolipram were shown to inhibit cyclic AMP hydrolysis o f hPDE4ALivi w ith 
greater potency than that o f human monocytic PDE4, w ith K i values o f 6 InM  
and 390nM fo r (R ) and (S )-rolipram respectively. Human monocytic PDE4 
hydrolytic activity was not inhibited in a stereospecific manner by rolipram, and 
was inhibited relatively less potently w ith a K i o f 0.8pM. PDE4 inhibitor (R )~ 
rolipram along with RO-20-1724 showed greater potency (10 - 100 fold) for 
displacing ^H-rolipram  from the high a ffin ity  site than fo r inh ib ition o f 
hPDE4ALivi* Selectivity fo r competition at the high a ffin ity  site over PDE4 
inhibition has also been shown for rolipram anologues in mouse brain (Koe et 
al 1990). This difference o f rank order potency between displacement o f ^H-
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rolipram  and inh ib ition  o f PDE4, along w ith the discrepancy between 
concentrations o f rolipram needed to inhib it PDE activity over that needed to 
displace ^H-rolipram, could indicate that the high affin ity site has a function 
other than inhibition o f catalysis. This idea can only be treated speculatively 
considering the differences o f rolipram inhibition between the recombinant 
PDE4 and that isolated and purified from human monocytes. One argument for 
this could be that the groups necessary for high affin ity binding are susceptable 
to cleavage upon the purification proceedure. PDE4 isolated from U937 cells 
(DiSanto &  Heaslip 1993, 1995) was shown to be activated by phosphatidic 
acid (5 - 50 jig  /  m l). This activation was inhibited by nM concentrations o f 
rolipram which suggested that phosphatidic acid could be interacting with the 
high affin ity rolipram binding site. However, the authors DiSanto and Heaslip 
(1995) could not detect any high affin ity binding in crude, purified or stabilised 
U937 cells, whereas they could detect such in rat brain homogenates. Thus, the 
inability to detect high affin ity binding seems unlikely to be associated w ith the 
purification o f PDE4 from U937 cells. The ability o f enantiomers o f rolipram to 
show selectivity fo r the inhibition o f PDE4 isolated from guinea pig eosiniphils 
was effected by purification (Souness et al 1993), however, the authors could 
not detect high a ffin ity  binding o f rolipram in  either purified or crude cell 
samples.
(v)High A ffin itv  Rolipram Binding Outwith the CNS
High a ffin ity  rolipram  binding has been associated w ith 
stimulation o f acid secretion in isolated rabbit gastric glands (Barnette et al 
1995) and the accumulation o f cyclic AMP in guinea pig eosiniphils (Souness et 
al 1993).
In clinical trials which measured the efficacy o f rolipram as an 
antidepressant, one o f the side effects noted was gastrointestinal problems 
(Horowski &  Sastre-Y -Hernandez 1985). PDE4 inhibitors were since found to 
inhibit cyclic AMP elevation in parietal cells which resulted in the stimulation o f
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acid secretion via PKA. This was shown to be sim ilar to the acid secretion in 
response to histamine, an activator o f cyclase (Choquet et al 1990). The ability 
o f rolipram  to increase acid secretion in isolated gastric glands has been 
correlated with binding to a high affin ity rolipram binding site (Barnette et al 
1995). Similar to the study w ith recombinant PDE4 (Torphy et al 1992), the (R 
)-rolipram enantiomer was more potent than the (S )-enantiomer for competition 
at the high a ffin ity binding site and increase in acid secretion (Barnette et al
1995). (R )-rolipram was shown to displace ^H-rolipram with an IC50 o f 3nM, 
to increase acid secretion w ith an EC50 o f 4nM but the IC 50 fo r PDE4 
inhibition in these cells was 1.4|iM. Thus, there was an ~350 fold difference in 
the concentration o f rolipram needed to compete for the high affin ity site and 
that necessary for inhibition o f substrate hydrolysis. However, there was little  
correlation between increase in  acid secretion and PDE4 inhibition, which 
suggests, according to the author, that the functional effect o f rolipram in this 
tissue is through an interaction with the rolipram high affin ity site.
In explanation o f this data and the anomolous kinetics observed 
with rolipram, Torphy et al (1992) and Barnette et al (1995) have suggested that 
/ catalysis and inhibitor binding occur at the same site, but that this site exists on 
two non-interconvertible forms o f PDE4 which have similar affinities for cyclic 
AMP, as shown by the linear kinetics o f cyclic AMP hydrolysis, but differ with
i respect to their inhibition by compounds such as rolipram  or RO-20-1724 
giving rise to the non-competitive inhibition observed.
In support o f the theory by Barnette et al (1995) that the high 
affin ity site is not involved in the inhibition o f catalysis, a sim iW  conclusion 
was reached by Schudt and Hatzelmann (1995). PDE4 isolated from human 
neutrophils was shown to have both high and low affin ity binding components 
(Schudt and Hatzelmann 1995). Competition studies using ^H-rolipram or ^H- 
RP73401, a Rhdne-Poulenc compound, in the presence o f the Syntex 
compound RS25344 showed that high and low a ffin ity  K i values could be
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calculated for several PDE inhibitors. In conclusion of this study in neutrophils, 
the authors demonstrate that the low affin ity binding and inhibition o f catalysis 
are related, whereas high affin ity binding and catalysis are not.
The accumulation o f cyclic AMP in response to PDE4 inhibitors 
in guinea pig eosiniphils is also thought to be through interaction with a high 
affin ity rolipram binding site (Souness et al 1993). In this study (R )~rolipram 
was shown to inhib it solubilised PDE4 more potently than (5 )-rolipram, and 
this stereoselectivity was only evident upon the solubilisation o f the membrane 
bound form. Although high a ffin ity  rolipram  binding sites could not be 
detected, the stereoselectivity shown by rolipram upon solubilisation o f the 
enzyme suggested that a high affin ity site similar to that detected by Torphy et al 
(1992) and Barnette et al (1995) was involved. The authors determined a 
correlation between the ability o f PDE4 inhibitors to displace ^H-rolipram from 
binding sites on rat brain membranes, w ith the ability to inh ib it catalysis o f 
solubilised PDE4 from eosiniphil membranes and w ith the stimulation o f cyclic 
AMP accumulation in whole cells (Souness et al 1993). Souness et al (1993) 
suggest that upon solubilisation o f eosiniphil membranes a stereospecific site is 
exposed, which is similar to that detected in rat brain (Schneider et al 1986) and 
which allosterically regulates catalysis. Thus, in contrast to Torphy et al (1995), 
Souness et al (1993) suggest that the functional effect o f rolipram  on 
eosiniphils, that is, cyclic AMP accumulation, is the result o f the interaction o f 
rolipram with a high affinity site and also to the catalytic site.
1.20 PDE7 High A ffin titv  Cvclic AMP Specific PDE
This relatively recent class o f cyclic AMP specific PDEs was 
originally cloned from a human glioblastoma cell line (Michaeli et al 1993). This 
study used a sim ilar principle to that fo r the isolation o f DPD (C olicelli et al 
1989) and the yeast PDE2 gene (Sass et al 1986), where a ras2 va ll9  mutation 
in the yeast expression system resulted in constitutively high cyclic AMP levels 
and rendered the yeast sensitive to heat shock (see section l . l l ( i i )  fo r details).
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Michaeli et al (1993) took a slightly different approach in that cyclic AMP levels 
were elevated by deletion o f both o f the PDE genes present in Saccharomyces 
cerivisiae PDEl and PDE2 and so the yeast were sensitive to heat shock.
The human gene isolated by this method, HCPl, encoded a PDE 
with significant homology to other cyclic AMP PDEs including the -270 amino 
acid region proposed to contain the catalytic site (Chabonneau et al 1986, Chen 
et al 1986). However, upon biochemical analysis HCPl activity displayed a 
high a ffin ity fo r cyclic AMP (Km 0.2|iM ), but was distinct from the PDE4 in 
that HCPl was insensitive to inhibition by RO20-1724 or rolipram. HCPl 
activity was also unaffected by cyclic GMP. Northern blot analysis showed that 
H CPl was predominantly expressed in skeletal muscle w ith less activity 
expressed in heart and kidney.
PDE7 soluble PDE activ ity has also been isolated from  
hepatocytes which is insensitive to inhibition by IBM X and shows an aberrant 
response to M g^+, in contrast to PDE4 activity also present in hepatocytes 
which are activated dose-dependently by Mg^+ and Mn^+ (Lavan et al 1989).
The novel PDE7 class, their distribution and physiological role 
remains a topic under current investigation.
In conclusion, PDE4 fam ily is one o f great importance and has 
certain therapeutic potential as the target for specific inhibitors. However, to 
enable this a greater understanding o f this enzyme class is needed, particularily 
concerning the kinetics o f rolipram inhibition and the regulation o f the enzyme 
class, which can be achieved through the study o f cloned enzymes efficiently 
expressed in yeast and mammalian derived cell lines.
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Table 1 E^ prgssÎQii 9f £KA,i>»Myp^s I and II
Tissue Subtype PKA Expressed Upon Stimulation W ith Hormone
Typ.e I Typçn
Hepatocytes Glucagon —
Ovarian --- HGH
Corpus Luteum HGH ---
Osteoblasts Parathyroid Hormone Prostaglandin E%
HGH = Human Gonadotrophic Hormone
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Tabig la Comparison of. Ctiaragtgristiçs of ProsophUa 4unç 
PPEjsilh RPl and PPB.
Enzyme Kjjj cyclic AMP 
(itM )
K i (jiM ) 
Rolipram RO-20-1724
dune 2 >100 >100
RDI 4.111.1 0.710.1 4.210.6
DPD 2.910.5 0.510.1 1.710.2
This data was from Henkel - Tigges and Davis 1989
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Table lb  Pgtgçtjpn of Human FPE4 m Hwman Tisgpgs and 
PgünM -.Çgll Lings
PDE4A PDE4B PDE4C PDE4D
Brain + + 4—l- -j—t- ■f-f-
Liver ++ 4—l- 4—h 4-4-
Lung 4-4- 4-4- -K-f •4--+-
Trachea 4-4- 4-4- 4—h ■p-f-
Kidney 4-4- -H-}- 4-4- 4-4-
Placenta 4—H 4-4- f- 4-4-
Heart 4-4- 4—h -f-1 4-4-
Blood ■4-4- 4—h - -f--f-
U937 cells 4-4- 4-4- - 4-4-
Jurkat cells 4—k - - -
Namalwa cells 4"+* 4-4- - -
Neutrophils ± 4-4- - ±
Eosinophils 4-4- 4-4- - 4-4-
Neuroblastoma cells 4-4- -1— 4-4- 4-4-
This data was taken from Engels et al 1994. 
++ = expression 
± = weak expression 
- = no expresion
Table le  Nbffigpçlatiire„£Qi: RaLÏ^PE.4 Spfçigjg
Present
Nomenclature
Previous
Nomenclature
Conti &  Swinnen (1990) 
Nomenclature
4A IVA ratPDE2
4B IVB ratPDE4
4C IVC ratPDEl
4D IVD ratPDES
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Fis. L lil Reaction Scheme of Adenvlvl Cuclase
The figure shows the reaction scheme of adenylyl cyclase with the conversion 
of adenosine triphosphate to 3'5' - cyclic AMP.
i
1
'■5:I.sc
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ADENOSINE TRIPHOSPHATE (ATP) Y " '
O
I t
o
II o
O - CH
OH OH
A d en y ly  cyclase 
+ Mg2+
3’5  CYCLIC ADENOSINE 
MONOPHOSPHATE
+  2 P i
CH
iOH0 = P O
Fig. 1.4.2 Schematic of G-Protein Cycling
Binding o f the agonist to the receptor causes dissociation o f the beta-gamma 
complex from the activated alpha subunit,which has exchanged GDP for OTP. 
The alpha subunit is able to interact w ith such effector systems as adenylyl 
cyclase. The intrinsic GTPase activity o f the alpha subunit switches o ff the 
signal via the hydrolysis o f GTP to GDP. The GDP bound alpha subunit can 
reassociate with the beta-gamma complex.
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Fig. 1.10.3 Schematic Alignment of Mammalian PDE
Isoform Families
This figure diagramatically shows the structural features o f mammalian PDE 
isoforms. (Beavo &  Reifsnyder 1990).
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calmodulin binding 
domain
l**4 catalyticdomain
Ca^^-calmodutin-dependerfamily
cGMP binding domain catalyticdomain
cGMP-stimulatedfamily
? cAMP-specific
|4-
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cGMP binding catalyticdomain domain
cGMP-specificfamily
Fig. hlOA Scheiiiatlc_R€DresentatiQn Qf the Four Rat PDE 
£z±jQ£S
Numbers at the right indicate the number o f amino acid residues. The highly 
conserved region is shown by the unshaded area. The less homologous N and 
C terminal regions are shown by the shaded areas. F illed areas indicated by 
serine corresponds to the region which is homologous to the cyclic AMP 
binding domain o f PKA. PDE4A, B, C and D isoforms correspond to ratPDE2, 
4, 1 and 3 respectively. (Conti &  Swinnen 1990).
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Pro28
rat PDE1
Ser186 Met306
m  >411
Pro84
rat PDE2
Ser242 Met362
61(
Pro136
ratPDE3
Ser295 Met415 a  584
Leu132
ratPDE4 ]
Ser291 Met411
564
duncePDE
Ser82 Met202
362
100 —(
Fig. 1.13^ Aiisnm^nt of Puman and...EatJ"I>.E4 idRNA
Shown is the schematic representation o f the four human and rat PDE4 
mRNA's, at the top and bottom respectively. Common sequences are shown by 
heavy merged lines. Areas o f unique sequence which are conserved between 
human and rats, and are unique to any PDE4 subtype are shown by the thin 
cross hatched lines. Thin solid lines indicate variant sequence which is not 
conserved between human and rat. Triangles in the rat clones show variants 
lacking a block o f sequence as compared to other transcripts from the same 
locus. Initiation codons are shown by small boxes and termination codons by *. 
Vertical dashed lines show splice points that occur in homologous positions in 
clones from different loci. Roman numerals show various alternative spliced 
isoforms from the dune locus.
(Bolger et al 1993).
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Chapter - 2
Materials and Methods
 : ____________________
2. Matgriata and M t^hodis.
2.1 Solutions 
A ll solutions were prepared in double-distilled deionised water
and all pH measurements were determined using an Horiba F.8L pH meter.
2.2 Chemicals 
A lis t o f the chemicals used and their suppliers are listed in
appendix I.
2.3 Preparation o f Soluble and Pellet Associated Enzvme From
Xg.ast
A  primary yeast cell culture was made by selecting an isolated 
yeast colony from a plate o f yeast extract peptone dextrose (YPD) agar, using a 
sterile Eppendorf tip, which was placed into 50ml YPD liquid media and grown 
fo r 16 hours in a shaking incubator at 30°C. A fter this in itia l 16 hours o f 
growth, the entire 50ml primary culture was used to innoculate IL  o f YPD 
liqu id  media and grown fo r 20 hours, at 30^0 in  a shaking incubator. 
Follow ing the 20 hour incubation, the cell suspension was centrifuged at 
3200rpm (lOOOgav) for 10 minutes in the Beckman J21 centrifuge w ith a JA20 
rotor. Cell pellets were resuspended in 80mM Triethanolamine - HCl, 5mM 
MgCl2 buffer pH 7,4 with KOH containing a mixture o f protease inhibitors at a 
final concentration o f 40p.g/ml - PMSF, 156p,g/ml benzamidine and Ip-g/ml 
each o f aprotonin, leupeptin, pepstatin A, and antipain. The protease inhibitors 
were in itia lly  dissolved as a lOOOx stock in 100% DMSO before addition to the 
buffer. Cells were lysed by subjection to 4 passes through a FrenchR Pressure 
Cell Press (SLM Instruments Inc.) at 960 psi. The resultant lysate was 
centrifuged 48,000rpm (210,000gav) for 45 minutes using the Ti50 rotor in a 
Beckmann ultracentrifuge. Aliquots o f both pellet and supernatant were assayed 
for PDE activity immediately and residual material stored at -BOOC for later 
analysis.
2.4 Phosphodiesterase Assav
60
 :   ....
Cyclic nucleotide phosphodiesterase activity was assayed by a 
modification o f the two - step procedure o f Thompson and Appleman (1971) 
and Rutten et al (1973) as described previously by Marchmont and Houslay 
(1980). Here ^H -cyclic AMP (S-^H-adenosine 3'5'-cyclic phosphate) was 
diluted in 20mM Tris-HCl, lOmM MgCl2 pH7.4 and the unlabelled cyclic 
AMP. 50pl o f this solution (approx. O.ZpCi) was then added to the tubes 
containing 15-30|ig protein and the volume made up to l(X )|il w ith 20mM Tris- 
HCl, lOmM MgCl2 pH7.4. Samples were incubated at 30^C for 10 minutes 
and boiled for 1 minute to terminate the reaction. The protein concentration used 
was shown to be w ithin the linear range o f the reaction o f protein vs activity, as 
shown in fig  2.4.2. This figure demonstrates that, at 3 |iM  cyclic AMP, the 
reaction is linear over the range o f 1 - 240pg protein. That the reaction was 
linear, shows that substrate is not a lim iting factor. To ensure that the 10 minute 
assay incubation time was in the linear range o f the reaction, enzyme activity 
was assayed over the range o f 1 - 10 minutes at 1 - 20|xM cyclic AMP (fig  
2.4.1). This analysis showed that a 2 minute lag occured in itia lly , w ith the 
reaction becoming linear after this time.
A fter allowing the samples to cool, 25pg o f snake venom (Ophiphaeus 
hannah-cobra. 1 mg/ml in 20mM Tris-HCl, lOmM MgCl2 pH7.4 ) was added, 
and the samples were incubated again at 30<^ C fo r 10 minutes. 400p,l o f a 
freshly prepared slurry o f Dowex:H20:ethanol (1:1:1) was then added, and 
follow ing incubation on ice fo r 30 minutes, the samples were centrifuged at 
12,000 rpm fo r 3 minutes in  a Jouan MR1812 bench centrifuge. 150pl o f 
supernatant was then removed into 2ml o f 'Ecoscint' scintillation flu id . The 
amount o f ^H-adenosine present was determined by counting on an LKB 
scintillation counter. A diagram describing the PDE assay reaction scheme is 
shown in figure 2.4,3.
For estimation o f kinetic parameters, the PDE assays were 
conducted using cyclic nucleotide concentrations ranging from  0,05p,M -
61
_________
100}iM. In order to calculate Km values, the data were fitted to the Michaelis 
Menton equation Vobs = (Vmax[cyclic AMP] /  (Km+[cyclic AM P]) using the 
U ltrafit graphical package. This non-linear fitting  programme obviates errors in 
fitting to the Lineweaver-Burke plot using regression analysis, where the spread 
o f errors is not evenly distributed as it  is a double-reciprocal plot. In each case, 
the 'robust weighting' fac ility  was used and the 'goodness o f fit ' index was no 
less than 0.99 with each estimation, 1 being a perfect fit..
Inhibitor analysis was performed w ith 3|iM  cAMP as substrate 
over a range o f inhibitor concentrations as shown in the appropriate figures.
PDE inhibitors were dissolved in 100% DMSO as a lOmM stock and diluted in 
20mM Tris - HCl lOmM MgCl% pH7.4 to provide a range o f concentrations for 
use in the assay. Inhibitors were added at a volume o f 25|o.l, which was 
included in the assay volume o f lOOpl. As such, a 4 times fina l inhib itor 
concentration was prepared, o f which, 25pl was added to the reaction. For each 
inhibitor, a DMSO control was included in the assay which contained the 
highest DMSO concentration used. In each case, the DMSO concentration was 
shown to have no effect.
2.5 Thermal Dénaturation.
Pellet and soluble fractions were prepared as described. Each
sample was pipetted into pre - warmed 20mM Tris - HCl lOmM MgCl% pH7.4 
contained in a glass bijoux which had been placed on a stirrer in a water bath set 
at the temperature for the particular experiment. A t the time points shown on the 
appropriate figure a lOOjil sample was removed and placed in  an Eppendorf I
microfuge tube which had been kept on ice. PDE activities were then measured 
at IfiM  cAMP in the assay mixture described above in section 2.4.
2.6 Protdn Pgfôrniipation
Protein was measured by the method o f Bradford (1976).
Standard solutions o f bovine serum albumin were prepared in the range o f 0- 
100jig  in  d istilled  water. The unknown samples were solubilised by the
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addition o f 0.2% Triton X -100 and left on ice for 30 minutes. The standard and 
unknown protein solutions were made up to a volume o f SOOpl w ith distilled 
water before the addition o f 200pl o f Bradford reagent. Absorbances were 
determined at 595nm using an LKB spectrophotometers and the unknown 
concentrations determined from the standard curve.
2.7 Preparation o f Svnaptosomes
The method detailed here is as described in Dunkley et al
(1988),
i) Tissue preparation
Brain tissue ( - Ig )  was removed from freshly sacrificed adult 
male Sprague-Da wley rats and placed in ice cold gradient buffer containing 
0.32M sucrose, Im M  EDTA and 0.25mM dithiothreitol pH7.4. The tissue was 
then roughly chopped and homogenised in 10 volumes o f gradient buffer using 
10 passes at 700rpm (Janke &  Kunkel IKA-Labortechnik RW20). Homogenate 
was then filtered through two layers o f guaze before centrifugation at 3200rpm 
(lOOOg) for 10 minutes in the Beckman J21 centrifuge w ith a JA20 rotor. This 
post nuclear supernatant (S I) was loaded onto the step gradients.
ii) Percoll-Sucrose Solutions
Solutions o f 23%, 15%, 10% and 3% Percoll (density 1.129g/l) 
were made up in gradient buffer and adjusted to pH7.4 w ith HCl or NaOH 
before use. Volumes o f 2ml o f each o f the Percoll-Sucrose solutions were 
layered in 15ml corex tubes using an LKB 2232 Microperspex S peristaltic 
pump. A  2ml volume o f the S I fraction was then layered onto the gradients 
which were centrifuged at 20,000rpm (32,500g) for exactly 5 minutes in  a 
Beckmann J21 centrifuge with the JA20 fixed angle head.
iii)  Fraction Collection
Interfacial fractions, 4 bands and a pellet, were collected using a
pastuer pipette and pooled from each gradient. Fractions were washed twice by
resuspension in 10ml gradient buffer and centrifuged fo r 15 minutes at
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13,800rpm (15,000g) using the Beckmann JA20 rotor in  the 121 centrifuge. 
A fter this final stage the fractions were resuspended in 0.6ml gradient buffer 
w ith the exception o f experiments where the synaptosomal fractions were 
hypotonically shocked to prepare pellet and soluble fractions. The hypotonic 
buffer was the same as the gradient buffer except it  did not contain 0.32M 
sucrose. Protease inhibitor cocktail containing a mixture o f protease inhibitors at 
a final concentration o f 40)ig/ml - PMSF, 156|ig/ml benzamidine and Ipg/m l 
each o f aprotonin, leupeptin, pepstatin A, and antipain was added to the buffer. 
The protease inhibitors were in itia lly  dissolved as a lOOOx stock in 100% 
DMSO before addition to the buffer. The lysate was then centrifuged 
48,0(X)rpm for 45 minutes in a Beckmann ultrcentrifuge using the TL-100 
rotor. The resultant pellet was re suspended in a suitable volume o f gradient 
buffer. A ll fractions were then aliquoted, frozen in liquid nitrogen and stored at 
-80'C.
2.8 Subcellular Fractionation o f Svnaptosomes bv Continuous
Sucrose Gradients
Subcellular fractionation was carried out essentially as per 
Shakur et al (1993).
i) Cell Lvsis
Synaptosomal fractions were prepared as in chapter section 2.7
iii)  except at the final resuspension stage where fractions 2,3 and 4 were pooled 
and resuspended in 1ml o f lysis buffer pH8.1 containing 5mM Tris-HCl and 
50|iM  calcium chloride. Lysate was le ft on ice fo r 45 minutes before 
rehomogenisation and centrifugation at 2000rpm in a Jouan MR 1812 bench 
centrifuge to give a post-nuclear supernatant.
ii) Preparation o f Membranes
Gradients were layered using an LKB 2232 Microperspex S 
peristaltic pump. Post-nuclear supernatant (~ lm l) was loaded onto a gradient 
consisting o f 3ml 0.5M sucrose layered onto 1ml o f 1.6M sucrose, and
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centrifuged 50,000rpm fo r 30 minutes using an SW55 swing out rotor. 
Membranes were harvested at the 0.5M/1.6M interface. Solid sucrose was then 
added to the membranes to give a concentration o f >1.6M. A ll sucrose solutions 
were made up in lysis buffer (see chapter section 2.8 i) fo r recipie).
iii) Continuous Sucrose Gradient
A continuous gradient o f 0.6M - 1.6M sucrose was prepared 
using a gradient mixer. Membranes were loaded into the bottom o f the tube and 
centrifuged at 50,000rpm for 18 hours in the SW55 rotor. Samples were 
collected in 2(X)|il aliquots using the perstaltic pump, frozen in liquid nitrogen 
and stored at -80*C.
2.9 Acetvlcholinesterase Assav
Acetylcholinesterse hydrolyses acetylthiocholine to produce a 
th io l which exchanges w ith 5,5'-dithiobis-2nitrobenzoate (DTNB). This 
compound is yellow and can be measured by following the change in the optical 
density at 412nm. This method was as described by Ellman et al (1961).
B riefly, activity was measured using the follow ing method. For 
this experiment an LKB spectrophotometer set at 412nm was linked to a chart 
recorder. Solutions containing KXlpl tissue sample (0.5-2.5mg/ml protein) and 
2.7ml o f O.IM  phosphate buffer pH8 were set up in 4ml glass tubes and 
incubated at 37"C fo r 30 minutes. Solutions were then cooled to room 
temperature. 0.1ml o f lOmM 5,5'-dithiobis-2nitrobenzoate in phosphate buffer 
and 0.1ml o f 15mM acetylthiocholine iodide were then added to the tubes and 
mixed rapidly. The trace was followed for several minutes.
Activity was calculated using the following:
Molar extinction coefficient = 1.36x10^
p = protein concentration in mg/ml
A ctivity = Abs.units/min x Cuvette vol. x i  x 10^
1.36x10"^ Sample vol. p 
= |Limoles/min/mg
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2.10 Lactate Dehydrogenase Assav
Lactate dehydrogenase activity was measured as described by 
Marchbanks (1967). Enzyme activity was measured by the rate o f oxidation o f 
NADH which absorbs at a wavelength 340nm therefore, the rate o f decrease of 
optical density at 340nm is a measure o f enzyme activity. B riefly, 1.35ml o f 
0.15M Tris/HCl pH7.4 and 50|il o f each lOmM sodium pyruvate and tissue 
sample were added to a 1.5ml cuvette and used to zero a spectrophotometer set 
at 340nm and linked to a pen recorder. Free lactate dehydrogenase activity was 
measured by the addition o f 50|ll o f 2mM 6-NADH and the trace followed for 
several minutes. Finally 10% Triton/tris was then added to the cuvette to release 
entrapped activity and the total activity was calculated from this trace.
Lactate dehydrogenase activity was then calculated using the
following:
Occluded lactate dehydrogenase = Total - Free
Molar extinction coefficient = 6.22 x 10^
p = protein concentration in mg/ml
Activity = Abs. units/min. x Cuvette vol. x 1 x 10^
6.22x10^ Sample vol. p 
= nmoles/min/mg protein
2.11 5'-nucleotidase Assav
The activity o f 5'-nucleotidase was assayed according to the 
protocol detailed by Newby et al (1975) which was a m odification o f the 
radioassay o f Avruch (1971).
5'-nucleotidase activity was measured by the release o f 
adenosine from ^H-AMP. Reactions were set up in a 500pl volume containing 
a substrate solution o f 200|iM  AMP 'spiked' w ith 3pl/m l o f tritiated nucleotide 
which gave '-25,000 c.p.m. The volume was made up to 500pl w ith 50mM 
Tris-HCl pH8.0 buffer. Reactions were initiated with the addition o f lO jil o f 
particulate fraction and incubated for 15 minutes at 37“C, and then terminated
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by the addition o f lOOjil o f 0.15M ZnS0 4  and subsequently lOOjil o f 0.15M 
Ba(OH)2. Samples were then centrifuged for 5 minutes at 12,000rpm in a 
Jouan MR 1812 bench centrifuge. 500fil o f supernatant was then added to 5ml 
o f 'Ecoscint' and radioactivity was determined in an LKB scintilation counter.
2.12 Assay o f Adenylate Cyclase Activity
Adenylate cyclase (B.C. 4.6.1.1) activity was measured as 
described by Houslay et al (1976). Here an assay cocktail was prepared 
consisting o f an ATP-regenerating system (1.5mM ATP, 7.4mg/ml creatine 
phosphate, 0.2mg/ml creatine kinase and 0.8mg/ml BSA) in a buffer o f 25mM 
triethanolamine, 5mM MgS0 4 , lOmM theophylline, Im M  EDTA and Im M  
dithiothreitol, pH7.4. Drugs and membranes (20 - lOOpg) were then added as 
appropriate to give a final assay volume o f lOOpl.
Samples were then incubated at 30°C fo r 10 minutes, and the 
reaction was terminated by boiling for 2 minutes. The precipitated protein was 
pelleted by centrifugation fo r 5 minutes at 12,000rpm in a Jouan MR1812 
bench centrifuge and the supernatants were then removed fo r cyclic AMP 
determination (see chapter section 2.13).
2.13 Cyclic AMP Determination
Determination o f cyclic AMP content was based on the 
saturation assay o f Brown et al (1972) as described by Whetton et al (1983).
This assay depends upon the specific binding ability o f the cyclic 
AMP nucleotide to a cyclic AMP binding protein isolated and purified from 
bovine adrenal glands (see chapter section 2.14). Samples and binding protein 
are incubated together until equilibrium occurs and bound cyclic AMP is then 
separated from unbound by the use o f a charcoal/BSA suspension. The charcoal 
absorbs free nucleotides and therefore estimation o f ^H-cyclic AMP bound to 
the protein can be made.
Using a range o f known cyclic AMP concentrations, it is 
possible to construct a standard displacement curve from which estimations o f
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cyclic AMP content can be made. This is done by incubating increasing 
amounts o f unlabelled cyclic AMP with a fixed amount o f the tritiated nucleotide 
and binding protein. The portion o f cyclic AMP can in this way be reduced, as 
the unlabelled and tritiated species compete for a finite number o f binding sites 
on the protein.
Total cyclic AMP binding to the protein was determined by 
incubating the tritiated cyclic AMP in the absence o f the unlabelled species, 
whilst non-specific binding is estimated by the incubation o f tritiated cyclic 
AMP in the absence o f binding protein as well as unlabelled cyclic AMP.
For the assay, a series o f unlabelled cyclic AMP solutions were 
prepared ranging from 0-320pmoles m l"l. This was done by dissolving cyclic 
AMP in a buffer containing 50mM Tris/5mM EDTA pH7.4. Tritiated cyclic 
AMP (5.8-^H-adenosine 3'5’ cyclic phosphate) in 50% ethanol was diluted in 
this Tris/EDTA buffer to give approximately 500,000cpm/ml. lOOpl o f this 
solution was added to tubes containing 50|il each o f assay buffer, standard 
cyclic AMP solution or supernatant from the unknown samples. A fter mixing, 
100|il o f binding protein was added to the samples which were mixed again. 
Following incubation at 4"C for 2 hours, the binding reaction was terminated by 
the addition o f 0.25ml o f a BSA/charcoal suspension. This solution consisted 
o f 2% GSX-100 charcoal and 1% BSA suspended in ice cold assay buffer. The 
charcoal was pelleted from  the samples by centrifugation fo r 5 minutes at 
12,000rpm in a Jouan MR1812 bench centrifuge at 4”C. 400jil o f supernatant 
was removed into 'Ecoscint* scintillation flu id, and the samples counted in an 
LKB scintillation counter. This counter had an R IA curve fitting  programme 
which produced a standard curve (described above) by plotting cpm o f standard 
sample vs pmol cyclic AMP. Cyclic AMP content in  the unknown samples was 
automatically calculated from the standard curve. The binding assay gave 
optimum sensitivity between 0.25 and 8 pmoles/sample.
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2.14 Preparation o f Cyclic AMP Binding Protein from Bovine 
Adrenal Glands
The buffer used throughout this procedure contained 250mM 
sucrose, 25mM KC l, 5mM M gS04 and 50mM Tris-HC l pH 7.4 and all 
operations were performed at 4*C.
i) Dissection
Approximately 30 fresh bovine adrenal glands were used. The 
surrounding fat was removed and the gland was opened to lie flat. Medulla area 
(pale brown/pink) was removed by gently scraping w ith a scalpel. The darker 
cortex area was retained and the coating o f connective tissue was removed from 
it.
ii) Homogenisation
Tissue was homogenised in 200ml o f buffer in  a Waring
blender.
iii) Centrifugation
Homogenate was filtered through two layers o f muslin, which 
was washed in a small volume o f buffer, and centrifuged at 15,000rpm in a 
JA20 rotor at 4°C for 15 minutes. Supernatant was decanted through filte r 
paper, aliquoted and stored at -20°C.
2.15 SDS-PAGE Electrophoresis
Separation o f proteins by electophoresis was carried out in 10% 
polyacrylamide gel slabs as described by Laemmli (1970).
Samples (KXlpg protein) were dissolved in 20pl o f Laemmli 
loading buffer containing 5M urea, 0.18M SDS, 0.38M dithiothreitol, 0.05M 
Tris/HC l pH8 and bromophenol blue as the tracking dye and boiled fo r 5 
minutes. Electrophoresis was carried out in  a 'running buffer' o f 0.025M 
Tris/HCl, 0.19M glycine and 0.(X)35M SDS. When the dye front reached the 
edge o f the gel electrophoresis was stopped and the proteins transferred to 
nitrocellulose (see chapter section 2.16)
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2.16 Western Blotting
Proteins were transferred from  the polyacrylam ide gel to 
nitrocellulose 100% setting for 2 hours in a transblot apparatus (Hoefer 
Instruments). This method is essentially as detailed by H uff et al (1985). The 
'blotting buffer' used here contained 0.025M Tris with 0.19M glycine/methanol 
(4:1 v/v).
The nitrocellulose was then incubated in 20mM Tris/HCl pH7.5 
w ith 500mM NaCl (ie TBS) and 5% dried m ilk powder fo r 2 hours at room 
temperature. This stage blocks any non-specific protein binding. A fter 2 hours 
the 5% dried m ilk powder/TBS was poured o ff and the nitrocellulose washed 
briefly with distilled water before washing twice w ith TBS containing 0.2% 
Nonident P40 and twice with TBS each fo r 5 minutes. The nitrocellulose was 
then immunoblotted with TBS containing 1% dried m ilk powder and a 1:500 
dilution o f the appropriate antisera fo r 2 hours.
The antisera used in these experiments was 271 which was 
generated in rabbits against a peptide corresponding to the last 12 amino acids 
o f the R D I protein ((C)-T-P-G-R-W-G-S-G-G-D-P-A). R D I (rat '^ /wMC-like' 
cyclic AMP phosphodiesterase) is a type-IVA PDE which was cloned by 
homology from a rat brain cDNA library using the drosophola dune PDE 
cDNA as a probe (Davis et al 1989). The peptide was conjugated w ith keyhole 
limpet haemocyanin (KLH) facilitated by the synthesis o f a cysteine residue at 
the N terminus o f the peptide, according to the procedure o f Lemer (1981).
A fter immunoblotting the nitrocellulose was washed as before 
and incubated for 2 hours in TBS with 1% dried m ilk powder plus lOpl o f anti­
rabbit peroxidase linked IgG. The nitrocellulose was then washed 4 times for 5 
minutes each in TBS and labelled bands were detected using the Amersham 
ECL Western Blotting visualisation protocol.
2.17 Concentration o f Protein Samples
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I f  the samples to be used for Western B lotting were too dilute 
the follow ing precipitation protocol was followed. 100% trichloroacetic acid 
was added to the samples to give a final concentration o f 20%. Samples were 
left on ice fo r 10 minutes before centrifugation for 5 minutes at 12,000rpm in a 
Jouan MR1812 bench centrifuge. Supernatant was discarded and 20pl o f ice 
cold IM  Tris-base plus 20|il o f Laemmli loading buffer (see chapter section 
2.15) were added to the samples prior to boiling for 5 minutes.
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Results Chapter ■ 3
Characterisation of Human PDE4A h6.1
 ,  ___
3.1 Introdiifctisa.
The first PDE4 cDNA to be isolated was for the Drosophila dune 
enzyme (Chen et al 1986). Subsequent studies used this cDNA to probe 
mammalian cDNA libraries for PDE4 isoforms from rat (Davis 1990, Conti et al 
1990,1991) and human (L iv i et al 1990, McHale et al 1991, Bolger et al 1993, 
Sullivan et al 1994).
The PDE cDNA clone h6.1 (Sullivan et al 1994) described in 
this chapter was isolated from a human T-lymphocyte cDNA library using a 
PDE specific probe. This probe was generated by per using primers based on 
the published sequence o f hPDE4ALivi (L iv i et al 1990), a PDE4A isoform 
isolated from human monocytes. The per primers were fo r a highly conserved 
region representing part o f the catalytic domain o f hPDE4ALivi. This identified 
two overlapping clones which represented a PDE4 sim ilar to that isolated by 
L iv i et al (1990), but lacked the first 13 amino acids. These first 13 amino acids 
o f hPDE4ALivi were engineered onto the sequence o f h6.1 to provide an open 
reading frame as per that seen in the L iv i et al (1990) clone.
Expression o f h6.1 was enabled by engineering the cDNA for 
integration into the genome under the transcriptional control o f a constitutive 
yeast promoter at the pep4 locus (see Sullivan et al 1994 for details). This was 
done in a strain o f Saccharomvces cerivisiae which did not express either o f the 
two endogenous yeast PDE genes. Yeast strains rendered pde'^fpde'^ display 
the heat shock phenotye, due to elevated cyclic AMP levels, previously 
described (section l . l l ( i i ) ) .  Saccharomvces cerivisiae strains pde'^/pde'^ 
expressing the h6.1 cDNA clone, strain YMS 6, were shown to be insensitive 
to heat shock, whereas the pde~^fpde~^ untransformed control strain YMS 5 
did not, therefore it  was concluded that the h6.1 cDNA encoded a functional 
PDE.
Expression o f h6.1 in yeast provided an available source o f PDE 
that could be analysed in detail, in a manner which has not previously been
7 2
reported for a PDE4 isoform. The emphasis here is on defining the mechanism 
o f inhibition by the PDE4 specific inhibitor rolipram. Previously published data 
have suggested that the mechanism o f rolipram inhibition may be anomolous 
(McLaughlin et al 1993, Bolger et al 1993). In particular, the studies on the 
monocytic PDE hPDE4ALivi which appeared to show that the inhibition by 
rolipram did not comply with simple competitive inhibition. Detailed discussion 
o f the possible sources for this anomolous behaviour is given in chapter 1 
section 1.19, which relate to a rolipram binding site distinct from the catalytic 
site.
This chapter describes the characterisation o f a PDE4A isoform 
h6.1 (proposed GeneBank descriptor HSPDE4A7, accession number U18087). 
It reports on the kinetics o f substrate hydrolysis, the kinetics o f inhibition by the 
PDE4 selective inh ib itor rolipram  and the non-selective inh ib itor IB M X, 
inhibitor profile to other PDE inhibitors, thermostability, and divalent cation 
dependancy.
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3 .2  RgSUltS
filA c tiv itv  o f Yeast Cell Lvsates Expressing h6.1 and Yeast Cell 
Lvsate Expressing Control Yeast Strain YMS5 
Cell homogenates o f the control yeast strain YMS 5 and the yeast 
strain expressing h6.1, YMS6, were disrupted by means o f a cell press and 
assayed for PDE activity at the substrate concentration o f l|xM  cyclic AMP. 
Control strain cell lysate YMS5 failed to hydrolyse cyclic AMP, whereas YMS6 
cell lysate hydrolysed cyclic AMP with specific activity o f 5 - 9 pmol cyclic 
AMP /min /  mg over a range o f 25 separate preparations.
Characteristically h6.1 behaved as a PDE o f the PDE4 isoform 
class. The cyclic AMP hydrolysing activity o f h6.1 was unaffected by the 
addition o f calcium/calmodulin (20ng/ml), low concentration o f cyclic GMP 
(lOpM) and was unable to utilise cyclic GMP as a substrate (<1% activity seen 
with cyclic AMP).
tiPLocation o f h6.1 to the Pellet or Soluble Fraction o f YMS 6 
Lvsates
Disrupted cell homogenates were centrifuged 210,000gav for 
45min, after which the pellet and supernatant fractions were assayed fo r PDE 
activity at a substrate concentration o f Ip M  cyclic AMP. Over a range o f 25 
observations it  was noted that between 22-48%  o f the total PDE activity was 
present in the supernatant fraction, the residual activity being in the pellet. 
Specific activities were shown to range from 16.5 - 34.4 pmol cyclic AMP /min 
/  mg fo r the pellet fraction, and 2.1 - 6.3 pmol cyclic AMP /m in /  mg for the 
soluble fraction, over a range o f 25 observations. The considerable activity 
present in the pellet was not removed by recentrifugation or made soluble with 
either TXlOO, used over the range (0.1% - 2%) or sodium chloride used at a 
range o f 0.5M - 2M,
(iii)Thermostabilitv o f Pellet and Soluble h6.1
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The thermostability o f both pellet and soluble h6.1 was assessed 
at 45“C and 50"C. In each case the pellet and soluble forms o f h6.1 decayed as 
a single exponential yielding linear semi-log plots o f residual activity against 
time (fig  3.2.1). A t both temperatures studied the pellet form  o f h6.1 was 
considerably more stable w ith tQ.5 values o f >30 minutes and 20 minutes fo r 
45“C and 50"C respectively. The to.5 values calculated fo r the soluble form 
were 10 minutes and 2 minutes fo r the temperatures 45°C and 50°C 
respectively.
fivlBivalent cation Dependencv
Addition o f the chelating agent EDTA in the PDE assay medium 
(Mg2+ free) resulted in the dose-dependent inhibition o f PDE activity. The 
ab ility o f magnesium chloride, manganese chloride, and calcium chloride to 
reactivate the PDE activity was assessed (fig  3.2.2). Both magnesium and 
manganese chloride were able to activate native PDE activity and reactivate PDE 
activity in the presence o f 0.25mM EDTA. However, calcium inhibited the 
native PDE activity (fig 3.2.2, table 2).
IvlK inetics o f Cvclic AMP Hvdrolvsis bv h6.1
The Km  value fo r the hydrolysis o f cyclic AMP by both the 
soluble and pellet forms o f h6.1 were determined from Lineweaver-Burke plots 
(fig3.2.3). In each instance, the double-reciprocal plots o f in itia l rate versus 
cyclic AMP concentration for h6.1 activity were linear over a wide substrate 
concentration range o f 0.05 - lOOfiM cyclic AMP and displayed simple 
saturation kinetics. In  order to calculate Km values, the data were fitted to the 
Michaelis Menton equation Vobs -  (Vmaxlcyclic AMP] /  (Km+[cyclic AMP]) 
using the U ltrafit graphical package. This non-linear fitting programme obviates 
errors in fitting  to the Lineweaver-Burke plot using regression analysis, where 
the spread o f errors is not evenly distributed as it  is a double-reciprocal plot. In 
each case, the 'robust weighting' fac ility  was used and the 'goodness o f fit ' 
index was no less than 0.99 w ith each estimation, 1 being a perfect fit. This
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analysis yielded Km values o f 4.1±1.7|iM  for the soluble form and 5.2±1.5|j.M 
for the pellet form o f h6.1 (n=6 in each case).
(vi)Inhibitor Profile o f h6.1
The ability o f PDE4 selective compounds rolipram and RO-20- 
1724, the non-selective compound IB M X  and the PDE3 selective compound 
cilostim ide to inh ib it substrate hydrolysis o f h6.1 activity was assessed. The 
substrate concentration used in these experiments was 3jJ,M, a concentration 
which reflects that o f the Km value.
The inhibitor profile for h6.1 was typical o f a PDE4 isoform, where substrate 
hydrolysis was more potently inhibited with rolipram (fig. 3.2.4,, table 3) and 
RO-20-1724 (fig. 3.2.5, table 3) than IBM X (fig. 3.2.6, table 3) or cilostimide 
(fig. 3.2.7, table 3). IC 50 values (concentration o f inhib itor which produced 
50% reduction in substrate hydrolysis) were then calculated for each compound 
from the dose response curves, and K i (inhibition constant) was calculated by 
application o f the Cheng-Prusoff equation (Cheng and Prusoff 1973) K j = IC50 
/  1 + (S /  Km)> which assumes competitive inhibition (table 3).
(vii)Kinetics o f Inhibition o f h6.1 bv IBM X and Rolipram
Both the soluble and pellet fractions o f h6.1 were competitively
inhibited by rolipram (fig . 3.2.8). This was determined from  the double- 
reciprocal plots (fig. 3.2.8) o f h6.1 activity versus cyclic AMP concentration in 
the presence o f increasing inhib itor concentration. These Lineweaver-Burke 
plots and the slope and Dixon (1953) replots o f these data (figs. 3.2.8, 3.2.9, 
3.2.10) remained linear over a wide range o f substrate and inh ib ito r 
concentrations, indicative o f simple competitive inhibition.
S im ilarity, IB M X  was shown to be a simple competetive 
inhibitor o f the pellet form o f h6.1 as shown in the linear Lineweaver-Burke 
plots (fig. 3.2.11)^ slope and Dixon replots (fig. 3.2.12, 3.2,13).
The relationship between increasing protein concentration and 
PDE activity was also shown to be linear, even in the presence o f rolipram at a
7 6
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concentration which gave half-maximal inhibition o f activity (fig. 3.2.14). This 
demonstrates that rolipram is not a tight-binding inhibitor o f h6.1.
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3.3 Conclusions and Discussion
PDE h6.1 can be characterised as belonging to the PDE4 
isoenzyme fam ily. This was evident from the specificity and high a ffin ity for 
cyclic AMP as substrate (3.2.v, fig  3.2.3). Also, that the hydrolysis o f cyclic 
AMP was unaffected by either calcium /  calmodulin or low  concentrations o f 
cyclic GMP (3.2.i), further confirms h6.1 as belonging to the PDE4 class. The 
inhib itor profile o f h6.1 was also typical fo r a PDE o f the PDE4 class, in 
particular the sensitivity to rolipram  and RO-20-1724 (table 3, figs 3.2.4, 
3.2.5). PDE h6.1 also shares sequence sim ilarities and biochemical 
characteristics o f other PDE4 isoforms, in particular R D I. This suggests that 
h6.1 can therefore be classified as a member o f the PDE4A subclass (Sulhvan et 
al 1994).
The present study showed that h6.1 was present in both the 
pellet and soluble fractions o f YMS6 cell lysates. However, in COS-1 cells 
(Sullivan et al 1994), h6.1 was present only in the cytosol. Comparison o f h6.1 
expressed in both yeast and COS-1 cells (table 4) show sim ilar Km values for 
cyclic AMP hydrolysis and more importantly, sim ilar IC 50 and K i values for 
inhibition by rolipram. Furthermore, the present study also shows that the pellet 
and soluble forms o f the enzyme are identical w ith respect to substrate 
hydrolysis and inhibitor profile, and d iffer only in their thermostability (table 
3). This suggests that the catalytic activity and the inhibitor binding o f the pellet 
insoluble fraction in yeast was unaffected by its location w ithin the cell. Both 
the soluble and pellet forms o f h6.1 activity decayed as a single exponential, 
suggesting a homogeneous population o f enzyme. However, the pellet form 
was more stable (fig  3.2.1, table 3). Thus, whatever caused h6.1 to become 
pellet associated in yeast did not affect enzyme activity, but did constrain the 
enzyme in such a way as to resist thermal dénaturation. The pellet form o f h6.1 
was unaffected by treatment with either T X 100 or NaCl. Therefore, h6.1 is not 
an integral membrane protein or a peripherally bound enzyme but simply
7 8
formed an insoluble complex in  yeast as a result o f its overexpression. 
Alternatively, the pellet form o f the enzyme could have been composed o f yeast 
which had not been properly lysed. Therefore, the pellet associated enzyme 
could have formed a leaky' complex into which cyclic AMP could enter and 
access PDE. It is like ly  that the soluble form  represents that o f the native 
enzyme because in COS-1 cells h6.1 is exclusively cytosolic.
An engineered version o f h6.1, called h6.1his5» was purified by 
D r N eil Brown. PDE h6.1his5 was engineered w ith 5 histidine residues to 
provide a zinc binding m otif at the C-terminal end and allow purification by 
binding specifically to a nickel chelate column. Using this purification 
procedure a single peak o f protein o f 74kDa ±  3 was isolated. This was 
comparable with the value obtained using a crude soluble fraction o f native h6.1 
(73kDa ±  3) and the single protein band observed on a non denaturing gel 
(73kDa ± 2). The molecular size determined for h6.1 was as predicted from the 
DNA sequence. This data was consistent w ith the observation from  the 
thermostability studies (3.2.1, table 3) in which it was determined that soluble 
h6.1 was expressed as a single population o f enzyme species and not as the 
product o f proteolysis.
Dependency on the presence o f bivalent cations for PDE activity 
has been previously observed by other investigators (Grant &  Colman 1984, 
Lavan et al 1989). This study has shown that treatment o f h6.1 w ith EDTA 
rendered the PDE inactive which could be overcome in a dose-dependent 
fashion by either Mg^+ or M n^+ (fig  3.2.2, table 2). This suggests that there 
is a distinct negatively charged site w ithin the PDE active site to which cations 
bind and enhance substrate hydrolysis. Indeed, Francis et al (1994) have noted 
a conserved m otif in  a ll PDEs, Hx3Hx-20E, which is thought to function as a 
zinc binding site and is essential fo r activity. O f interest, Pyne and coworkers 
have shown that the inhibitory effect o f zaprinast on PDE5 could be due to its 
ability to chelate zinc (Beavo et al 1994). This bivalent cation binding site on
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PDE4 could also be important for inhibitor binding, for it has been reported that 
the ability o f ^ H-rolipram to bind to sites on rat brain membranes is dependant 
on the presence o f divalent cations (Schneider et al 1986). However, it is not 
simply the case that the more electro-positive an element then the more potent it 
w ill be as an activator o f PDE activ ity because Ca^+, which is more 
electropositive than either M g^+or M n^+, dose-dependently inhibited PDE 
activity.
PDE inhibitors have been developed on the basis o f analogy to 
cyclic AMP. This would suggest that all inhibitors would be competitive against 
substrate hydrolysis, however, i f  such an inh ib itor was found to be tight 
binding then it can be expected that anomolous kinetics may occur as a result. 
Fig. 3.2.14, shows a linear relationship between protein concentration and h6.1 
activity in  the presence and absence o f rolipram, which demonstrates that 
rolipram is not a tight binding inhibitor.
The mechanism o f inhibition by rolipram o f PDE4 is one o f the 
least understood aspects o f this fam ily o f enzymes. It has been suggested on the 
basis o f dose-response curves o f PDE4 that the kinetics o f rolipram inhibition 
may be anomolous (McLaughlin et al 1993, Bolger et al 1993). Although 
analyses o f rolipram inhibition have been so far basic, it has been demonstrated 
that several orders o f magnitude ('3  log orders in the case o f h6.1 (fig  3.2.4, 
table 3) ) are necessary to completely inh ib it the enzyme. In addition, kinetic 
studies on hPDE4ALivi was reported not to fit to simple competitive inhibition 
(L iv i et al 1990). Clearly, rigorous analysis o f the kinetics o f rolipram inhibition 
was necesary to determine any kinetic anomolies w ith h6.1. This study has 
shown however, that both rolipram and the non-selective inhibitor IBM X acted 
as simple competitive inhibitors o f h6.1 as shown by the linear double- 
reciprocal plots (fig  3.2.8, 3.2.11), slope replots (fig  3.2.10, 3.2.13) and 
D ixon replots (fig  3.2.9, 3.2.12). Schematic representation o f competitive
8 0
inhibition is given in fig  (3.2.15) showing that the inhibitor simply competes 
w ith substrate for the active site.
Analysis of hPDE4ALivi indicated that rolipram did not serve as 
a simple competitive inhibitor from the authors double-reciprocal plots (Livi et 
al 1990, Torphy et al 1992). In support of this, a plot of slope versus rolipram 
concentration for hPDE4ALivi (%  3.2.16) was curved in a concave fashion.
/  This would not occur i f  more than one molecule o f rolipram bound to the 7
\  I ^ enzyme as hypothesised by the authors, as the plot would be upwardly curving. %
L Further analysis of this data showed that the slope versus rolipram 
concentration plot for hPDE4ALivi could be linearised by replotting a double­
reciprocal of each axis (Dixon and Webb 1979), which is indicative of partial 
competitive inhibition. A scheme of partial competitive inhibition is shown in 
fig 3.2.17, in which the inhibitor competes with the substrate to form an E l 
complex which can interact further with substrate to form an EIS complex. In 
such a case both complexes break down to form products at the same rate.
Torphy et al (1992) have suggested that the kinetic anomalies 
seen with hPDE4ALivi are the result o f the presence o f a high a ffin ity binding 
site fo r rolipram, distinct from  the site o f catalysis (Introduction 1.19(iii)). 
Thus, the abnormalities seen w ith the inhibition by rolipram, would be due to 
more than one molecule o f inhibitor binding per molecule o f enzyme. However, 
this study has shown that both rolipram and IB M X  are simple competitive 
inhibitors o f substrate hydrolysis by a PDE4A isoform h6.1.
Sequence analysis of hPDE4ALivi and comparison with that of 
h6.1 (Sullivan et al 1994) have shown the two to be highly related but differ in 
five amino acids. These amino acids are located within or next to the catalytic 
domain (Chen et al 1986, Jin et al 1992), y 317/d , r 523/m , r 527/p , e 589/ a  
and n398/s (chapter4 fig  4.2.2). It is possible that these sequence changes 
could explain the kinetic differences seen with h6.1 and hPDE4ALivi, and 
cause alterations in the way in which the active site of hPDE4ALivi folds
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therefore, allowing both the substrate and inhibitor to bind at the same time. An 
alternative explanaition could be that a modification occured in the preparation 
of the enzyme.
Sullivan et al (1994) have shown that h6.1 as opposed to 
hPDE4ALivi, represents that of the native PDE. Several lines of evidence 
support this. Using commercially available cDNA libraries, human PDE4A 
clones were isolated which failed to match the sequence of hPDE4ALivi> yet all 
matched with h6.1. Moreover, the genomic sequence of a human PDE4A gene 
matches that of h6.1 (Sullivan et al 1994). Sequence differences in hPDE4ALivi 
may be the result of a mutant enzyme or that there are two PDE4A genes, 
however it is more probable that they represent sequencing errors.
Addition to chapter 3. paragraph 1. page 80
The dependancy o f h6,1 catalytic activity on the presence o f bivalent cations 
could be related to the ability o f these cations to form a complex with the 
substrate. In such a case, this complex o f substrate and bivalent cation would 
allow a more efficient interaction between enzyme and substrate. W ith respect to 
the bivalent cation dependancy results obtained with h6.1 it could be considered 
that both magnesium and manganese formed a complex with cyclic AMP to 
stimulate hydrolysis, whereas, calcium was unable to and was therefore 
inhibitory.
Addition to chapter 3. paragraph 3. page 80
The dose response curves for rolipram inhibition o f h6.1 (fig  3.2.4) were 
shown to spread over several orders o f magnitude to completely inhibit enzyme 
activity. Therefore, the concentration range o f rohpram chosen to investigate the 
drugs inhibitory mechanism (0 - 5pM) in figs 3.2.8 a and b on h6.1 activity 
could have biased the results towards competitive inliibition.
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Table 2 I£ 5 0 ..and..JICso ,yalygs iQr.JnhibjliQn / AçtivatiQb pf
Peikt h6.1 Activity- by EDTA and Divalent Catipng
Divalent Cation ICsoCmM) EC50 (mM) EC50 (mM)
Reactivation
Magnesium
Chloride
N .A . 1.8+0.5 2.4+0.5
Manganese
Chloride
N .A . 4.1±0.4 1.6±0.2
Calcium
Chloride
1,4+0.06 N .A . N .A .
EDTA 0.08+0.03 N .A . N .A .
Results are shown as mean values ±  the standard deviation fo r three 
observations in each case.
IC 50 was the concentration which resulted in 50% inhibition o f h6.1 activity. 
EC50 was the concentration which resulted in 50% activiation o f h6,l activity. 
N.A. = not applicable.
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Tabled Km, IbhiWtor Profilg-abd ThgrmQstabiiitY for
Soluble and Pellet. Forms of h6.1
Soluble h6,l Pellet h6.1
Kn,cAMP(p^M) 5.2+1.5 (n=6) 4.1+1.7 (n=6)
Rolipram IC50 (|iM ) 0.51+0.15 (n=6) 1.35±0.5 (n=6)
K i (tiM ) 0.4+0.1 (n=6) 0.7±0.3 (n=6)
IB M X IC 50 (tiM ) 25.6+2.2 (n=3) 37.2+4.5 (n=3)
K i (\xM) 15+3 (n=3) 19±2 (n=3)
Cilostimide IC50 (P-M) N.D . 129±41 (n=3)
K i(p M ) N .D . 81.8+26 (n=3)
RO-20-1724IC50 (tiM ) N.D . 7.2+1.2 (n=3)
K i (\iM) N.D. 4.5+0.8 (n=3)
Values are given as mean ±  the standard deviation fo r the number o f 
observations in parenthesis.
IC50 was the concentration which resulted in 50% inhibition o f h6.1 activity. 
The K i value was the inhibition constant calculated from the Cheng-Prussoff 
equation as described in results section 3.2.vi.
N.D, = not determined.
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Table 4 ComparisQU. pf h^.l AçtivitY.. E^pressç  ^ in iH  
Splufck,,.,Eraçti.ons pf COSrl-Cglls. and 
Saccharomvces Cerivisiae
COS-1Cells* Saccharomyc^ s
Cerivisiae
KmcAMP(nM) 6±2 (n=3) 4.1+1.7 (n=6)
Rolipram IC 50 (P-M) 0.6±0.2 (n=3) 0,51+0.15 (n=6)
K i (|liM) 0.6 0.4±0.1 (n=6)
* = Data from Sullivan et al (1994).
Values are shown as the mean ±  standard deviation fo r the number o f 
observtions in parenthesis.
IC50 was the concentration which resulted in 50% inhibition o f h6.1 activity. 
The K i value was the inhibition constant calculated from the Cheng-Prussoff 
equation as described in results section 3.2.vi.
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Fis. 3.2.1-a Thermostabilitv of Soluble and Pellet h6J at
Thermostability o f h6.1 was measured at 45°C. The resulatant to.5 values were 
calculated to be 10 minutes and >30 minutes for soluble and pellet activity 
respectively.
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Fig. 3.Z. I  h Thermostability of Soluble and Pellet h6.I_at
Thermostability o f h6.1 was measured at 50°C. The resulatant to.5 values were 
calculated to be 2 minutes and 20 minutes fo r soluble and pellet activity 
respectively.
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Fig. 3.?.2 a Treatment of Pellet h6.1 with EDTA
h6.1 activity was measured in ion free Tris pH7.4 buffer in the presence of 
increasing concentration o f EDTA, which dose-dependently inhibited activity as 
shown. Result is shown in table 2.
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h6.1 activity was measured in the presence o f increasing concentration o f 
magnesium chloride in Tris pH7.4 buffer, which dose-dependently activated 
activity as shown. Result is shown in table 2.
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Fis Reactivation of EDTA Treated Pellet h6.l with
Magnesium Chloride
Activation o f native pellet h6.1 and reactivation o f EDTA treated h6.1 with 
magnesium chloride is shown. Result is shown in table 2.
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F ig 3.2.2 d TrgaWl . f g ik t M,1 with
Manganese Chloride
Activation o f native pellet h6.1 and reactivation o f EDTA treated h6.1 with 
maanganese chloride is shown. Result is shown in table 2.
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Fig 3.2.2 e Inhibition of Native Pellet h6A_with_CaIcium.
C hiprW g
Inhibition o f native pellet h6.1 w ith calcium chloride is shown. Result is shown 
in table 2.
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Fi^. 3.2.3 a Determination of Km  «yc"»: a m p  ppr Soluble
M J .
Lineweaver-Burke plot was constructed by the measurement o f soluble h6*l 
activity in the presence o f increasing cyclic AMP concentrations. Activity was 
linear over the ranges 0.1 - lOOpM (insert), and 0.05 - lOpM cyclic AMP. Km 
values were calculated using the U ltrafit programme as described in results, and 
the data is shown in table 3.
This experiment is representative o f one carried out with at least six different 
preparations.
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Fig, 3t2«3 J? D eterm ination o f ^ ^ ^ - For-E ei let
MJL
Lineweaver-Burke plot was constructed by the measurement o f pellet h6.1 
activity in the presence o f increasing cyclic AMP concentrations. A ctivity was 
linear over the range 1 - 20|iM  cyclic AMP. Km value was calculated using the 
U ltrafit programme as described in results, and the data is shown in table 3.
This experiment is representative o f one carried out w ith at least six different 
preparations.
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Fig. 3. .^4 Ppsg-Rgsponsf to RQlipram of Solublg ana
P ollg t W ,1
Soluble (a) and pellet (b) activity was measured at a fixed concentration o f 
cyclic AMP (3jiM ), which approximated that o f the Km for each enzyme, in the 
presence o f increasing rolipram concentration. Resultant IC50 values are given 
in table 3.
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Fig. 3,.2..5. Dose-Response to RQ-20-1724 of Pellet h6.1
Pellet h6.1 activity was measured at a fixed concentration o f cyclic AMP 
(3|iM ), which approximated that o f the Km, in the presence o f increasing Ro- 
20-1724 concentration. The resultant IC 50 value is given in table 3.
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Fis.— Dose-Response to IB M X  of Soluble and
Pellet h^. i
Soluble (a) and pellet (b) activity was measured at a fixed concentration o f 
cyclic AMP (3|lM ), which approximated the Km fo r each enzyme, in the 
presence o f increasing IBM X concentration. Resultant IC50 values are given in 
table 3.
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Fig. 3.2.7 D.a§fcE.e§p.smg,i^ y f..Pgiiet h<?,^
Pellet h6.1 activity was measured at a fixed concentration o f cyclic AMP 
(3|iM ), which approximated that o f the Km, in the presence o f increasing 
cilostimide concentration. The resultant IC50 value is given in table 3.
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Fig. 3,2.8 a Kingtiçs of Rplipram Inhibition of 
h6.1
Soluble h6.1 activity was measured over the range o f 1 - 20fiM  cyclic AMP in 
the presence o f increasing concentration o f rolipram. This experiment is 
representative o f one done at least three times.
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Fig. 3.2.8 b Kinetics of Rolipram Inhibition of Pellet 
MJ.
Pellet h6.1 activity was measured over the range of 1 - 20fiM  cyclic AMP in the 
presence o f increasing concentration o f rolipram . This experiment is 
representative o f one done at least three times.
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Fig. 3.2.9 a Dixon, Replot of Rolipram Inhibition of Soluble 
h J L l
Data is shown as the reciprocal o f activity versus increasing concentration o f 
rolipram (Dixon and Webb 1979). This experiment is representative o f one 
done at least three times.
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Dixon ReplQt of Rolipram Inhibition of Pellet 
MJL
Data is shown as the reciprocal o f activity versus increasing concentration o f 
rolipram (Dixon and Webb 1979). This experiment is representative o f one 
done at least three times.
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Data is shown as the slope replot o f activity versus increasing concentration o f 
rolipram. This experiment is representative o f one done at least three times.
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Fig. 3.2.10 b SiQpg. EmM  of R9lipram. ypyiiMtiQa..M-±.elkt.
h 6:1
Data is shown as the slope rcplot o f activity versus increasing concentration o f 
rolipram. This experiment is representative o f one done at least three times.
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F ig , d a d i Kinetics of IBMX Inhibition of Pellet
h ^  tiXi
Pellet h6.1 activity was measured over the range o f 1 - 20|i.M cyclic AMP in the 
presence o f increasing concentration o f IB M X . This experiment is 
representative o f one done at least three times.
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Fis. 3 ^ 2 Dixon Repïot of IB M X  Inhibition où PeHet
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Data is shown as the reciprocal o f activity versus increasing concentration o f 
rolipram (Dixon and Webb 1979). This experiment is representative o f one 
done at least three times.
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Data is shown as the slope replot o f activity versus increasing concentration o f 
rolipram. This experiment is representative o f one done at least three times.
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h6.1 activity was measured over the protein concentrations shown ± 2p,M 
rolipram, at a substrate concentration o f l|iM  cyclic AMP. I
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riSr.-3 ilJ.S  Schematic Representation of Compétitive
In h ib itio n
Shown diagramatically is the scheme o f competitive inhibition showing that the 
inhibitor simply competes with substrate for the active site.
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Fig. 3.2.16 Slope Replot of Rolipram Inhibition of
hPDE4AT ivi
Data is shown as the slope replot o f activity versus increasing concentration o f 
rolipram. This data was obtained from L iv i et al 1990.
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Ftg. 3.2.17 Sçhgmatiç Représentation of Eartial 
Competitive Inhibition
Shown diagramatically is the scheme o f partial competitive inhibition. This 
shows that the inhibitor competes w ith the substrate to form  an E l complex 
which can interact further with substrate to form an EIS complex. In such a case 
both complexes break down to form products at the same rate.
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Results - Chapter 4
Analysis of Truncated Versions of 
h6.1. Chimeric PDE H Y Bl and an N-terminal 
Domain Extension PDE lOAORF
4 .1  IntrQ^tiÇtiQn
The cloning and analysis o f h6.1, as described in chapter 3, has 
shown that hPDE4ALivi and h6.1 are highly related proteins but d iffe r with 
respect to five amino acids contained w ithin, or next to, the catalytic domain 
(Sullivan et al 1994, Jin et al 1992. The amino acid residues which d iffe r 
between hPDE4ALivi and h6.1 are shown in fig  4.2.2. A t the time o f this 
study, it was thought that the differences between h6.1 and hPDE4ALivi were 
the result o f either cloning errors or mutations, or that h6.1 and hPDE4ALivi 
represented alternative species. Also, Torphy et al (1992) reported that a high 
affin ity binding site for rolipram, distinct from the catalytic site, was present on 
hP D E 4A L iv i* Thus, Torphy et al (1992) proposed that the ab ility  o f 
hPDE4ALivi to bind more than one molecule o f rolipram per enzyme molecule 
was consistant w ith the kinetic anomalies seen with hPDE4ALivi- As shown in 
chapter 3, both rolipram and IB M X  were simple competitive inhibitors o f 
substrate hydrolysis (figs 3.2,8, 3.2.11), therefore, substrate and inhibitor 
binding occur at the one site in h6.1. It was anticipated that i f  h6.1 displayed 
anomolous kinetics, perhaps through the binding o f rolipram to a site other than 
the catalytic site as proposed by Torphy et al (1992), then trimming o f the 
surrounding sequences o f the basic catalytic domain would reveal this.
Analysis o f the catalytic domain (Jin et al 1992) has shown that, 
while members o f any one PDE class show 60 - 90% homology in  the catalytic 
region, those belonging to different classes are much less homologous. The 
catalytic region o f PDE4 (Jin et al 1992) can be identified by homology with 
other PDE species (fig  4.1.1), and is conserved throughout the PDE4 class. 
However, it  is evident that the N and G terminal regions o f PDE4 A, B, C and 
D isoforms, outwith the catalytic region, d iffe r widely (fig  4.1.2) Bolger et al 
(1993). Thus, these N and C terminal regions presumably perform other 
functions which could influence enzyme stability or catalysis. In order to 
address whether the N and C terminal regions o f h6.1 influenced enzyme
1 1 2
activity, D r M. Sullivan (Sandoz), created a series o f mutants o f h6.1 which 
were engineered for expression in Saccharomvces cerivisiae as per h6.1. These 
truncations, which refer to the sequence o f h6.1, took the form o f an N-terminal 
deletion o f residues 1 -172 (YMS 10 yeast strain), a deletion at the N-terminus 
o f residues 1 - 172, and C-terminus o f residues 608 - 692 leaving the basic 
catalytic domain (YMS 11 yeast strain) and a C-terminal deletion o f residues 608 
- 692 (YMS 12 yeast strain) (fig  4.2.1).
In addition, a hybrid form  o f h6.1 was constructed which 
involved an N-terminal domain swap o f h6.1 with a 33 amino acid unique N- 
terminal region o f a novel PDE4A splice variant, which has been called 2EL 
(HSPDE4A8, GcnBank accession number U18088) (Horton et al 1995) (fig  
4.2.2). 2EL was isolated from a human, resting, T cell cDNA library, which 
was screened w ith a PDE specific probe generated by per as reported for h6.1 
(Sullivan et al 1994). Sequence analysis o f the putative proteins encoded by 
2EL and h6.1 showed that they differed in  two regions. 2EL was shown to 
encode a unique 33 amino acid N-terminal sequence, after which their identity 
extends over a further 275 amino acids. After this region o f homology there is a 
34bp insertion, within the putative catalytic region, where premature termination 
o f 2EL would occur as a result o f the frameshift o f the 2EL ORE. The insertion 
o f the 34bp fragment disrupts the catalytic region o f 2EL in such a way as to 
produce a protein which is inactive when the cDNA is transfected into COS 
cells (Horton et al 1995). To investigate the function o f the unique N-terminal 
region o f 2EL, as the 2EL enzyme was inactive, the hybrid H Y B l was 
constructed, H Y B l was generated by exchanging the N-terminal region o f 2EL 
w ith the corresponding region o f h6.1 to assess the effect o f the N-terminal 
region o f 2EL on catalytic activity.
Studies by Bolger et al (1993) have shown that a longer open 
reading frame, than that for either h6.1 or hPDE4ALivi» can be generated from 
the PDE4A gene (fig .l Bolger et al 1993). The product encoded by the cDNA
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isolated, which represented the PDE4A gene, was named PDE46 (GeneBank 
name HSPDE4A5, GeneBank accession number L20965). PDE46 was shown 
to be related to hPDE4ALivi. in that hPDE4ALivi was a truncated version. In 
relevance to this. D r Mike Sullivan (Sandoz) has isolated a cDNA clone which 
represented an extended version o f h6.1 which has been named lOAORF. The 
sequence o f lOAORF is identical to PDE46, except fo r a 14 amino acid 
extension at the N-terminal region (fig  4.2.3).
To analyse the effects o f the structural alterations o f the truncated 
enzymes, lOAORF and H Y B l we considered the kinetics o f cyclic AMP 
hydrolysis and the effect o f rolipram  thereon. The thermostability o f the 
enzymes were also analysed as an indication o f alterations to the catalytic unit.
It was hoped that it  would be possible to determine the relative 
amounts o f the truncated enzymes, lOAORF and H Y B l as expressed in yeast 
using antisera which would cross react with each enzyme, and thus, enable the 
determination o f Vmax values for each o f the enzymes. This would have been 
done, in itia lly, by western blot analysis o f increasing protein concentration from 
the soluble fraction o f transfected yeast cells. The resultant blots would then 
have been scanned to obtain a plot o f OD value vs }ig protein, in order to 
estimate the concentration o f RDI in each sample relative to each other. Then, 
amounts o f protein from transfected yeast, which would provide equivalent 
amounts o f R DI could have been immunoprecipitated. The immunoprecipitates 
would have been assayed fo r PDE activity over a range o f cyclic AMP 
concentrations, and the data plotted as a Lineweaver-Burke plot to define the 
relative Vmax fo r each enzyme. From this, it would have been possible to 
determine any effect on enzyme activity as a result o f changes to the N and C 
terminal regions. However, we were unable to generate an antisera despite 
repeated attempts using various peptides. This antisera could also have been 
used to look at the expression and determine the molecular weight, o f such 
proteins in. v iv n .
1 1 4
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This chapter describes the characterisation o f the truncated 
enzymes, the lOAORF enzyme which has an extended N-terminal region with 
respect to h6.1, and the chimeric enzyme H Y B l. These experiments were 
designed to investigate effects on catalysis and enzyme stability induced by the 
changes to the N and C terminal regions o f h6.1.
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4 .2  Results
(riSeauence Alignments ofh6.1. lOAORF. HYB 1. YMS 10.
YMS 11 and YMS 12
The truncations o f h6.1, which were created by D r M ike 
Sullivan (Sandoz), took the form o f an N-terminal deletion o f residues 1 - 172 
(YMS 10 yeast strain), a deletion at the N-terminus o f residues 1 - 172, and C- 
terminus o f residues 608 - 692 leaving the basic catalytic domain (YMS 11 
yeast strain) and a C-terminal deletion o f residues 608 - 692 (YMS 12 yeast 
strain). These truncations are shown diagramatically in  fig  4.2.1, and their 
amino acid sequences are shown in the alignment in fig  4.2.4. The sequences o f 
the truncated enzymes, h6.1 and H Y B l are all aligned to the sequence o f 
PDE46,
The sequence alignment o f h6.1, H Y B l and 2EL are shown in 
fig  4.2.2. Shown in this alignment is the unique N-terminal region o f 2EL 
which has been exchanged for the N-terminal region o f h6.1.
The identity o f lOAORF with PDE46 is shown in fig  4.2.3. The 
sequence o f lOAORF is identical to PDE46, except fo r a 14 amino acid 
extension at the N-terminal region o f PDE46. In addition, this alignment shows 
that the amino acid base changes seen in hPDE4ALivi are absent from the 
sequence o f PDE46.
(ii)Expression o f lOAORF. H Y B l. YMS 10. YMS 11 and,
YMS 12 in Saccharomyces cerivisiae
Cell suspensions o f yeast expressing lOAORF, HYB 1, YMS 10, 
YMS 11 and YMS 12 were disrupted by means o f a cell press. Cell homogenates 
were centrifuged 210,000gav fo r 45 minutes, after which the pellet and 
supernatant fractions were assayed for PDE activity at a substrate concentration 
o f IjiM  cyclic AMP. A ll yeast strains expressed measurable PDE activity in 
both the pellet and soluble fractions, w ith the exception o f the YMS 10 strain. It 
is unclear as to why only the YMS 10 strain did not express PDE activity.
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however, i f  yeast transfected w ith plasmid are not placed under any selection 
pressure, as in this case, then the cells secrete the plasmid. As a result the yeast 
which do not contain the plasmid grow more rapidly. This could have been the 
case with YMS 10.
The specific activities determined (in pmol cyclic AMP /  min /  
mg ± standard deviation from the mean) for each o f the enzyme preparations 
expressed in yeast, fo r pellet and soluble fractions respectively were, HYB 1 
1.14 ±  0.3, 1.4 ± 0.4 (n=3), lOAORF 21.7 ± 1.7, 15.7 ±  1.8 (n=3), YMS 11 
0.43 ± 0.1, 0.76 ±  0.2 (n=3) and YMS 12 5.99 ±  1.2, 0.46 ± 0.2 (n=3) (table 
5). The control yeast strain for HYB 1 was YMS5X and for the truncations and 
lOAORF the control yeast strain was YMS5. In each case the control strain 
failed to hydrolyse cyclic AMP.
The activity distribution between the soluble and pellet fractions 
expressed in yeast (table 5) were similar fo r H Y B l, lOAORF and YMS 11 with 
40 - 60% o f the activity in the soluble fraction. However, considerably less o f 
the YMS 12 activity was present in the soluble fraction. The values in table 5 are 
representative o f at least three different preparations.
(iii)K inetics o f Cvclic AMP Hvdrolvsis bv the Soluble Forms o f 
lOAORF. HYB 1. YMS 11 and YMS 12 
The Km value fo r the hydrolysis o f cyclic AMP by the soluble 
fractions o f yeast expressing lOAORF, H Y B l, YMS 11 and YMS 12 were 
determined from Lineweaver-Burke plots (figs 4.2.5, 4.2.6, 4.2.7 and 4.2.8 
respectively). In each instance, the double-reciprocal plots o f in itia l rate versus 
cyclic AMP concentration fo r each activity was linear over the substrate 
concentration range o f 0.1 - 50|iM  and displayed simple saturation kinetics. In 
order to calculate Km values, the data were fitted to the Michaelis Menton 
equation Vobs = (Vmax[cyclic AMP] /  (Km+[cyclic AM P]) using the U ltra fit 
graphical package. In each case, the 'robust weighting' fa c ility  was used and 
the 'goodness o f fit ' index was no less than 0.99 w ith each estimation, 1 being
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a perfect fit. This non-linear fitting  programme obviates errors in fitting  to the 
Lineweaver-Burke plot using regression analysis, where the spread o f errors is 
not evenly distributed as it is a double-reciprocal plot. This analysis yielded Km 
values for each o f the enzyme activities which were a ll in the low |iM  range. 
The Km values are shown in table 6. Each experiment is representative o f that 
carried out at least three times.
rivlDose Response to Rolipram o f the Soluble Forms of 
lOAORF HYB 1. YMS 11 and YMS12 
The ability o f the PDE 4 selective inhibitor rolipram to inhibit 
substrate hydrolysis o f lOAORF, HYB 1 and the truncated enzyme activities 
was assessed. To ensure an accurate comparison w ith h6.1, the dose response 
curves were constructed using an identical substrate concentration, 3|iM , which 
reflected that o f the Km value o f h6.1. Rolipram was used in the concentration 
range o f 0.05 - 10|iM.
IC 50 values (concentration o f inhibitor which produced 50% 
reduction in substrate hydrolysis) were then calculated fo r each enzyme from 
the dose response curves shown in figs 4.2.9, 4.2.10, 4.2.11 and 4.2.12 for 
lOAORF, H Y B l, YMS 11 and YMS 12 respectively. The IC 50 values are 
shown in table 6.
(vlKinetics o f Inhibition o f the Soluble Form lOAORF bv 
Rolipram
The mechanism o f inhibition by rolipram o f PDE4A was further 
investigated in this study. In chapter 3, it was shown that both the non-selective 
inh ib itor IBM X, and the PDE4 inh ib itor rolipram, competitively inhibited 
substrate hydrolysis (figs 3.2.7 &  3.2.10) o f h6.1. The isolation o f the 
extended version o f h6.1, lOAORF allowed the further analysis o f rolipram 
interaction. In addition, determination o f the IC 50 value o f rolipram inhibition 
o f lOAORF, showed a greater potency o f inhibition compared to that for h6.1 
(table 6). It was necessary, therefore, to investigate whether this shift in
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potency was the result o f a change in the mechanism by which rolipram 
inhibited the enzyme.
To address this question, double-reciprocal plots were 
constructed o f soluble lOAORF activity versus cyclic AMP concentration in the 
presence o f increasing concentration o f inhibitor. Soluble lOAORF activity, in 
contrast to h6.1, was partially competitively inhibited by rolipram. Linear 
Lineweaver-Burke (fig . 4.2.13) and Dixon (1953) (fig . 4.2,14) plots were 
obtained w ith lOAORF, which remained linear over a wide range o f substrate 
and inhibitor concentrations. However, a slope replot (fig. 4.2.15) o f this data 
was shown to be curvilinear, indicative o f partial competetive inhibition.
CvilThermostabilitv o f lOAORF. HYB land YMS 12 at 45°C
The thermostability o f soluble lOAORF, HYB 1 and YMS 12 
were assessed at 45“C. In each case, the enzyme activités decayed as a single 
exponential yielding linear semi-log plots o f residual activity against time (fig 
4.2.16). A t the temperature studied the extended version o f h6.1, lOAORF, 
was considerably more stable than either o f the soluble forms o f HYB 1, YMS 
12 or h6.1 with a Tq.5 value o f >30 minutes. The values calculated fo r h6.1, 
YMS 12 and HYB 1 are shown in table 7.
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4,3 Conclusions and Discussion
Analysis o f the four human and rat PDE4 genes by Bolger et al 
(1993) has further highlighted the complexity o f this isoenzyme fam ily. W ith 
relevance to this present study, analysis o f the PDE4A gene revealed that a 
product, PDE46, could be transcribed which has been shown since to represent 
the fu ll length version o f h6.1 described in Chapter 3. PDE46 (Bolger et al 
1993) was shown to contain complete ORFs, with stop codons present in  all 
three reading frames upstream o f the putative initiation codon. The isolation o f 
h6.1 from  a human T-lymphocyte cDNA library, in itia lly  involved the 
identification o f two overlapping clones which represented a PDE4 sim ilar to 
that isolated by L iv i et al (1990), but lacked the first 13 amino acids. These first 
13 amino acids o f hPDE4ALivi were engineered onto the sequence o f h6.1 to 
provide an open reading frame as seen in the L iv i et al (1990) clone. Since non­
native amino acids had to be engineered onto the N-terminal region o f the 
sequence o f h6.1 to provide an open reading frame, this indicated that the h6.1 
sequence isolated was not complete. In addition, Bolger et al (1993) had shown 
that a longer product, PDE46, could be transcribed. Using a sim ilar strategy to 
that which resulted in the isolation o f h6.1, D r M ike Sullivan (Sandoz) isolated 
a clone which represented an N-terminally extended version o f h6.1. This clone 
was named lOAORF, and was found to be an extension o f the sequence o f h6.1 
by ~ 190 amino acids at the N-terminus. The sequence alignment o f PDE46 with 
lOAORF (fig  4.2.3), shows that lOAORF differs from PDE46 by only a 14 
amino acid extension at the N-terminal region.
Originally it was considered (Bolger et al 1993) that the PDE4A 
enzyme isolated by L iv i et al (1990), hPDE4ALivi» represented a partial clone 
o f PDE46 which maintained catalytic activity despite being truncated at the N- 
terminus. Sequence alignment o f lOAORF, PDE46 and h6.1 (fig  4.2.4) have 
shown the complete identity o f their internal amino acid sequence apart from the 
N-terminal amino acids. The lOAORF enzyme was also shown to be an N-
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terminally extended version o f h6.1 (fig  4.2.4). The importance o f the identity 
o f lOAORF and h6.1 w ith PDE46, is that it provides confirmation that the 
sequence o f h6.1 is correct. This can be concluded since the amino acid changes 
seen in the sequence o f hPDE4ALivi, were not seen in the sequence o f PDE46 
isolated by Bolger et al (1993).
Comparison o f the sequences o f the four human PDE4 genes, 
and the PDE4 gene o f Drosophila melanogaster (Bolger et al 1993) has 
highlighted that the most divergent region found was at the N-terminus. Thus, 
the catalytic region o f PDE4 genes is conserved between species, however, 
flanking sequences have been shown to be different at both the N and C 
term inii. Indeed, analysis o f the human PDE4 genes and the Drosophila  
melanogaster dune gene (Davis &  Davidson 1984), has shown that no 
homologous sequences are found either between human genes or the dune 
gene. It is o f interest that the mammalian PDE4 isoforms, and not the dune 
gene product, are inhibited by the characteristic PDE4 inhibitors rolipram and 
RO-20-1724 (Henkle-Tigges &  Davis 1989). This may suggest that the N- 
terminus o f the human PDE4 genes contain the information to allow the 
interaction w ith these inhibitors, since this region was shown to be the most 
divergent.
The observation that the mammalian PDE4 isoforms have unique 
N and C terminal regions (Bolger et al 1993, Swinnen et al 1989) suggested 
that these regions could perform specific functions, such as, affecting catalytic 
activity. In order to investigate such roles for the N and C term inii, D r Mike 
Sullivan (Sandoz) constructed a series o f truncated forms o f h6.1 which were 
analysed in this present study. The truncations o f h6.1 took the form  o f an N- 
terminal deletion o f residues 1 - 172 (YMSIO yeast strain), a deletion at the N- 
terminus o f residues 1-172, and C-terminus o f residues 608 - 692 leaving the 
basic catalytic domain (Y M S ll yeast strain) and a C-terminal deletion o f 
residues 608 - 692 (YMS12 yeast strain). These truncations are shown
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diagramatically in fig  4.2.1, and their amino acid sequences are shown in the 
alignment in fig  4.2.4. The N-term inally extended version o f h6.1, lOAORF, 
was sim ilarily investigated. In addition, a chimeric PDE4A was constructed to 
investigate the function o f the N-terminal domain o f 2EL (Horton et al 1995).
The chimeric PDE4A was called H Y B l, and was constructed by swopping the 
unique N-terminal region o f 2EL w ith the corresponding region o f h6.1. The 
PDE 2EL has been shown by Horton et al (1995) to be a splice variant o f the 
PDE4A gene. The activity of 2EL could not be examined by expression in  a cell 
system because it  is inactive catalytically. This catalytic inactivation is due to a 
34 bp insert in the presumed catalytic domain, which results in the premature 
truncation o f the protein sequence. The significance, physiologically, o f the 
production o f catalytically inactive proteins is unknown. Bolger et al (1993) 
have isolated a variant of PDE46, called TM3. In this study, Bolger et al (1993) 
described TM3 as being a product which is expressed only in yeast, and not 
translated as a protein product in human cells. It has been considered by Horton 
et al (1995) that the production o f non-functional mRNAs, such as 2EL and 
TM3, in human cells is a type o f safety mechanism used to control the 
expression level o f functional PDE activity. However, it  could be that such 
variants influence PDE activity. Here we wanted to know whether 2EL was 
inactive due to the 34bp insert, or an inhibitory 5' domain. To test the latter, a ■ i
chimera was made o f the 5 'domain o f 2EL and the complete C-terminal region 
o f h6.1. O f interest in this present study, was the unique N-terminal region o f 
2EL which was investigated using the chimeric protein H Y B l.
Yeast strains Y M S ll, YMS12, H Y B l and lOAORF a ll 
expressed activity which was distributed between the pellet and soluble 
fractions (table 5). Pelleted h6.1 activity (chapter 3 section 3.2.Ü), was shown 
not to be affected by either centrifugation or treatment w ith either high 
concentrations o f salt or the detergent TX1(X). It was anticipated that i f  h6.1 had
a weak interaction w ith the membrane, then it  would be released by
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recentrifugation. S im ilarily, i f  the enzyme was either peripherally bound or an 
integral membrane protein, then the activity would have been released by 
sodium chloride and TXlOO respectively. Irrespective o f treatment, the activity 
remained in the pellet fraction. The insoluble pellet fraction o f each Y M S ll, 
YM S12, H Y B l and lOAORF could be an artifact o f the expression in yeast, as 
h6.1 expressed in COS-1 cells is exclusively cytosolic (Sullivan et al 1994). 
The pellet material could also represent either a sediment o f partially broken 
cells which settle upon centrifugation, or simply an aggregate o f protein.
Comparison o f the catalytic activities o f Y M S ll, YMS 12, 
H Y B l and lOAORF showed that each form  hydrolysed cyclic AMP with high 
a ffin ity and displayed linear kinetics (figs 4.2.5 - 4.2.8, table 6). Statistical 
analysis (table 6) o f the Km values calculated fo r each enzyme form, 
demonstrated that the values were not significantly different from h6.1, with the 
exception o f lOAORF (p=0.025). Y M S ll, YMS 12, H Y B l, lOAORF andh6.1 
a ll share an identical core catalytic region which would explain the observed 
sim ilarity in the Km- The N-term inally extended version o f h6.1, lOAORF, 
hydrolysed cyclic AMP w ith a significantly lower Km than that calculated for 
h6.1 (table 6). This would suggest that the N-terminal region o f lOAORF can 
affect substrate hydrolysis. Shakur et al (1995) have previously shown the 
regulation o f catalytic activity by the N-terminal region o f a rat PDE4A enzyme 
R D I. In this case, the relative Vmax values calculated fo r R D I and the N- 
terminally truncated species m et^^RDl, showed that the extended N-terminal 
region o f R D I was inhibitory. Further studies on a splice variant o f R D I, 
RPDE6 (McPhee et al 1995), in rat brain showed that the alternative splicing o f 
the N-terminus allows a further attenuation o f catalytic activity. Thus, it seems 
like ly  that the difference found in the Km value between h6.1 and the N- 
term inally extended lOAORF is a true observation, considering the evidence 
reported for the control o f catalysis by the N-terminus o f proteins encoded by a 
related rat gene. Whether differences in the Vmax values exist between enzymes
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reported in this present study remains to be determined. It was an aim o f this 
study to calculate such values, using an h6.1 antiserum. The h6.1 antiserum 
could have been used to immunoprecipitate equal amounts o f activity from each 
o f the yeast strains. Thus, one could define relative Vmax values, and determine 
any differences in such, for each yeast strain. This has already been shown for 
R D I expressed in COS-1 cells (Shakur et al 1995), to demonstrate a reduced 
Vmax for R DI as compared to the truncated met^hRDl. However, this present 
study was unable to determine relative Vmax values for either YMS 11, YMS 12, 
H Y B l, lOAORF or h6.1 due to the inability to produce an h6.1 antisera (Dr 
N eil Brown). Despite repeated attempts using several peptides a suitable 
antibody could not be produced.
Comparison o f the Km values calculated fo r Y M S ll, YMS 12 
and H Y B l showed that there was no significant difference with that o f h6.1 
(table 6). The Km value calculated for lOAORF was found to be significantly 
different from h6.1, which suggests a role for the N-terminally extended region 
o f lOAORF in catalysis. The next stage in  this study was to determine 
differences, i f  any, between the various enzyme forms w ith respect to the 
inhibition by the PDE4 inhibitor rolipram, and thus, elucidate a possible role for 
the N and C termini o f h6.1 in the interaction with inhibitor. In order to do this, 
IC50 values were calculated from the dose-rcsponse curves to rolipram for each 
o f the enzyme forms (figs 4.2.9 - 4.2.12). Statistical analysis o f these values 
(table 6) have shown a significant difference between the IC50 for each enzyme 
from h6.1, with the most significant being Y M S ll, YMS 12 and H Y B l. This 
observation indicates that both the N and C terminii have a role in the interaction 
o f inhibitor. O f particular importance is the observation that Y M S ll, which 
consists o f only the catalytic unit, can s till bind and interact w ith inhibitor 
despite the lack o f flanking N and C terminal regions. The most profound 
difference was shown between the IC 50 to inh ib it lOAORF as compared to 
either Y M S ll, YMS 12 or H Y B l, where approximately ten fo ld less inhibitor
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was necessary to inh ib it lOAORF. Thus, although the C-terminal region does 
play a role in inhibitor interaction, as shown by the elevated IC50 compared to 
h6.1 for Y M S ll and YMS 12, the N-terminus is likely to be more important.
The N-terminus o f h6.1, and the extended N-terminus o f 
lOAORF must contain specific information for inhibitor interaction. Removal o f 
either the C-terminus only (YMS 12), or the N and C term in ii together 
(Y M S ll), have sim ilar effects w ith respect to the IC 50 , which suggests that 
any truncation o f the h6.1 sequence disrupts the way in which the protein folds 
and orientates for interaction with substrate and inhibitor. It is the conclusion of 
this study, however, that the N-terminus is more important in these functions. 
Evidence to support this is that the extension o f the N-terminus o f h6.1 
enhances catalysis and interaction with inhibitor, where approximately ten fold 
less inhibitor is necessary to inhib it substrate hydrolysis o f lOAORF than either 
o f the truncates or H Y B l. Additionally, substituition o f the N-terminus with a 
different sequence (H Y B l) from  h6.1, causes an increase in the IC 50 for 
rolipram inhibition (table 6). Taken together, this evidence supports a role for 
the N-terminal region in allowing the optimal orientation and conformation 
necessary, for catalysis and interaction with inhibitor.
W ith the observation that lOAORF was more potently inhibited 
by rolipram than h6.1 (table 6), the next stage was to investigate whether this 
increased sensitivity arose from an alteration in the kinetics o f inhibition. As 
described in chapter 3, rolipram was shown to be a simple competitive inhibitor 
o f h6.1. In this chapter a comparitive analysis fo r rolipram inhibition was 
carried out fo r lOAORF. Linear Lineweaver-Burke (fig. 4.2.13) and Dixon (fig 
4.2.14) plots were obtained fo r lOAORF. Using the Lineweaver-Burke plot 
data (fig. 4.2.13), slope replots (4.2.15) were constucted which were shown to 
be curvilinear as found w ith the hPDE4ALivi enzyme (chapter 3, fig. 3.2.16). 
It would seem therefore, that lOAORF is partially competitively inhibited by 
rolipram, whereas h6.1 is competitively inhibited. This data would suggest that
1 25
............................................ ...........
the extended N-terminal domain o f lOAORF, alters the conformation o f the 
active site to allow both substrate and inhibitor to bind at the same time. A 
schematic representation o f partial competitive inhibition is shown in chapter 3, 
fig . 3.2.17.
Measurement o f an enzymes thermostability, over a time course, 
at a fixed temperature, can provide two important pieces o f information. Firstly, 
the to.5 value, that is, the time at which activity decays to half maximal, gives an 
indication as to how stable the enzyme is. Therefore, it  is possible to determine 
i f  alterations to the enzyme structure, sim ilarily alter enzyme stability. Secondly, 
the progress o f the time course gives an indication o f whether the sample which 
is being assayed, consists o f a single or mixed population o f enzyme. Using 
this experimental method the thermostability, at 45 'C, was measured for each 
lOAORF, YMS 12 and H Y B l. The resultant to.5 values would reveal i f  changes 
to the N-terminal region o f h6.1, either the extension o f this region (IGAORF), 
or sequence substituition (H Y B l), affected the thermostability. In addition, 
measurement o f the thermostability o f YMS 12 would show i f  the C-terminal 
region had any influence. Shown in figure 4.2.16 are the plots o f log 
percentage activity versus time for lOAORF, YMS 12 and H Y B l. Each enzyme 
form  decayed as a single exponential, thus, the enzyme activity assayed is 
represented by a single population. Statistical analysis o f this data (table 7) has 
shown that the N-terminus o f h6.1 has a vital role in stability o f the enzyme. 
The extension o f h6.1 N-term inal region, in  lOAORF, increased the 
thermostability by more than three fold. This to.s value calculated for lOAORF 
was significantly greater than that calculated fo r h6.1 (p=0.0(X)l table 7). 
S im ilarily, the domain swop contained w ithin the sequence o f H Y B Î, was 
shown to cause a significant reduction in the thermostability o f h6.1 activity 
(p=0.001 table 7). The truncation o f the C-terminal region (YMS 12) had the 
least significant effect on thermostability (p=0.021 table 7). The extension o f 
the N-terminal region o f h6.1 (lOAORF) increased enzyme thermostability.
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presumably, by allowing the protein to adopt a conformation in which the 
enzyme could resist thermal dénaturation. By swopping the N-terminal domain 
o f 2EL w ith h6.1 (H Y B l), and therefore changing the sequence o f the N- 
terminal region, the ability to resist thermal dénaturation was reduced compared 
to h6.1. This loss o f thermostability presumably occured, because the protein 
could not adopt the same conformation as h6.1 due to N-terminal sequence 
differences. Thus, the to.5 value o f H Y B l was reduced significantly lower than 
that o f h6.1 (p-0.001 table 7). The observation in  this study, that protein N- 
terminal regions promote stability o f enzyme activity is not a novel one. The N- 
terminal region o f the PDE4A R D I was shown by Shakur et al (1993) to be 
necessary for enzyme stability. The N-terminal tmncate met 26rd1 displayed a 
to.5 value which was less than that calculated for RDI.
Studies on the rat PDE4A species (McPhee et al 1995, Shakur et 
al 1993,1995) has highlighted the important contributary role o f the N-tenninal 
domain o f these enzymes in cell location, thermostability and enzyme activity 
(see discussion section chapter 5). As described in chapter 5, the N-terminal 
domain o f the rat enzyme had profound effects on Vmax and thermostability. 
By analogy to the rat species, this study has determined an important role o f the 
N-terminal domain o f the human species in thermostability, substrate hydrolysis 
and inh ib itor interaction. Analysis o f the mechanism by which rolipram 
inhibited lOAORF has indicated that a change in the enzyme conformation had 
occured from that o f h6.1. This change in conformation allowed a switch from 
competitive inhib ition (h 6 ,l) to partial competitive inh ib ition (lOAORF). 
Evidence in  support o f a conformational change is provided by the 
thermostability data (fig. 4.2.16, table 7). A t 45*C, lOAORF was shown to be 
significantly more thermostable than h6.1, which would indicate that a 
conformational change had occured.
O riginally it  was thought that the amino acid differences seen 
between hPDE4ALivl and h6.1 were the cause o f the differences in mechanism
.2,
o f inhibition by rolipram. However, this study conducted on lOAORF would 
dispute this since partial competitive inhibition was seen w ith rolipram, as per 
hPDE4ALivi. It is the conclusion o f this study that a conformational change 
occured to the lOAORF enzyme, induced by the N-terminal domain extension.
This could account for the difference in kinetics of rolipram inhibition seen with 
h6.1. The reason for kinetic differences, with respect to inhibition by rolipram, 
between h6.1 and hPDE4ALivi remain unclear. However, it is possible that a 
modification to hPDE4ALivi occured during the enzyme preparation.
Future studies are like ly  to focus on the investigation o f h6.1 
and lOAORF in vivo. Indeed, studies are necessary to investigate the functions 
o f the various true splice variants o f the human PDE4A gene isolated so far, 
such as PDE46, TM3 (Bolger et al 1993), 2EL (Horton et al 1995). It w ill also 
be necessary to establish i f  a protein o f the size o f h6.1 is expressed in vivo.
This would clarify i f  h6.1 is a true splice variant o f the PDE4A gene, as 2EL is, j
or simply a truncated protein o f the PDE46 sequence. Irrespective o f this, h6.1 |
provides a good model fo r the pharmacological investigation o f PDE4A 
selective inhibitors, since its sequence includes the catalytic domain.
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TabIe..JS Spgçific-A.gt?YUi€S of PPE AçtTYity in SaççM rQ m yç^?  
c.mvism  Espipgsins-HYBliYMSll» YMSi? and 
1MÛEE
Enzyme Species Specific Activity (pmol/min/mg)
Pellet Soluble
H Y B l 1.14 ±0 .3 1.4 ± 0.4
lOAORF 21,7+1 .7 15.7 ±  1.8
Y M S ll 0.43 ± 0.1 0.76 ±  0.2
YMS 12 5.99 ±  1.2 0.46 ±  0.2
The results are shown as mean ± standard deviation fo r three separate 
preparations.
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Table 6 Kin'y'”'  aiid .ICso'’"” '^'”'". Cata .for SoluMe
H Y B l. Y M S ll. YMS12 and lOAORF. in Comparison 
with 1)6.1
Enzyme Species Km  cyclic AMP 
(pM)
IC 50 ^tipram
(liM )
h6.1 4.1±1.7 0.51 ±0.15
H Y B l 2.04+0.2 1.93 ±  0.23
(p=0.0001)
lOAORF 1.9±0.2 0.19 ±0 .02
(p=0.025) (p=0.004)
Y M S ll 4.3±1.3 2.4 ±  0.2
(p=0.0001)
YMS 12 5.9±0.7 1.7±0.14
(p=0.0001)
Values are shown as mean ±  standard deviation fo r at least three separate 
experiments.
Data in parenthesis are significance values calculated using the students t - test. 
The significance values were calculated to examine differences between h6.1 
and the other enzyme species.
IC 50 was the concentration which resulted in 50% inh ib ition  o f enzyme 
activity.
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Table d Thermostability Values Calculated for Soluble 
YMSI2^10AOKE-âiidJ Y B l at.....45°£» and 
ComparisQg wltb b^.I
Enzyme Species Thermostability at 45“C 
(to.5)
Significance Value 
Students t-test
h6.1 10 minutes
YMS 12 13 minutes p=0.021
lOAORF >30 minutes p=0.0001
H Y B l 3 minutes p=0.001
Significance values were calculated using the students t -test to compare the 
values for H Y B l, YMS 12 and lOAORF with h6.1.
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Fie, 4.1.1 Schematic Alignment of Mammalian PDE 
IsofQrm Famiiigs
This figure diagramatically shows the structural features o f mammalian PDE 
isoforms. (Beavo &  Reifsnyder 1990).
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caJmodülin binding 
domain
Ca^'^-calmodulin-dependerfamily
catalyticdomain
•i
cGMP binding 
domain catalyticdomain
cGMP-slimulatedfamily
catalyticdomain
cAMP-spedfîcfamily
cGMP binding catalytic
domain domain
cGMP-specificfamily
F ig. 4.1.2 Alignment of Jauman and Rat PDE4 mRNA
Shown is the schematic representation o f the four human and rat PDE4 
mRNA's, at the top and bottom respectively. Common sequences are shown by 
heavy merged lines. Areas o f unique sequence which are conserved between 
human and rats, and are unique to any PDE4 subtype are shown by the thin 
cross hatched lines. Thin solid lines indicate variant sequence which is not 
conserved between human and rat. Triangles in  the rat clones show variants 
lacking a block o f sequence as compared to other transcripts from the same 
locus. Initiation codons are shown by small boxes and termination codons by *. 
Vertical dashed lines show splice points that occur in homologous positions in 
clones from different loci. Roman numerals show various alternative spliced 
isoforms from the dune locus.
(Bolger et al 1993).
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IV
IVA
V7 Dunce
*  PDE4A
8 V
PDE4B
PDE4C
14
PDE4D15
17
19 V
Consensus UCR1 UCR2 Catalytic
F i^. 4.2.1 Schematic Representation o f Truncations o f
h Â d
Shown diagramatically are the truncations made to the sequence o f h6.1 to 
obtain YMSIO, YMS 11 and YMS 12.
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h6.1
Met’
1
G lu-^
168
Glu
601
-Thr/Stop
686
YMS 10
Met/Glu
168
Glu
601
Thr/Stop
686
YMSll
Met/Glu-
168
Glu
601
Thr/Stop
686
YMS 12
Met-----
1
Glu
168
Glu/Stop
601
F ig . 4.2.2 A lig n m m l_ 9 f thg S?qm?hçgs p f M â t  . f îy p i
andJEL.
Sequence alignments were made using the Gene Jockey programme, and were 
aligned to the sequence o f h6.1. The amino acids o f h6.1 which are different to 
that o f hPDE4ALivi are shown boxed.
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30 40 50
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  MCPFPVTTVPLGGPTPVCKATLSEETCQQLARETLEELDWCLEQLE'IMQTYRSVSE 
HYB 1 p ep  san d o z  
2EL p e p t i d e
60 70 80 90 100
I
110
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  MASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEIPSPTMKEREKQQ 
HYB 1 p ep  san d o z  
2EL p e p t i d e
120
I
130 140 150 160
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
APRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTDQEELLAQE
MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQE
MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQE
170 180 190 200 210 220
I I I I I I
C o n tig #  1    * ...................* • • • •
h 6 .1  a a  ORF e n g in e e r e d  LENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLED 
HYB 1 p ep  sa n d o z  LENn^GLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLED
2EL p e p t i d e  LENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLED
230 240 250 260 270 280
I I I I I I
C o n tig #  1 * ............................................. .........................................................................................
h 6 .1  a a  ORF e n g in e e r e d  HYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 
HYB 1 p e p  san d o z  HYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV
2EL p e p t i d e  HYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV
290 300 310 320 330
I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
SNQFL1MNSELALMYNDESVLENHHLAVGFKLLQE0SICDIFQNLSKRQRQSLRKM
SNQFLIM!NSELALiy[YNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKM
SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSRRQRQSLRKM
340 350 360 370 380 390
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
VIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADL
VIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRHMVHCADL
VIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRJSjMVHCADL
400 410 420 430 440
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p ep  san d o z  
2EL p e p t i d e
SNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDY 
SNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDY 
SNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVQARGI
450 460 470 480
I
490 500
IVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLP
IVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLP
DGRAQGGFY
510 520 530 540 550 560
I I I I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  DKFQFELTLEEEEEEEI^QlgOTAQEALTEQGLGGVEEALDATIAWEASPAQES 
HYB 1 p e p  san d o z  DKFQFELTLEEEEEEEISMAQIPCTAQEALTEQGLSGVEEALDATIAWEASPAQES
2EL p e p t i d e
570 580 590 600 610
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  sa n d o z  
2EL p e p t i d e
LEVMAQEASLEAELEAVYLTQQAQSTG^VAPDEF^REEFWAVSHS S PSALAL 
LEVMAQEASLEAELEAVYLTQQAQSTGSAPVAPDEFSSREEFWAVSHS S PSALAL
620 630 640 650 660 670
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
QSPLLPAWRTLSVSEHAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSA
QSPLLPAWRTLSVSEHAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSA
680
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
2EL p e p t i d e
LPAPGGGGSGGDPT
LPAPGGGGSGGDPT
Fig. 4.2.3 Alignment of the Sequences of lOAORF and
PDE46
Sequence alignments were made using the Gene Jockey programme, and were 
aligned to the sequence of PDE46 (top sequence).
136
____ ____
■10 20 30 40 50 60 70
I I I I ! i I
MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQPHRPIERADAMDTSDRP
IPALPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQPHRPIERADAMOTSDRP 
I I I I I I10 20 30 40 50 60
80 90 100 110 120 130 140 150
I I I I I I I I
GLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRSDSDY
GLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRSDSDY 
1 I I I I I I 1 .
70 80 90 100 110 120 130 140
160 170 180 190 200 210 220 230
I I I I I I I I
DMSPKTMSRNSSVTSEAHAEDLIVTPFAQVLASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLA
DMSPKTMSRNSSVTSEAHAEDLIVTPFAQVtASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLA 
I I I I I I I
150 160 170 180 190 200 210
240 250 260 270 280 290 300
I I I I I I I
RETLEELDWCLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEIPSPTMKER
r e t l e e ld w c le q l e tm q ty r s v s e m a s h k f k r m ln r e l th l s e m s r s g n q v s e y i  s t t f l d k q n e v e i  p s p tm k e r  
I I I I I I I I
220 230 240 250 260 270 280 290
310 320 330 340 350 360 370 380
I I I I I I I I
ek q q a pr pr psq pppppv ph lq pm sq itg lk k lm h sn sln n sn iprfg v k td q eella q elen lisik w g ln ifc v sd y
e k q q a p r p r p s q p p p p p v p h lq p m s q i tg lk k lm h s n s ln n s n ip r f g v k td q e e l la q e le n ln k w g ln i f c v s d y  
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300 310 320 330 340 350 360 370
390 400 410 420 430 440 450 460
I I I I I I I I
AGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLEiAADVLQSTHVLLATPALDAVFTDLE
a g g r s l t g  i m y m i f q e r d l lk k f r i  p v d t m v ty m l t l e d h y h a d v a y h n s lh a a d v lq s th v l l a tp a ld a v f td le  
I I I I I ! I I
380 390 400 410 420 430 440 4S
470 480 490 500 510 520 530
I I I I I I 1
ila a lfa a a ih d v d h pg v sn q flin tn sela lm y n d esv len h h la v g fk llq ed n c d ifq n lsk r q rq slr k m v id
i l z v a l f a a a ih d v d h p g v s n q f l i n tn s e l a lm y n d e s v le n h h la v g f k l lq e d n c d i f q k ls k r q r q s l r k m v id  
I I I I I I I460 470 480 490 500 510 520
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540 550 550 570 580 590 600 610
I I I I I I I I
MVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ
MVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ 
I I I I I I I I
530 540 550 560 570 580 590 600 '
620 630 640 650 660 670 680 690
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GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEE
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEE ,
610 620 630 640 650 660 670
710 720 740700 730 750 760 77
ESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASL '
ESRGPGHPPLPDKFQFELTLEEEEEEEISMAQÏPCTAQEALTEQGLSGVEEALDATIAWEASPAQESLEVMAQEASL
690 710 720 730 740 750700
790 800 820 840780 810 830
EAELEAVYLTQQAQSTGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLPSTAAEVE
EAELEAVYLTQQAQSTGSAPVAPDEFSSREEF
760 770 780 790
850 860 870 880
AQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
Fig. luZA A lignment o f the Sequences o f h 6 ,l. H Y B l. 
2EL. YM SIO . Y M S ll. YMS12. lOAORF and 
E M M
Sequence alignments were made using the Gene Jockey programme, and were 
aligned to the sequence o f PDE46. The amino acids o f h6.1 which are different 
to that o f hPDE4ALivi are shown boxed.
137
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I 1 I I IC o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p ep  sa n d o z  
YMS1 1 /PEPTIDE
HPDE4 6 . PEP MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAE,
YMS12
YMSIO/PEPTIDE
60 70 30 90 100 110
I I I I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  sa n d o z  
YM Sll/PEPTIDE
HPDE46 . PEP RERQPHRPIERADAMDTSDRPGLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAEN
YMS12
YMSIO/PEPTIDE
120 130 140 150 160
I I I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p ep  san d o z  
YMS 1 1 /PEPTIDE
HPDE4 6 . PEP GPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRSDSDYDMSPKTMSRNSSVT
YMS12
YMSIO/PEPTIDE
170 180 190 200 210 220
I I I I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  MVLPSDQGCPFPVTTVPLGGPTPVCKATLSE
HYB 1 p e p  san d o z  
YM Sll/PEPTIDE
HPDE4 6 . PEP SEAHAEDLIVTPFAQVLASLRSVRSNESLLTNVPVPSNKRSPLGGPTPVCKATLSE
YMS12 MVLPSDQGCPFPVTTVPLGGPTPVCKATLSE'
YMSIO/PEPTIDE
230 240 250 260 270 280
I I ! I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  ETCQQLARETLEELDWCLEQLETMQTYRSVSEMASHKFKRMDNRELTHLSEMSRSG. 
HYB 1 p e p  san d o z  
YM Sll/PEPTIDE
HPDE4 6 . PEP ETCQQLARETLEELDWCLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSG
YMS 12 ETCQQLARETLEELDWCLEQLETMQTYRSVSEMASHKFKRMDNRELTHLSEMSRSG
YMSIO/PEPTIDE
290 300 310 320 330
I I I I I
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  NQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQIT 
HYB 1 p e p  san d o z  
YM Sll/PEPTIDEHPDE4 6. PEP NQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPPILQPMSQIT ■
YMS 12 NQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQIT
YMSIO/PEPTIDE --------------------------------------------------------------------------------------------------------
340 350 360 370 380 390
I I ! I I I
C o n tig #  1 » ....................................................
h 6 .1  a a  ORF e n g in e e r e d  GLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLT 
HYB 1 p ep  sa n d o z  MFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLT
YM Sll/PEPTIDE MELENLNKWGLNIFCVSDYAGGRSLT
HPDE4 6 . PEP GLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELENHNKWGLNIFGVSDYAGGRSLT
YMS12 GLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELEMLNKWGLNIFCVSDYAGGRSLT
YMSIO/ PEPTIDE MELENLNKWGLNIFCVSDYAGGRSLT
 ■  ___
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
Y M Sll/PEPTIDE 
HPDE46.PEP 
YMS12
YMSIO/PEPTIDE
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p e p  san d o z  
YM Sll/PEPTIDE 
HPDE46.PEP 
YMS12
YMSIO/PEPTIDE
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d  
HYB 1 p ep  sa n d o z  
Y M Sll/PEPTIDE 
HPDE46.PEP 
YMS 12
YMSIO/PEPTIDE
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d
HYB 1 p e p  san d o z
YM Sll/PEPTIDE
HPDE46.PEP
YMS12
YMSIO/PEPTIDE
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d
HYB 1 p e p  san d o z
YM Sll/PEPTIDE
HPDE46.PEP
YMS12
YMSIO/PEPTIDE
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d
HYB 1 p ep  san d o z
YM Sll/PEPTIDE
HPDE46.PEP
YMS12
YMSIO/PEPTIDE
400
I
410 420
I
430 440
CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVL 
CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVL 
CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVL. 
CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVL 
C IMYMIFQERDLLKKFRI PVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVL 
CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVI,
450 460 470 480 490 500
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLEN’
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLEN
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTMSELALMYMDESVLEN'
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELAIMYNDESVLEN
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLEN
LATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLEN
510
I
520
I
530
I
540
I
550
I
560
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
HHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMV
570 580
I
590 600 610
ETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ
ETKKVTSSGVLLLDNYSDRIQVLFNMVHCADLSNPTKPLELYRQWTDRIMZiEFFQQ
ETKKVTSSGVLLLDNYSDRIQVLRM4VHCADLSNPTKPLELYRQWTDRIMAEFFQQ
ETKKVTSSGVLLLDNYSDRIQVLRMMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ
ETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ
ETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQ
620 630
I
640
I
650
I
660
I
670
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
GDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTL
680
I
690 700 710 720
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
EDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPC
730 740 750 760 770 780
C o n tig #  1 ....................... ........................................................................................ ........................
h 6 .1  a a  ORF e n g in e e r e d  TAQEALTEQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQ 
HYB 1 p e p  sa n d o z  TAQEALTEQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQ
YMSll /  PEPTIDE TAQEALTEQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQ
HPDE4 6 . PEP TAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQ
YMS 12 ta q ea lteqg lsg v eeald a tia w ea spa q eslev m a qea slea eleAvyltqqaq
YMS 1 0 / PEPTIDE TAQEALTEQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQ
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d
HYB 1 p e p  san d o z
YM Sll/PEPTIDE
HPDE46.PEP
YMS12
YMSIO/PEPTIDE
790
I
800 810 820 830
I
840
STGSAPVAPDEFSSRE^FWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP-
STGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP'STGSAPVAPDEFSSREE
STGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP
STGSAPVAPDEFSSREE
STGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP
850 860 870 880
C o n tig #  1
h 6 .1  a a  ORF e n g in e e r e d
HYB 1 p ep  san d o z
YM Sll/PEPTIDE
HPDE46.PEP
YMS12
YMSIO/PEPTIDE
STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
Fis. 4 .2..5. Determination of Km ^^P_EQr_Soluble 
I Q A Q R F
Lineweaver-Burke p lo t was constructed by the measurement o f soluble 
lOAORF activity in  the presence o f increasing cyclic AMP concentrations. 
A ctiv ity  was linear over the ranges o f cyclic AMP shown. Km values were 
calculated using the U ltra fit programme as described in results, and the data is 
shown in table 6.
This experiment is mpresentative o f one carried out at least three times.
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Fis. 4,2.6 D eterm ination o f Km  For 8oX#W
H -Y .£ l
Lineweaver-Burke plot was constructed by the measurement o f soluble H Y B l 
activity in the presence o f increasing cyclic AMP concentrations. A ctivity was 
linear over the ranges o f cyclic AMP shown. Km values were calculated using 
the U ltra fit programme as described in results, and the data is shown in table 6. 
This experiment is representative o f one carried out at least three times.
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Eig....,4x2xZ Determination of am p y q t  Soluble
Y M S ll
Lineweaver-Burke plot was constructed by the measurement o f soluble YMS 11 
activity in the presence o f increasing cyclic AMP concentrations. A ctivity was 
linear over the ranges o f cyclic AMP shown. Km values were calculated using 
the U ltrafit programme as described in results, and the data is shown in table 6. 
This experiment is representative o f one carried out at least three times.
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Fig,_A2.S Determination of a m p  por Soluble
XMS12
Lineweaver-Burke plot was constructed by the measurement o f soluble YMS 12 
activity in the presence o f increasing cyclic AMP concentrations. Activ ity was 
linear over the ranges o f cyclic AMP shown. Km values were calculated using 
the U ltra fit programme as described in results, and the data is shown in table 6. 
This experiment is representative of one carried out at least three times.
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Figi 4.3,9 Ppsg-R^ sponsg to Rolipram of SpluMg.
IQA.QEF
Soluble lOAORF activity was measured at a fixed concentration o f cyclic AMP 
(3|J.M), which approximated that o f the Km, in the presence o f increasing 
rolipram concentration. The resultant IC50 value is given in table 6.
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Fis»—A.2.tl.Q. Dose-Response to Rolipram of Soluble
H Y B l
Soluble HYB 1 activity was measured at a fixed concentration o f cyclic AMP 
(3|i.M), which approximated that o f the Km, in the presence o f increasing 
rolipram concentration. The resultant IC50 value is given in table 6.
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Fig. Dose-Response to Rolipram of Soluble
XMSn
Soluble YMS 11 activity was measured at a fixed concentration o f cyclic AMP 
(3|LtM), which approximated that o f the Km, in the presence o f increasing 
rolipram concentration. The resultant IC50 value is given in table 6.
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Fig, 4,2,13 Pose-Response to Rolipram of Soluble
YM S12
Soluble YMS 12 activity was measured at a fixed concentration o f cyclic AMP 
(3|xM), which approximated that o f the Km, in the presence o f increasing 
rolipram concentration. The resultant IC50 value is given in table 6.
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Kinetics Qf RQliDram Inhibition of Soluble
IQAORF
Soluble lOAORF activity was measured over the range o f 1 - 20p.M cyclic AMP 
in the presence o f increasing concentration o f rolipram. This experiment is 
representative o f one done at least three times.
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Dixon Reolot of Rolipram Inhibition of Soluble 
IM Q E E
Data is shown as the reciprocal o f activity versus increasing concentration o f 
rolipram (Dixon and Webb 1979). This experiment is representative o f one 
done at least three times.
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F ig. _.A,2J5 Slope Reolot of Rolipram Inhibition of Soluble
lOAORF
Data is shown as the slope replot o f activity versus increasing concentration o f 
rolipram. This experiment is representative o f one done at least three times.
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T herm ostab ility  o f Solub le  XQAORF. H Y B l 
aj2.0MSi-2jaL.45.:£
Thermostability o f lOAORF, H Y B l and YMS12 was measured at 45°C. The 
resulatant to.s values are shown in table 7.
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Results - Chapters 
Analysis of Rat PDE4A RDI
 :  •  ...................
5.1 Introduction
Dune mutants o f Drosophila, melano g aster carry a genetic 
mutation at the chromomere region 3D3 - 3D4 and display particular phenotypic 
characteristics which include learning difficulties (Byres et al 1981), and both 
female (Mohler 1973, 1977) and male (Kiger 1977) in fe rtility . The phenotype 
o f dune mutants is the result o f abnormal cyclic AMP metabolism, due to a 
genetic mutation o f the dune gene. Isolation o f the dune gene (Davis &  
Davidson 1984) and the subsequent biochemical, genetic and molecular analysis 
(Byres et al 1981, Davis &  K iger 1981, Chen et al 1986) have shown that it 
encodes a cyclic AMP specific PDE.
Given the importance o f the dunce gene in  D roso p h ila  
melanogaster it was considered whether the gene was structurally and 
functionally conserved in mammals. Using a probe representing dune, Davis et 
al (1989), screened a variety o f genomic cDNA libraries, including rat, which 
led to the isolation o f the rat dune -1 gene. A fragment o f the rat dune -1 
genomic clone, which had a high degree o f homology to the Drosophila  
melanogaster dune gene, was used to probe a rat brain cDNA library. From 
this screen, three clones R D I, RD2 and RD3 were isolated. R D I was shown to 
be the largest clone, w ith a complete ORF encoding a protein o f some 610 
amino acids and predicted molecular weight o f 68kDa. The RD2 and RD3 
clones were smaller, w ith truncations at the 3' end. However, the isolation o f 
RD2 and RD3 suggested that R DI may be alternatively spliced in vivo and that 
RDI may not reflect a fu ll length PDE. The pattern o f tissue expression o f RDI 
was also analysed (Davis et al 1989). The major RNA transcripts detected in the 
whole rat brain and cerebellum were o f a different size (4kb) to that detected in 
heart, lung and testes (4.4 kb), suggesting different levels o f control o f R D I 
mRNA transcription in different tissues. However, it was found that mRNA for 
RDI occuredpredominantly in the brain.
1 5 0
The amino acid sequence o f R D I was found to be 76% 
homologous to the dune gene product w ithin a conserved region suggested to 
contain the catalytic domain (Charbonneau et al 1986), although lim ited 
sequence sim ilarity was seen outside o f this region. Expression o f R DI in yeast 
(Henkel-Tigges &  Davis 1989) allowed the characterisation o f the enzyme, with 
respect to both inhibitor sensitivity and substrate specificity. R DI was shown to 
hydrolyse cyclic AMP specifically w ith a Km o f -  4pM. It was also highly 
sensitive to inhibition by the compounds rolipram and RO-20-1724, with IC 50 
values o f 0,7 and 4.2pM respectively. The inhibition o f the cyclic AMP 
hydrolysing activity o f RDI by rolipram was the factor which distinguished the 
mammalian enzyme from the Drosophila melanogaster dune gene product. 
Therefore, the sequences outwith the homologous region o f R DI may allow for 
the interaction o f PDE4 inhibitors. Rolipram, on the basis o f studies done on 
R D I, was suggested as being selective fo r this group o f cyclic AMP specific 
PDEs now known as the PDE4 family.
It is intriguing that dune mutants lacking the gene which 
encodes a cyclic AMP specific PDE exhibit a learning and memory defect in 
Drosophila melanogaster (Dudai 1983) whereas, in humans the PDE4 inhibitor 
rolipram  has anti-depressant properties (Watchel et al 1983). In addition, 
Nighom et al (1991) found that the dune PDE was concentrated in  a brain area 
in the rat, which has been associated w ith the processes o f learning and 
memory.
R D I activity has been analysed upon its expression in COS-1 
cells transfected w ith the recombinant vector pSVL-RDl (Shakur et al 1993). 
Isolation o f RNA from pSVL-RD l transfected COS-1 cells and hybridisation 
with a 32p.iabelled R D I cDNA, revealed a band o f 3.1kb. Translation o f R DI 
mRNA in vitro  revealed a 68kDa product. Membranes o f COS-1 cells 
transfected with pSVL-RDI expressed ~75% o f the total R D I activity, with the 
remainder being found in the cytosol. Engineered deletion o f the firs t 25 N-
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terminal amino acids o f R D I, yielded a truncated enzyme which was called 
met^bRDl. In COS-1 cells transfected w ith pSVL-met^bRDl, this truncated 
PDE activity was found as an active species located exclusively in the cytosolic 
fraction. Subcellular fractionation studies o f COS-1 cell membranes showed 
that R DI prim arily associated w ith the plasma membrane, but with a fraction 
which occured associated w ith the golgi. This was confirmed w ith confocal 
microscopy studies (Shakur et al (1995). RDI did not behave as a peripheral 
membrane protein, but required detergent such as TX-lOO, to solubilise 
activity. However, unlike integral membrane proteins there was no evidence for 
a transmembrane domain. This suggested that it  bound to the membrane 
through some other action. One suggestion made, was that the attachment o f 
R D I to the membrane might be through the acylation o f the N-terminal 
cysteines found in the 1 - 25 amino acid domain. Recent evidence (McPhee et al 
1995) has shown that the 'cytosolic R D I' activity found in COS-1 cells (Shakur 
et al 1993) was actually the N -term inally truncated protein met^^RD 1.
Expression o f met^^RDl resulted from the positioning o f the met^b residue o f 
R D I w ithin a suboptimal Kozak sequence. As such, in systems like COS-1 
cells, products could be formed from initiation o f the sequence at the met^^ 
residue, A soluble R D I activity is unlikely to exist in vivo , since soluble I
activity could not be immunoprecipitated from rat cerebellum homogenates I
(McPhee et al 1995).
Sequence comparison o f RD1 with the Drosophila melanogaster 
dune PDE, and another PDE4 species from the rat called the DPD enzyme 
(C ollice lli et al 1989), shows that they share homology over a central domain 
containing the catalytic region. However, the N and C terminal regions were 
shown to be distinctly heterologous (Davis 1990). It was thought, therefore, i
that the N-terminal region o f R D I might perform a specific function. R DI and i
met^bRDl shared similar properties regarding substrate specificity and inhibitor 
sensitivity (Shakur et al 1993). However, thermostability studies revealed that,
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at 50*C, membrane-associated R D I was more thermostable than either 
met^bRDl or the membrane-associated activity which had been solubilised. 
Therefore, the N-terminal domain contains information to locate R D I to the 
membrane, which allows the protein to adopt a conformation which increases 
its thermostability. This N-terminal domain also confers an inhibitory effect on 
catalytic activity (Shakur et al 1995). The truncate, met^bRDi, had a Vmax 
value for cyclic AMP hydrolysis which was two fold greater than that fo r RDI. 
The unique N-terminal region o f RDI not only determines the location o f RDI 
within the cell, but also has a regulatory effect on the catalytic activity.
Northern blot analysis o f various rat tissues revealed that R DI 
transcripts were found predominantly in the brain (Davis et al 1989, 1991). It 
was an objective o f this study to determine i f  a PDE species o f the molecular 
weight o f R DI was indeed expressed in brain, and to determine the properties 
that it had. In order to address these questions, this study focused the analysis 
on a specific membrane region, the cerebellum. In particular, it was investigated 
as to whether R D I, i f  it  was expressed, was associated w ith nerve terminals 
where the receptor /  adenylyl cyclase system occured. In the mammalian CNS 
the role o f cyclic AMP is less w ell characterised. However, it  has been 
associated with the processes o f neurotransmission by virtue o f its synaptic 
localisation (Therien and Mushynski 1979) and in mood regulation (Schneider 
et al 1986). To look at the role o f R D I, the use o f rat cerebellum synaptosomes 
were employed.
Neurones, and their support cells glia, do not survive the 
process o f homogenisation intact. Homogenisation causes the cell bodies to 
become disassociated from the nerve endings. Synaptosomes form when the 
post-synaptic cells and pre-synaptic membrane reseal to form osmotically active 
particles (Dunkley et al 1988). This process o f resealing entraps organelles o f 
the synapse (fig  5.1.1), including post-synaptic densities, synaptic vesicles, 
mitochondria and cytoplasmic enzymes such as lactate dehydrogenase, to form
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metabolically active synaptosomes (Gordon-Weeks). Synaptosome preparations 
were originally described using rat brain (Gray &  Whittaker 1962, DeRobertis 
et al 1962). The subcellular fractions which are enriched in synaptosomes, such 
as synaptic vesicles, have been used to study aspects o f synaptic function, for 
example, neurotransmitter release o f acetylcholine (Thorne et al 1991).
Availability o f antisera to R DI enabled the study o f the enzyme 
in rat brain. In particular, to study whether RDI was indeed expressed, and i f  
so, determination o f its location. This was done w ith the original intention o f 
extending the study to human tissue had a suitable PDE4A antibody been 
forthcoming. This proved not to be the case at the time o f this study. This 
chapter describes work carried out on a rat PDE4A species, with the purpose of 
investigating the distribuition between the membrane and soluble fractions o f 
the rat cerebellum, and to determine whether the RDI activity expressed in vivo 
was o f similar molecular weight as found with pSVL-RDI transfected COS-1 
cells. This work was enabled using an antiserum directed against a decapeptide 
sequence found in the C-terminal region o f RDI.
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5 .2  Results
(ilPreparation and Identification of Synaptosomes From Rat
Cerebellum
Rat cerebellum synaptosomes were prepared according to the 
method described in Dunkley et al (1988) and Thome et al (1991). B riefly, a 
post-nuclear supernatant (S I), which was obtained from the centrifugation 
(lOOOg X lOmin) o f a homogenate o f rat cerebellum tissue, was loaded onto 
percoll /  sucrose step gradients. A fter centrifugation o f the gradients, as per 
Dunkley et al (1988), the material that collected at the four interfaces (F I - F4 
inclusive), plus the pellet fraction F5, were carefully removed using a Pasteur 
pippette. A fter the washing procedure, as described by Dunkley et al (1988), 
each o f the fractions were analysed fo r occluded lactate dehydrogenase (LDH) 
activity (Johnson 1960, m odified by Marchbanks 1967). Measurement o f 
occluded LDH, a cytoplasmic enzyme, determines the integrity o f the 
synaptosomes and also provides a means to assess the reproducability o f 
synaptosome preparation between experiments. Non-occluded LDH  activity 
was assessed, in itia lly , and occluded activity was measured by the addition o f 
Triton X-100 (2%) which resulted in synaptosome rupture. By subtracting the 
LDH  activity prior to the addition o f TX-lOO, from that obtained after the 
addition o f TX-lOO, the amount o f occluded activity could be calculated.
The disribution o f LDH activity across the gradient obtained in 
this study (fig  5.2.2, table 8), resembled that obtained by Thome et al (1991) 
(fig  5.2.3), w ith the exception o f the F I fraction. The F I fraction was 
suggested by Dunkley et al (1988) to contain contaminating synaptic 
membranes as opposed to functional synaptosomes. It could be the case, in this 
study, that the vesicles found in the F I fraction, and which gave rise to the 
elevated occluded LDH activity, were derived simply from membrane fractions 
which had resealed and were not functional synaptosomes as found in fractions
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F2 and F3 (fig  5.2.2). The distribution o f occluded LDH activity across the rest 
o f the gradient was comparable to that o f Thome et al (1991) (fig  5.2.3).
The fractions collected, F I - F5, have been characterised by 
Thome et al (1991) and Dunkley et al (1988) by the presence o f marker 
enzymes. Synapsin I, a nerve terminal phosphoprotein which is predominantly 
found associated with synaptic vesicles (DeCamilli et al 1983), was present in 
fractions F2 - F4 predominantly. The F5 fraction was characterised as that 
which mainly contained mitochondria, by the abundance o f the marker enzyme 
pymvate dehydrogenase (Dunkley et al 1988), and the absence o f LDH activity 
(Thome et al 1991). In addition, Dunkley et al (1988) have described that this 
method o f synaptosome preparation allowed the separation o f synaptosomes 
with post-synaptic densities attached. Thorne et al (1991) have characterised the 
fractions fu rther by the d is tribu tion  o f the cho linerg ic marker 
acetylcholinesterase, which terminates the action o f the neurotransmitter 
acetylcholine. The distribution o f acetylcholinesterase activity obtained by 
Thome et al (1991) (fig  5.2.5) was similar to that obtained in this study from rat 
cerebellum (fig  5.2.4). The sim ilarity o f the distribution o f marker enzymes, 
LDH  and acetylcholinesterase, suggest that the fractions obtained in this study 
are comparable to that by Thome et al (1991) and Dunkley et al (1988).
(iilWestem Blot Analvsis o f R D I in Rat Cerebellum
Svnaptosomes
Using the anti - RDI antisemm, the fractions obtained from the 
gradient used to separate rat cerebellum synaptosomes, including the original 
post-nuclear supernatant applied to the gradient, were immunoblotted fo r R D I. 
The RDI antisera identified a single band o f molecular weight 73 ±  3kDa, This 
molecular weight was higher than that determined from  the cDNA sequence 
(-68kDa). However, Shakur et al (1995) have determined that the R D I 
im m unoreactivity from  cerebellum membranes m igrated w ith  R D I 
immunoreactivity obtained from COS-1 cells transfected w ith the R D I cDNA
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(fig  la  o f Shakur et al 1995). In addition, the RDI immunoreactivity found in 
cerebellum was predominantly membrane associated (92 ±  3%) (Shakur et al 
1995), as was the R D I activity expressed in COS-1 cells (-75% ) (Shakur et al 
1993).
D ensitom etric analysis o f the d is trib u tio n  o f R D I 
immunoreactivity in samples from the gradient used to isolate rat cerebellum 
synaptosomes in this study, showed that RDI was present to a greater degree in 
the F2 and F3 fractions (fig. 5.2,6). R D I was found, to a lesser extent, in the 
F I and F4 fractions. In the m itochondrial fraction F5, negligable 
immunoreactivity was detected.
('iii)Subffactionation o f the F2 and F3 Synaptosome Gradient 
Fractions
The fractions from  the synaptosome gradient which were 
enriched in R D I immunoreactivity, F2 and F3, were pooled, lysed and 
fractionated further on a sucrose density gradient to resolve different membrane 
populations as described by Shakur et al (1993). The lysate was centrifuged 
(2000rpm x 5min) to obtain a post-nuclear supernatant which was then applied 
onto the top o f a sucrose step gradient. The step gradient consisted o f a step o f 
0.5M sucrose (3m l) layered onto a step o f 1.6M sucrose (1m l). A fter 
centrifugation (50,000rpm x 30min), the membranes were harvested from the 
0,5 /  1.6M sucrose interface. The membrane fraction (~200p.l was 
supplemented w ith solid sucrose to give a concentration o f >1.6M, which has 
an equivalent refractive index o f >4.5. The membrane fraction was then loaded 
under a 0.6 - 1.6M sucrose continuous gradient and centrifuged (50,000rpm x 
IShours). Samples were then removed from the gradient in  200|il aliquots 
using a peristaltic pump.
(iv)Assav o f Subcellular Fractionation Samples for 5' 
Nucleotidase and Adenvlv Cvclase Activity
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Samples were collected from the subfractionation gradient as 
described above (section (iii), and assayed for the plasma membrane markers 5' 
nucleotidase as described by Newby et al (1975), (fig  5.2.7) and adenylyl 
cyclase as described by Houslay et al (1986) (fig  5.2.8). The distribution of the 
plasma membrane markers were sim ilar across the gradient. Samples of similar 
5' nucleotidase activity were pooled to provide enough protein for western 
blotting with the R D I C-terminal antisera.
(v)Westem Blot o f Subcellular Fractionation Samples with RDI 
Antisera
Densitometric analysis o f the western blot o f samples from the 
subcellular fractionation described above (section (iii), probed with the RDI 
antisera, has shown that the peak o f R D I immunoreactivity correlated with the 
peak o f 5' nucleotidase activity (fig  5.2.9). This suggests that in vivo . RDI 
activity is associated with the plasma membrane. Association o f RDI with the 
plasma membrane has previously been shown by Shakur et al (1993) for COS- 
1 cells transfected w ith R D I cDNA, Furthermore, the RDI activity expressed in 
COS-1 cells is identical in molecular weight to that detected in membranes 
prepared from rat cerebellum (section (ii) above).
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5 .3  CopçltisiQ ïis aW ._D.muggi9n
Using a probe representing the Drosophila melanogaster dune 
gene, Davis et al (1989) isolated the rat dune-I gene from a rat genomic cDNA 
library, A  fragment o f the rat dune -1 genomic clone, which had a high degree 
o f homology to the Drosophila melanogaster dune gene, was used to probe a 
rat brain cDNA library. From this screen, three clones R D I, RD2 and RD3 
were isolated. RDI was shown to be the largest clone, w ith a complete ORF 
encoding a protein o f 610 amino acids and predicted molecular weight o f 
68kDa.
Shakur et al (1993) have demonstrated that upon expression in 
COS-1 cells, the R D I cDNA encodes a protein o f the PDE4A class which is 
predominantly associated w ith the membrane fraction, in particular the plasma 
membrane. Membrane association was shown to be dependant upon the 
presence o f the first N-terminal 25 amino acids, since the truncated met^^RDl 
lacking these amino acids was exclusively cytosolic. This N-terminal region 
was also shown to confer thermostability (Shakur et al 1993) as well as the 
inhibition o f catalytic activity (Shakur et al 1995), in addition to determining the 
cellular location of the enzyme.
The major RDI RNA transcripts which were originally detected 
in the whole rat brain and cerebellum which were o f a different size (4kb) from 
those detected in heart, lung and testes (4,4kb) (Davis et al 1989). This 
suggested that different levels o f control o f PDE4A mRNA transcription was 
occuring in different tissues. However, it  was found that R D I mRNA 
transcripts were predominantly located in  the brain (Davis et al 1989). Thus, 
although the mRNA data indicated the presence o f R D I in  rat brain, it  was 
unknown as to whether an R D I PDE was actually expressed in such tissues, 
and to which cellular location the enzyme was targeted.
Shakur et al (1995) have addressed this question, and have 
investigated the R D I activity which is expressed in the cerebellum o f the rat
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brain. Using a C-terminal antisera to R D I, rat cerebellum homogenate, high 
speed pellet and membrane free cytosol fractions were probed w ith the 
antibody. Approximately 92% o f the total R DI immunoreactivity was found to 
be associated predominantly w ith the high speed membrane fraction. This 
correlated with the data obtained from the study with RDI expressed in COS-1 
cells, which showed that -75%  o f the R D I activity associated w ith the 
membrane fraction. The difference between the percentage o f R D I activity 
bound to COS-1 cell membranes and cerebellum membranes, might reflect 
differences in the availability o f membrane attachment sites in foreign host cells, 
as opposed to that found in vivo .
Although RDI was found associated with the membrane fraction 
upon expression o f the RDI cDNA in COS-1 cells, the truncated RDI species 
m et^bRDl, was found to be an exclusively cytosolic enzyme (Shakur et al 
1993). RDI and met^^RDl were found to be essentially the same with respect 
to kinetics o f cyclic AMP hydrolysis and inhibitor profile. The existence o f 
kinetically sim ilar membrane /  cytosolic associated enzymes has already been |
reported for other cyclic AMP PDEs. The rat liver 'dense - vesicle', cyclic GMP 
inhibited PDE, is found both as an integral membrane protein (Pyne et al 
1987a), and a kinetically sim ilar soluble enzyme released upon 'hypotonic 
shock' o f hepatocytes (Loten et al 1978). The purified enzyme (Pyne et al i
1987a) was shown to have a native molecular weight o f 62kDa, 5kDa o f which i
behaved as a membrane anchor and was proteolytic all y cleaved upon 
purification. The particulate form , from  hepatocyte membranes, was also 
shown to be a substrate for phosphorylation by PKA (K ilgour et al 1989).
S im ilarily, two closely related but distinct PDE2 isoforms have been identified 
and purified to apparent homogeneity in  rat live r (Pyne et al 1986). Both 
enzymes were shown to possess sim ilar physical properties, such as, they were 
o f a dimeric form w ith molecular weight o f 134kDa. One isoform was found to 
be an integral membrane protein found associated with the plasma membrane,
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and the other was located to the cytosolic fraction. The two isoforms could be 
d iffe ren tia lly  regulated by cyclic GMP, in that, at low  cyclic AMP 
concentrations cyclic GMP was a more potent activator o f the particulate 
enzyme. In rabbit ventricular myocardium particulate and soluble PDE3 
isoforms have been identified, w ith the sarcoplasmic reticulum particulate 
enzyme more sensitive to inhibition by the inhibitor m ilrinone (Kithas et al 
1988), The partitioning o f kinetically sim ilar enzymes to membrane /  cytosol 
compartments, allows the control of the concentration o f specific pools o f cyclic 
AMP. In addition, these membrane /  cytosol isoforms can be differentially 
regulated by cyclic GMP (Pyne et al 1986) and PKA (K ilgour et al 1989), and 
show differences in the potency at which they are inhibited by isoform selective 
inhibitors (Kithas et al 1988) to exert a further control o f localised cyclic AMP 
levels. This compartmentalisation o f cyclic AMP enables the activation o f PKA 
isoforms selectively (Livisey et al 1982, Scott &  Carr 1992, Barsony &  Marx 
1990).
Shakur et al (1995) have shown the in vivo expression o f RDI 
in rat brain. In order to investigate whether R D I is expressed alongside the 
receptor /  adenylyl signalling system, this present study focused on rat brain 
synaptosomes. Synaptosomes are the metabolically and osmotically functional 
vesicles formed upon homogenisation o f neuronal tissue. Contained w ithin the 
synaptosomal membrane itse lf are the pinched o ff nerve endings (ie dendrites), 
synaptic vesicles containing neurotransmitters and mitochondria (fig  5.1.1). In 
addition, Dunkley et al (1988) have shown that these synaptosomes may have 
post-synaptic densities attached. The method used fo r the isolation o f 
synaptosomes in  this study, was the sucrose /  Percoll gradient system 
developed by Dunkley et al (1988) and Thome et al (1991) and used a low 
speed supernatant fraction (S I) to resolve populations o f synaptosomes. The 
resultant fractionation in this study, was similar to that o f Thome et al (1991) 
w ith  respect to the d is trib u itio n  o f marker enzymes LD H  and
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acetylcholinesterase (figs 5.2.2, 5.2.3, 5.2.4, 5.2.5). O f the 5 fractions 
obtained, R D I was found to be enriched in fractions 2 and 3 (fig  5.2.9), with 
less R D I immunoreactivity in fractions 1 and 4, and detected m inimally in the 
mitochondrial fraction F5.
Those fractions which were found to be enriched w ith R D I, F2 
and F3, were lysed and fractionated further on a continuous gradient o f 0.5 - 
1.6M sucrose (Shakur et al 1993), in order to isolate a plasma membrane 
fraction. Using markers fo r the plasma membrane, adenylyl cyclase and 5' 
nucleotidase, enabled the identification o f R D I w ith the plasma membrane 
fraction (figs 5.2.7, 5.2.8, 5.2.9). Fractions 2 and 3 represent those 
synaptosomes which have post-synaptic densities attached, as opposed to those 
found in F4 which are predominantly pre-synaptic in origin. This suggests that 
R D I may associate with the post-synaptic junction along w ith the receptor /  
adenylyl cyclase system thus enabling the transduction o f the signal from the 
receptor to be terminated. This study confirms that the in vivo expression o f 
R D I is predominantly restricted to the plasma membrane, as has been shown 
both biochemically and w ith  immunofluoresence studies, in  COS-1 cells 
transfected with the R DI cDNA (Shakur et al 1993,1995).
In rat brain there is evidence fo r the PDE4 gene encoding 
multiple protein products as has been also shown for the PDE4B gene (Lobban 
et al 1994, Monaco et al 1994). The isolation o f transcripts representing RD2 
and RD3 in addition to R D I, suggested that the PDE4A gene in rat brain could 
produce proteins o f variant size (Davis et al 1989). Recently, a PDE4A enzyme 
(RPDE6, Gen Bank name RNPDE4A5, Gen Bank accession number L27057) 
has been isolated from rat brain which was shown to be related to R D I (Bolger 
et al 1994b). Sequence alignment o f RPDE6 and R D I showed that they were 
identical over the entire C-terminal region, until 23 amino acids from the N- 
terminus o f R D I. This sequence divergence o f RPDE6 provided a unique N-
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terminal region distinct form  that o f R D I. This data determined RPDE6 and 
RDI as splice variants o f the PDE4A gene (McPhee et al 1995).
In whole rat brain homogenates, the antisera directed against the 
C-terminal region o f RDI detected an -109kDa band which co-migrated with 
RPDE6 expressed in COS-7 cell membranes (McPhee et al 1995), as well as an 
~79kDa band which co-migrated w ith R DI immunoreactivity from COS-1 
transfected cell membranes. RPDE6 immunoreactivity was detected in the 
whole brain homogenate, low speed pellet (P I), high speed pellet (P2) and the 
supernatant fraction (S I). The R D I immunoreactive band was detected only in 
the homogenate and high speed pellet fractions. This suggested that the 
differences in the N-term inal regions o f R D I and RPDE6, resulting from 
alternative splicing, removed the region confering membrane association with 
R D I, since RPDE6 was found in all fractions. Indeed, the point o f alternative 
splicing occured at the 5' position which allowed a complete N-terminal 
exchange.
RPDE6 was characterised as a product o f the PDE4A gene 
(McPhee et al 1995) as has R DI (Shakur et al 1993). The different N-terminal 
region o f RPDE6 was shown to allow the expression o f the enzyme in a 
membrane and cytosolic associated form (McPhee et al 1995), whereas, that o f 
R D I confines the enzyme to the membrane fraction (Shakur et al 1993, 1995). 
Shakur et al (1995) have previously shown a 2-fold difference between the 
relative Vmax value o f R D I and met^^RDl, where the extended N-terminal 
region o f R D I had an inhibitory effect. In this regard, membrane associated 
RPDE6 had an even lower relative Vmax, which was -10%  o f that shown by 
m et^^RDl, and 67% o f that expressed in COS-7 cell cytosol transfected with 
the cDNA fo r RPDE6. Thus, the N-terminal region o f these PDE4A enzymes 
attenuated the catalytic activity. Furthermore, membrane-association o f the 
enzyme activity also lead to the inhibition o f catalysis, which presumably 
resulted from a conformational change induced by membrane attachment.
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In conclusion, R DI cDNA transfected into COS-1 cells resulted 
in  the expression o f a PDE4A enzyme (Shakur et al 1993), which co-migrated 
w ith a species detected in rat brain by an R DI specific antisera (Shakur et al 
1995). This R D I species was found associated with rat cerebellum membranes, 
in  particular, those which had post-synaptic densities attached. In addition, 
subfractionation o f such synaptosomal membranes resulted in the migration of 
R D I w ith the plasma membrane marker 5' nucleotidase. Thus, R D I in 
cerebellum is located to the plasma membrane along with the receptor /  adenylyl 
cyclase machinery, enabling the termination o f the cyclic AMP signal.
Other studies have demonstrated the presence o f a larger splice 
variant o f R D I, RPDE6 , in rat brain (McPhee et al 1995, Bolger et al 1994b). 
These two splice variants differ with respect to their N-terminal domains, which 
exert profound effects on their cellular location and enzyme activity (Shakur et 
al 1995, McPhee et al 1995). Alternative splicing o f the N-terminal region o f 
enzymes from the PDE4A (McPhee et al 1995, Bolger et al 1994b) and PDE4B 
(Lobban et al 1994) families allow the cellular distribution o f PDE4 isoenzymes 
to both membrane and cytosol compartments, with the ability o f the N-terminal 
region to regulate activity upon membrane attachment. As a consequence, 
discrete changes in the cyclic nucleotide concentration, either occuring at a 
membrane or cytosolic site can be controlled efficiently. This evidence for splice 
variants o f the PDE4A (McPhee et al 1995, Bolger et al 1994b) and PDE4B 
(Lobban et al 1994) isoforms, implies that drug development strategies 
designed to produce inhibitors for the PDE4A fam ily in mammalian brain, for 
conditions such as depression, need to consider the effect these inhibitors w ill 
have on the variant products o f the one gene.
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Table S Lactate Dehydrogenase (LDH) Activity Determined
f£Qin-Rat.-C,€r.fi.bellMm SynaptosQme Préparation
Fraction Total LDH 
(nmol/min/mg)
Occluded LDH 
(nmol/min/mg)
SI 1.2 ±0 .16 0.15 ±0 .1
F I 0.68 ± 0.06 0.57 ±  0.08
F2 1.00 ±  0.02 0.61 ±  0.01
F3 1.21 0.66 ± 0.04
F4 0.76 ±  0.06 0.37 ±  0.06
F5 0.17 ± 0.03 0.05
Data is shown as mean nmol o f NADH oxidised /  min /  mg protein ±  standard 
deviation for triplicate samples.
The distribution o f LDH activity is representative o f that done at least three 
times.
Fraction SI refers to the supernatant applied to the gradient, fractions F I - F4 
refer to the samples collected at the Percoll /  sucrose gradient interface and F5 
refers to the pellet collected from the gradient.
Total LDH was measured in the presence o f Triton X-100 and occluded LDH 
was the difference between total and free levels o f the enzyme.
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Fig, 5,1,1 £mKaüfl.iL-.gI,.S..s:ï]ia,p.to5flmgs
Shown opposite is a diagramatic representation o f the form ation o f 
synaptosomes, (Gordon-Weeks, P,R., Neurochemistry - A  Practical 
Approach).
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Data is shown as mean nmol o f NADH oxidised /  min /  mg protein ±  standard 
deviation for triplicate samples. Standard deviation is represented by vertical 
bars. This graph is representative o f one carried out fo r at least three separate 
preparations. Fraction SI refers to the supernatant applied to the gradient, 
fractions F I - F4 refer to the samples collected at the Percoll /  sucrose gradient 
interface and F5 refers to the pellet collected from the gradient.
Total LDH was measured in the presence o f Triton X-100 and occluded LDH 
was the difference between total and free levels o f the enzyme.
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Kl,g. g...2.i3. Diütribution of Lactate Dehydrogenase Activity
as Determined bv Thorne et al (1991)
The method used to prepare the synaptosomes in this study was as used by 
Thome et al (1991). Shown opposite is a comparative distribution o f LDH 
activity obtained by Thome et al (1991). Data is shown as mean nmol o f NADH 
oxidised /  min /  mg protein ± standard deviation for triplicate samples. Fraction 
S1 refers to the supernatant applied to the gradient, fractions F I - F4 refer to 
the samples collected at the Percoll /  sucrose gradient interface and F5 refers to 
the pellet collected from the gradient.
Total LDH was measured in the presence o f Triton X-100 and occluded LDH 
was the difference between total and free levels o f the enzyme.
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F igi 5.2j4. AcetyïchQÜnesterase Activity in Rat
Cerebellum Synaptosomal Fractions
Data is shown as mean jim ol o f acetylthiocholine oxidised /  min /  mg protein ± 
standard deviation for triplicate samples w ith standard deviation shown as 
vertical error bars. The distribution o f acetylcholinesterase activ ity is 
representative o f that done at least three times. Fractions F I - F4 refer to the 
samples collected at the Percoll /  sucrose gradient interface and F5 refers to the 
pellet collected from the gradient.
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Fis. Distribution of AcetvkhQlinesterase Activity
as Determined bv Thorne et al (1991)
The method used to prepare the synaptosomes in this study was as used by 
Thorne et al (1991). Shown opposite is a comparative distribution o f 
acetylcholinesterase activity obtained by Thome et al (1991). Data is shown as 
mean p,mol o f acetylthiocholine oxidised /  min /  mg protein ±  standard deviation 
fo r triplicate samples. Fraction SI refers to the supernatant applied to the 
gradient, fractions F I - F4 refer to the samples collected at the Percoll /  sucrose 
gradient interface and F5 refers to the pellet collected from the gradient.
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F igi. Western Blot of RDI Immunoreactivitv in 
Fractions obtained from Rat Cerebellum 
Synaptosomes
Proteins elcctrophoresed on an SDS-PAGE gel were transferred to 
nitrocellulose and Western blotted for R D I immunoreactivity. The antisera was 
directed against a C-terminal region o f R D I. Equal amounts (lOOpg) o f protein 
were loaded on each gel track. Shown are the samples collected at the Percoll /  
sucrose interface F I - F4 and the pellet fraction F5. The data is shown as the 
distribution o f R D I immunoreactivity, mean ±  standard deviation, obtained 
densitometrically from electrophoresis o f samples from  a rat cerebellum 
synaptosome preparation.
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:Distribution of 5* Nucleotidase Activity In 
SvnaptQSOTnal SubcellulaiL Fractions Obtained
from a. gucrQS£-.DgnsitsL.Ora(fient
5' nucleotidase activity was measured in samples obtained from the subcellular 
fractionation o f synaptosomal samples F2 - F3. Results are shown as nmol 
substrate hydrolysed per minute ±  standard deviation for triplicate samples.
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D is trib u tio n  o f Adenvlvl Cvclase A c tiv ity  In  
SvnaptQSQma] iSubceilular F ra c tions Obtained 
from  a Sucrose Density_G radient
Adenylyl cyclase activ ity was measured in samples obtained from  the 
subcellular fractionation o f synaptosomal samples F2 - F3. Results are shown 
as pmol cyclic AMP /  min /  100|il assay ± standard deviation for triplicate 
samples.
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5 .2.9 RDUniTnunQrgactivitv_in_fractions Obtained
fmm SwbçfüWüi Fraçüonatfon of 
S.Ynapt.9Somes...iE2 & E3.1
Proteins electrophoresed on an SDS-PAGE gel were transferred to 
nitrocellulose and Western blotted for R DI immunoreactivity. The antisera was 
directed against a C-terminal region o f R D I. Equal amounts (lOOjig) o f protein 
were loaded on each gel track. To obtain sufficient protein fo r immunoblot 
analysis, fractions o f similar 5' nucleotidase activity were pooled. Shown is the 
distribution o f R D I immunoreactivity determined by densitometry, alongside 
the distribution o f the plasma membrane marker 5’ nucleotidase. Results are 
shown as mean ± standard deviation.
Western blot fraction Fractions pooled from
5'nucleotidase gradient
1 1 - 2
2 3 — 6
3 7 - 9
4 10
5 1 1 - 1 2
6 1 3 - 1 5
7 1 6 - 1 8
1 7 4
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6 . Final Discussion and Conclusions
The isolation and characterisation o f members o f the PDE4 
fam ily is a research area which has gained considerable attention. The interest in 
the PDE4 fam ily o f enzymes is a reflection o f the important role these enzymes 
play in  the regulation o f the intracellular cyclic nucleotide cyclic AMP 
concentration, and the possibility that selective inhibitors could be used as 
therapeutic agents.
O f particular interest in this study, was the characterisation o f a 
PDE4A enzyme isolated by D r M ike Sullivan (Sandoz), from a human T- 
lymphocyte cDNA library. The importance o f the cyclic AMP signalling system 
in the immune response has been established. In the mammalian immune 
system, cyclic AMP is known to be an important regulator o f such functions as 
attenuation o f lymphocyte blastogenesis (Epstein et al 1984), lymphocyte 
proliferation and differentiation (Coffey et al 1978, Hadden 1988), inhibition of 
release o f inflammatory mediators histamine and leukotriene C4 from basophils 
(Peachell et al, 1992) and the blockade o f the cytokine pathway due to the 
suppression o f tumour necrosis factor alpha production from  human 
mononuclear cells (Semmler et al 1993). Quiescent peripheral blood 
lymphocytes are stimulated to proliferate upon contact w ith antigen, which 
triggers the immune response. Sustained, elevated levels o f cyclic AMP have 
been shown to inh ib it lymphocyte activation, lymphocyte proliferation and 
differentiation (Coffey et al 1978, Hadden 1988). O f importance in this crucial 
role o f cyclic AMP is the role o f the PDE4 cyclic AMP specific PDEs which 
catalyse the degradation o f the cyclic nucleotide. Engels et al (1994) has already 
shown that the PDE4A isoform is the only one expressed in  the T-cell Jurkat 
cell line, which implies the importance o f this isoform in these cells.
The enzyme isolated from the T-cell cDNA library, studied 
herein was named h6.1 (HSPDE4A7, GenBank accession number U 18087). 
This present study has characterised h6.1 as a typical member o f the PDE4
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'enzyme fam ily. h6.1 was shown to hydrolyse cyclic AMP specifically and was 
insensitive to Ca^"*" /  calmodulin and cyclic GMP (chapter 3, 3.2.1). An
'
engineered version o f h6.1, called h6.1his5. was used by D r Neil Brown for
■ftthe purification and molecular weight determination o f the enzyme. h6.1 was 
shown to appear as a single band on a denaturing gel o f 73kDa ± 2. This was 
comparable to the molecular weight determined from the purification procedure 
as predicted from the cDNA sequence. DiSanto and Heaslip (1993) have 
suggested that in the promonocytic cell line U937, PDE4 is expressed as a large 
molecular weight species o f 210 - 250kDa. This large molecular weight protein
was cleaved, upon storage, to produce a protein o f ~45kDa. This was not the 
case w ith h6.1 as the purification data, along with the thermostability study 
(chapter 3, 3 .2.iii, fig  3.2.1), has shown that h6.1 was expressed as a single 
population o f enzyme and was not a proteolysis product.
Rolipram has been used as a tool to characterise PDE4 as such,
''fcbecause o f the selectivity o f the inhibitor fo r this enzyme class. The mechanism 
by which rolipram achieves inhibition is a subject which has generated a lot of 
interest. Several groups have suggested that the kinetics o f inh ib ition by 
rolipram are anomolous. This was based on the findings that shallow dose 
response curves were obtained w ith rolipram, which spread over several orders 
o f magnitude (Torphy et al 1992, Bolger et al 1993, McLaughlin et al 1993).
W ith the isolation o f human PDE4, it  has been questioned whether these
i"V:
' i
isoforms possess the high affin ity rolipram binding site which has been detected 
in rat brain (Némoz et al 1989, Schneider et al 1986) suggested to be 
responsible for the anomolous kinetics detected. This high a ffin ity  rolipram 
binding site was suggested as being present in the cloned enzyme isolated from 
human monocytic cells, hPDE4ALivi (L iv i et al 1990), rabbit gastric glands 
(Barnette et al 1995) and guinea pig eosinophils (Souness et al 1993). This high 
a ffin ity site has been shown to bind rolipram stereoselectively, w ith the (R ) 
enantiomer being the more potent w ith a o f ^ InM . In contrast, the inhibition
1 7 6
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Torphy et al (1992) and Barnette et al (1995), have suggested that rolipram 
binds to only one site on PDE4, the catalytic site. They suggested that different 
non-interconvertible forms o f PDE4 exist which hydrolyse substrate with 
similar Km values but differ with respect to the affin ity for binding o f inhibitors 
such as rolipram and Ro-20-1724 to the catalytic site. Analysis o f hPDE4ALivi 
indicated that rolipram did not seem to serve as a simple competitive inhibitor 
(Torphy et al 1992, L iv i et al 1990) from the authors double reciprocal plots. In 
support o f this, a replot o f slope versus rolipram concentration for hPDE4ALivi 
(chapter 3, fig  3.2.16) was curved in a concave fashion instead o f linear as 
would be expected o f a simple competitive inhibitor. Furthermore, analysis o f 
their data showed that the slope versus rolipram concentration plot for 
hPDE4ALivi could be linearised by replotting a double-reciprocal o f each axis 
(Dixon and Webb 1979), which is indicitive o f partial competitive inhibition. In 
the case of partial competitive inhibition the enzyme active site is able to 
accomodate both substrate and inhibitor at the same time as shown in fig 
3.2.17.
o f PDE4 catalysis requires rolipram  in the pM  range (Torphy et al 1992, 
Barnette et al 1995). Studies by Torphy et al (1992), Barnette et al (1995) and 
Schudt and Hatzelmann (1995) a ll suggest that the high a ffin ity  rolipram 
binding site is not associated with the ability o f rolipram to inh ib it catalysis. 
Indeed, more recent evidence has suggested that the irritational, gastric side 
effects found with the therapeutic dose o f rolipram is due to an interaction with 
this high affinity site (Barnette et al 1995).
Torphy et al (1992) and Barnette et al (1995), have suggested 
that rolipram binds to only one site. However, they suggest that this site is 
present on two non-interconvertable forms o f PDE4, which catalyse breakdown 
o f cyclic AMP with sim ilar Km values, but bind rolipram w ith either low or 
high affinity. Analysis o f hPDE4ALivi indicated that rolipram did not seem to 
serve as a simple competitive inhibitor from the authors double-reciprocal plots 
(L iv i et al 1990, Torphy et al 1992). In support o f this, a plot o f slope versus 
rolipram concentration for hPDE4ALivi (chapter 3, fig  3.2.16) was curved in a 
concave fashion. However, this would not be expected to occur i f  more than 
one molecule o f rolipram was binding to the enzyme as hypothesised by the 
authors, because the plot would be upwardly curving. Furthermore, analysis of 
their data showed that the slope versus rolipram  concentration p lo t fo r 
hPDE4ALivi could be linearised by replotting a double-reciprocal o f each axis 
(Dixon and Webb 1979), which is indicative o f partial competitive inhibition.
Kinetic analysis o f human PDE4A in this study, with respect to 
inh ib ition  by rolipram , showed that w hile inh ib ition  o f h6.1 was o f a 
competitive nature (chapter 3, figs. 3.2.8, 3.2.9 and 3.2.10), inhibition o f the 
N-terminally extended enzyme lOAORF was partially competitive (chapter 4, 
figs 4.2.13, 4.2.14 and 4.2.15). This alteration in the mechanism with which 
rolipram inhibited lOAORF can be explained by a conformational change in 
lOAORF induced by the additional N-terminal amino acids. This conclusion is 
supported by the therm ostability data, where at 45“C, lOAORF was
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considerably more thermostable than h6 .1, which suggests that a 
conformational change had indeed occured. In addition, the comparitive IC 50 
data fo r rolipram  inh ib ition  o f lOAORF (0.19fxM) and h6.1 (0.51|LiM), 
demonstrated that lOAORF was more potently inhibited. This decrease in 
suggested that an alteration in inhibitor interaction had occured 
w ith lOAORF. It would seem that as w ith the rat PDE4A species, the N- 
terminal domain o f the human equivalent is important in enzyme thermostability 
and activity.
Jin et al (1992), has shown that upon analysis o f the catalytic 
domian o f PDEs, members o f any one class show 60 - 90% homology in this 
region, while those belonging to different classes are much less homologous. 
The catalytic region o f PDE4 (Jin et al 1992) can be identified by homology 
with other PDE species (chapter 4, fig  4.1.1) and is conserved throughout the 
PDE4 class. Bolger et al (1993) has compared the sequences o f the four human 
PDE4 genes, and has shown that outwith the catalytic domain little , or no, 
sequence sim ilarity occurs. Thus, these N and C terminal regions presumably 
perform other functions which could influence enzyme stability or catalysis. In 
order to address whether the N and C terminal regions o f h6.1 influence 
enzyme activity, D r M. Sullivan (Sandoz), created a series o f mutants o f h6.1. 
These truncations, which refer to the sequence o f h6, l,  took the form o f an N- 
terminal deletion o f residues 1 -172 (YMS 10 yeast strain), a deletion at the N- 
terminus (residues 1 - 172) and also at the C-terminus (608 - 692) leaving the 
basic catalytic domain (YMS 11 yeast strain) and a C-terminal deletion (residues 
608 - 692) (YMS 12 yeast strain) (chapter 4, fig  4.2.1). Also analysed were the 
N-term inally extended version o f h6.1, lOAORF and the domain swop o f N- 
terminal regions o f h6 .1 w ith the catalytically inactive splice variant 2EL 
described in chapter 4.
The N-terminal region o f PDE4 was shown to perform several 
functions. W hile the extended N-terminus o f lOAORF enhanced catalysis.
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inhibitor interaction (chapter 4, table 6) and enzyme stability (chapter 4, table 7) 
the substituition o f the N-terminal region o f h6.1 with that o f 2EL was shown 
to be detremental. This suggests that the sequences involved in forming the 
catalytic region, and those adjacent to this region, are specific fo r the optimal 
functioning o f the enzyme with regards to catalysis and inhibitor interaction. In 
addition, the N-terminal sequence o f h6.1 might be specifically involved in the 
conformational folding o f the enzyme in such a way as to resist thermal 
dénaturation, as shown in the different thermostabilities o f h6.1 and H Y B l 
(chapter 4, table 7). The involvement o f the N-terminal region in such functions 
has already been demonstrated fo r R D I where the N-term inally truncated 
enzyme, met^hRDl had a greater Vmax for cyclic AMP hydrolysis and was less 
thermostable (Shakur et al 1993,1995).
Sullivan et al (1994) have suggested that the sequence o f h6.1 
represents the native PDE. Human PDE4A clones isolated from commercial 
cDNA libraries corresponded to the sequence o f h6.1 and not hPDE4ALivi- In 
addition, Bolger et al (1993) have isolated what is considered to be the fu ll 
length sequence encoded by the human PDE4A gene, PDE46. Alignment o f the 
sequences o f h6.1 and that o f PDE46 (chapter 4, fig  4.2.4), shows that the 
amino acid differences are not seen in PDE46. This data concludes the sequence 
o f h6.1 at these points to be correct. Transfection o f COS-1 cells with pSVL- 
R D l (Shakur et al 1993), allowed the analysis o f the rat PDE4A gene product 
R D I. Isolation o f mRNA front transfected cells, and in vitro  translation, 
showed that the cDNA encoded a 68kDa protein product. Subcellular 
fractionation studies showed that in transfected COS-1 cells, R D I associated 
predominantly with the membrane fraction, in particular the plasma membrane. 
A  small proportion o f the activ ity associated w ith  golgi fraction also. 
Approximately 75% o f the total RDI activity was membrane located, w ith the 
residual being cytosolic. A  recent study (McPhee et al 1995) has revealed that 
the cytosolic R DI species in COS-1 cells was that corresponding to met^^RDl
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(Shakur et al 1993). In this study, McPhee et al (1995) showed that the soluble 
fraction o f lysates o f R D I transfected COS-1 cells co-migrated with the that o f 
homogenates from m et^^R D l transfected cells. Expression o f m et^^R D l 
occured because the met^6  residue o f R D I was w ithin a suboptimal Kozak 
sequence (Kozak 1986). As a result o f the over-expression in  COS-1 cells 
shorter products could be formed by a second initiation start site which occured 
at this point. Expression o f a m et^^RDl like activity did not occur in vivo , as 
has been shown from immunoblot analysis o f the pellet and soluble fractions 
from various rat brain regions (McPhee et al 1995).
Early studies have provided prelim inary evidence which 
suggests a role fo r a cyclic AMP specific PDE, in  the process o f 
neurotransmission. The studies using Drosophila melano^aster have shown 
that genetic mutations o f components o f the cyclic AMP signalling pathway, 
result in disruption o f the processes o f learning and memory (Byres et al 1981, 
Nighorn et al 1991). These genetic mutations include dune , which encodes a 
cyclic AMP specific PDE, and ru t which encodes a calcium-calmodulin 
stimulated adenylyl cyclase (Dudai 1988, Levin et al 1992, Qiu et al 1991). In 
the mammalian CNS, Thérien and Mushynski (1979) have demonstrated that a 
particulate cyclic AMP PDE activity is concentrated over post-synaptic densities 
in rat brain. The cyclic AMP specific PDE inhibitors, including rolipram and 
RO-201724, have been evaluated as antidepressants, and studies in rat have 
demonstrated that a specific behavioural pattern is shown after PDE4 inhibitor 
administration (Watchel 1982). These behavioural effects were correlated with 
increased brain cyclic AMP levels in these animals (Kant et al 1980) follow ing 
PDE4 inhibitor treatment.
Davis et al (1989) provided evidence, using northern blotting, 
which suggested that R D I mRNA ocurred predominantly in  rat brain tissue. 
However, it was unknown as to whether a protein encoded by R D I mRNA was 
translated into protein in rat brain. To address this, the present study questioned
1 8 0
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whether R D I activity was associated w ith rat cerebellum synaptosomes. 
Synaptosomes are formed from the resealing o f post-synaptic and presynaptic 
membranes, which have been sheared from  the ce ll bodies upon 
homogenisation. The resealed membranes have w ithin them organelles o f the 
synapse, such as, post-synaptic densities, synaptic vesicles, mitochondria and 
enzymes o f the cytoplasm (Gray &  W hittaker 1962, DeRobertis et al 1962). 
Synaptosomes therefore provided a source o f rat brain neuronal membrane to 
study. Immunoblotting o f rat brain cerebellum membrane /  cytosol fractions 
(Shakur et al 1995), w ith antiserum directed against a C-terminal region o f 
R D I, showed that -92%  o f the activity was membrane associated. Analysis o f 
the rat brain synaptosome preparations w ith the R D I antiserum, identified a 
band o f -73kDa (chapter 5, fig  5.2.6). Shakur et al (1995) demonstrated that 
RDI immunoreactivity from rat brain cerebellum membranes, migrated with that 
o f COS-1 cells transfected w ith R D I cDNA. Interestingly, those fractions 
which were enriched in RDI immunoreactivity (chapter 5, fig  5.2.9), have been 
shown (Dunkley et al 1988) to have post-synaptic densities attached. This 
would correlate w ith the work o f Thérien and Mushynski (1979), who have 
demonstrated that a particulate cyclic AMP PDE activity is concentrated over 
post-synaptic densities in rat brain.
The particular membrane fraction with which R D I associated, 
was revealed upon sub-fractionation o f the synaptosomal fractions which were 
enriched in immunoreactivity. This sub-fractionation procedure identified RDI 
immunoreactivity, w ith the plasma membrane markers adenylyl cyclase and 5'- 
nucleotidase (chapter 5, figs 5.2.7 - 5.2.9. This study confirmed the 
observation in COS-1 cells that R D I associated w ith the plasma membrane 
fraction prim arily (Shakur et al 1993). The post-synaptic localisation o f R D I, 
and identification o f R DI w ith those fractions containing adenylyl cyclase and 
5'-nucleotidase outline a role for PDE4A in the process o f neurotransmission. 
Indeed, this data correlates with the studies discussed above which implied that
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a PDE4 was involved in this process. The recently published data (McPhee et al 
1995), on the larger PDE4A rat splice variant, RPDE6, showed that in rat 
cerebellum only R DI could be detected. This RDI activity was found only in 
the membrane fraction (fig  3 McPhee et al 1995). This would suggest that RDI 
is the main PDE4A activity involved in controlling cyclic AMP levels in this 
region o f rat brain.
In conclusion, this thesis has highlighted the prominant role o f 
products o f the PDE4A gene, in processes which involve the functioning o f T- 
lymphocytes and neurological events. These enzymes, and variants thereof, are 
like ly  to be considered targets fo r therapeutically useful drugs. Engels et al 
(1994) has shown that only PDE4A is expressed in the T-cell Jurkat cell line, 
which suggests that inhibitors o f PDE4A w ill be useful in treating inflammatory 
disorders. Indeed, elevation o f PDE4 activity is considered to be the underlying 
cause o f certain inflammatory disorders (Grewe et al 1982, Chan et al 1993). 
Current drug therapy in the treatment o f asthma relies on symptomatic relief, 
mainly w ith bronchodilatory agents, and leaves the underlying cause, the 
inflammation, unchecked. The ability to restore cyclic AMP levels, through 
PDE4 inhibition, would be a route to producing an anti-inflammatory effect. 
Sim ilarily, PDE4 is considered a target for drugs used to treat disOTders such as 
depression. Future studies w ill presumably focus on the development o f more 
potent inhibitors o f these enzymes, which posses few o f the side effects which 
are currently associated with inhibitors such as rolipram (Barnette et al 1995).
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Appendix 1
Supplier
Amersham International, Amersham, 
Bucks, England, U.K
Chemical
8-3H-adenosine 3'5' cyclic 
monophosphate
B.D.H Ltd., Poole, Dorset, 
England, U.K.
A ll other chemical reagents not 
listed here
Bio-Rad, Hemel Hempstead, 
Herts, England
Nitrocellulose 
Bradford reagent
Boehringer Mannheim (UK), 
Lewes, East Sussex, England, UK
ATP
GTP
Creatine kinase 
Tris
Triton X-100
Sigma Chemical Co.,
Poole, Dorset, England, U.K.
Adenosine
Bovine serum albumin
Creatine phosphate
Cyclic AMP
Dithiothreitol
Dowex
EGTA
Isobutylmethylxanthine 
Snake venom 
Temed 
Thimerosol
Phenylmethanesulphonyl fluoride
2 0 2
Peptide Research Foundation 
(Scientific Marketing Associates) 
Koch-Light Ltd.
Aprotinin 
Pepstatin A 
Antipain 
Leupeptin
Magnesium chloride 
Dimethylsulphoxide
Pharmacia (UK) Percoll
Schering Aktiengesellschaft (Berlin) G ift o f rolipram
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